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Abstract 
Objective 
Glioblastomas (GBMs) are the most prevalent primary brain tumours in adults and 
the outcome for this disease remains very poor. With treatment options limited, 
there is growing interest to find potential differences between normal and malignant 
molecular signaling pathways for this disease. SIRT1 is a histone deacetylase 
enzyme with key functions in cellular signaling responses including protecting DNA 
from damage and changing transcriptional events. SIRT1 can act as a switch to 
affect cellular senescence or anti-apoptotic responses, or alternatively affect 
autophagic and pro-apoptotic responses. The role of SIRT1 in GBM is unclear. 
This study aimed to investigate differences between glioma and normal astrocytes 
with respect to SIRT1. 
Research design and methods 
SIRT1 was analysed in murine normal and glioma astrocyte cell lines, and results 
compared to a normal human astrocyte cell line and a panel of human primary 
glioma cells taken from patients with GBM. Analysis of SIRT1 was assessed using 
Western blots and flow cytometry. Sub-cellular localisation was examined using 
Western blots and immunofluorescent microscopy. Activity for SIRT1 was 
assessed using acetylation of a key histone SIRT1 substrate, histone 4 lysine 16, 
and cell proliferation was measured using the MTT assay. Oxidative stress was 
induced using H2O2 and viability measured using propidium iodide exclusion and 
flow cytometry. To ascertain that activity was SIRT1 related, inhibition and 
activation of SIRT1 was done using nicotinamide and resveratrol, respectively. 
Results 
SIRT1 was mainly localised in the nucleus and to mitochondria of normal cells but 
was aberrantly distributed in the cytoplasm of glioma cells, which has not been 
reported before. This was consistent in both murine and human glioma models. 
Nicotinamide significantly inhibited cell proliferation more for glioma cells compared 
to normal, and resveratrol had the opposing effect. Nicotinamide rescued normal 
but not glioma cells from H202-induced oxidative stress, and resveratrol had the 
opposing effect. Western blots revealed secondary protein bands for SIRT1 
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indicating possible smaller species of SIRT1, and results for nuclear/cytoplasmic 
extractions suggested FL-SIRT1 and the smaller species of SIRT1 have a dynamic 
pattern of localisation under oxidative stress, nicotinamide and resveratrol 
treatments.  
Conclusions 
These results indicated SIRT1 is involved in both cell proliferation and oxidative 
stress responses, with a differential activity between glioma and normal astrocyte 
cells. Aberrant localisation of SIRT1 to the cytoplasm in glioma cells is a significant 
finding that needs further exploration. The need for further studies to elucidate 
changes in localisation for SIRT1 under different conditions is highlighted, as is the 
possible role of truncated variants of SIRT1. This study suggests there may be 
some potential for SIRT1 inhibition in patients suffering from glioblastoma. 
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The art of knowing, is knowing what to ignore. 
Rumi 
vi 
Acknowledgements 
The Rumi quote on the previous page may seem a strange choice given that this 
thesis is relatively long. It felt like an untameable beast at times. Every result threw 
up many more questions, and when you have a curious mind like I do, it can be a 
struggle to stop asking more, and to focus on a small aspect of the wondrous 
universe that is molecular biology. This study had so many changes in directions, 
had so many failed experiments, and it was a struggle for me to keep going. It was 
also a challenge for me to believe in myself. Then, there would be those few times 
in the lab when I saw an amazing result for the first time, or see the stunning 
internal world of a cell fluorescing under the microscope, and I felt so privileged to 
have been able to see into the secret life of SIRT1 for a brief moment, the ever-
changing, ever moving molecule that I have come to love. So I kept going. I left out 
a whole lot, and I probably should have left out a whole lot more. I’m still a student 
in the art of knowing. 
I am extremely thankful to the university for giving me assistance to complete. I got 
very stuck when writing this thesis. In particular, Shona de Sain and Patricia Stein on 
the VUW staff who have brought me to tears with kindness and support, thank you.  
To Dr Sheena Gallocher, without your help I would never have even stepped into 
the lab or the university to begin with. Your work is truly God’s service. Thank you. 
I am very grateful to Dr Melanie McConnell, who took me on as her student for this 
research. She gave me so much freedom perhaps a little too much! However, 
doing this work has meant a lot to me in ways that she may never know, and 
without her accepting me as her student, this would not have happened.  
Dr Bill Jordan has shown me support throughout this research, and in particular 
during the write-up, that I can only describe as magic. It would never have been 
completed without his care and help. Thank you so very much, Bill. 
The Malaghan Institute of Medical Research, where I did my experimental work 
was very supportive. The use of the well-equipped labs and their attitude of 
generosity was much appreciated. The people in my group were instrumental to 
the work behind this dissertation, in particular Kate Broadley, a fantastic scientist 
  vii 
who would willingly help me with anything she could. Also James Baty, whose 
humour keeps everyone buoyant, Carole Grasso, An Tan, Prof. Mike Berridge, and 
Dr Patries Herst, plus the lovely bunch of people in Room Patagonia who 
supported me so much: Liz, Ching-Wen, Sara, and Colin. I’d also like to thank Api, 
Dianne and Janine for their kindness and care; I’ll “pass it forward”.  
Other important people who have helped me include my ever-inspiring sister, Pip, 
and my son Barney who is a blessing and a treasure in my life. People know that 
they only need to mention Barney’s name to cheer me up. I’d like to thank Poppa, 
my grandfather, for working so hard in his lifetime so that his descendants could 
follow their passions. Penny and David, Martin, Barbara, Pam, and my 
accomplished scientific friends, Shirley Martin, Sandra Anderson, Isabel Castro, 
Kim Young and Edward Abraham and my dependable, fun-loving, very 
accomplished friend Judge Christina – you all have inspired and supported me, 
thank you. Daniel, you are a constant reminder to believe in things beyond our 
understanding.  
There have been some key people that have never stopped encouraging me after 
most others had given up. These people are so important in life, and I hope 
everyone is lucky enough to meet such people. Cornelia, Jess, Sally, thank you! 
At home my young boarders have been just wonderful in this last leg of my 
journey. Xia has infected me with the practical “no nonsense bug”, and Luke, my 
Godson, with his consideration and care – you are both ‘godsends’!  Renee, 
without you I would have been lost at the finish line. 
Thank you to the Wellington Research Medical Foundation and Motor Neuron 
Disease Association of NZ for helping to fund this research. 
Finally I’d like to acknowledge the patients who donated their tumours for this 
research. They have shown great courage and faith that glioblastoma will one day 
be treated effectively. I’d like to dedicate this thesis to them and to anyone else 
reading this who may be suffering from brain cancer or who has a loved one who 
has this cancer, or has died from this cancer. My wish is that this research gives 
some hope.
 vi 
Contents 
Abstract iii 
Acknowledgements vi 
Abbreviations xi 
Part 1: Introduction 13 
1.1 Glioblastoma Multiforme (GBM) 13 
1.2 Treatment of GBM 13 
1.3 Sirtuin Family of Histone Deacetylases 14 
1.4 Sirtuin 1 (SIRT1) 15 
1.5 SIRT1 in metabolism and cell proliferation 16 
1.6 SIRT1 in oxidative stress 17 
1.7 Control of SIRT1 19 
1.8 SIRT1 splice variants and cleavage products 21 
1.9 SIRT1 and cancer 21 
1.10 SIRT1 in glioblastoma 23 
1.11 Aims of this research 24 
Part 2: Materials and Methods 27 
2.1 Cell culture 27 
2.2 Protein extraction and western blotting 29 
2.3 Buffers 36 
2.4 Immunofluorescent staining 39 
2.5 Mitochondrial staining 40 
2.6 Intracellular staining and measurement by flow cytometry 41 
2.7 MTT Assay 41 
2.8 Oxidative stress 42 
2.9 Inhibition and activation 42 
2.10 Measurement of cell death 43 
  vii 
2.11 Statistical Analysis 43 
Part 3: Results – Basal Levels 45 
3.1 SIRT1 levels in murine and human glioma and normal astrocyte cells 45 
3.2 Acetylation for H4K16 showing SIRT1 activity in normal and glioma cells 51 
3.3 Subcellular localisation for SIRT1 – immunofluorescent microscopy 56 
3.4 Subcellular localisation for SIRT1 – Western blotting 60 
Part 4: Results – Cell Proliferation 67 
4.1 Proliferation measures for murine and human glioma and normal cells using 
MTT reduction assay 67 
4.2 SIRT1 activation and inhibition effects on cell proliferation rates in glioma and 
normal cells 72 
4.3 Effects of nicotinamide and resveratrol treatments on SIRT1 protein 77 
Part 5: Results: Oxidative Stress 81 
5.1 Introduction to oxidative stress and SIRT1 in GBM 81 
5.2 SIRT1 inhibition and activation in glioma and normal cells 82 
5.3 Immunoblotting to investigate changes in SIRT1 protein levels and H4K16-ac 
after oxidative stress 89 
5.4 Sub-cellular localisation changes for SIRT1 after NAM or RES treatment 98 
5.5 SIRT1 in the cytoplasm co-localised with mitochondria 102 
Part 6: Discussion 107 
6.1 SIRT1 in untreated normal astrocytes and glioma cells 107 
6.2 SIRT1 in relation to proliferation of glioma cells compared to normal 
astrocytes 112 
6.3 SIRT1 in glioma and normal cells under oxidative stress 116 
6.4 Potential therapeutic value of nicotinamide 121 
6.5 Conclusions and future directions 121 
Part 7: References 123 
 viii 
Figures 
bo manually. 
Figure 1. Simplified overview showing cellular substrates and pathways for SIRT1 
under oxidative stress conditions 17 
Figure 2. Efficacy of nicotinamide to inhibit SIRT1 activity 19 
Figure 3. Example of analysis of protein bands using Image J analysis 36 
Figure 4. Sirt1 levels were not significantly different between C8D1A and GL261 
cell lines 46 
Figure 5. Comparison of FL-hSIRT1 and hSIRT1 smaller species in human 
glioma and normal SVG astrocyte cell line and the relationship to 
patient survival 48 
Figure 6. Intracellular staining analysis of hSIRT1 protein levels in SVG normal 
astrocyte cell line and primary glioma cells 51 
Figure 7. H4K16 acetylation in GL261 and C8D1A cells 52 
Figure 8. H4K16-ac in human primary glioblastoma cells 54 
Figure 9. Neither FL-Sirt1 expression levels nor activity showed any significant 
change when FBS levels were altered 55 
Figure 10. Aberrant cytoplasmic localisation of Sirt1 in GL261 cells 57 
Figure 11. hSIRT1 is found aberrantly in cytoplasm of primary glioblastoma cells 
compared to SVG normal astrocytes 58 
Figure 12. Nuclear/Cytoplasmic fractionation and immunoblotting of C8D1A and 
GL261 cell lines. 60 
Figure 13. Nuclear/cytoplasmic extraction of C8D1A and GL261 cells after 
fixation 62 
Figure 14. Nuclear/cytoplasmic extraction for untreated SVG cells – using 
different processes 63 
Figure 15. Nuclear/cytoplasmic extraction for SVG and 0906 cells using 
formaldehyde fixation 64 
Figure 16. Human primary 0906 cells spontaneously immortalised in culture 65 
Figure 17. Cell proliferation in murine and human glioma and normal astrocytes 
compared to FL-SIRT1 69 
Figure 18. Relationship between MTT reduction, hSIRT1 and patient survival 70 
  ix 
Figure 19. Relative H4K16 acetylation across a panel of human primary glioma 
cells in relation to MTT reduction 71 
Figure 20. Proliferation in murine astrocyte normal and glioma cell lines with 
Sirt1 inhibition and activation 73 
Figure 21. Proliferation for human astrocyte SVG and primary glioma cell lines 
with hSIRT1 inhibition and activation 74 
Figure 22. Effect of hSIRT1 inhibition on proliferation in a panel of primary 
glioma cells 76 
Figure 23. Effect of resveratrol on SIRT1 79 
Figure 24. Nicotinamide does not change SIRT1 protein band 79 
Figure 25. Malignant glioma cells were more resistant to H2O2 compared to 
normal astrocyte cells. 83 
Figure 26. Nicotinamide rescued normal but not malignant murine astrocyte 
cells from lethal oxidative stress 85 
Figure 27. Low concentration nicotinamide rescued malignant murine astrocyte 
cells with reduced FBS 86 
Figure 28. Nicotinamide rescued normal but not malignant human astrocyte 
cells from lethal oxidative stress 87 
Figure 29. Resveratrol had no rescue effect to lethal H2O2 -induced oxidative 
stress in C8D1A or GL261 88 
Figure 30. Nicotinamide rescued murine glioma cells from lethal oxidative stress 
at an early time point, but not at a later time point. Resveratrol had 
opposing effects 89 
Figure 31. SIRT1 was cleaved under H2O2 -induced oxidative stress in murine 
and human normal astrocyte cells, but not in malignant cells 91 
Figure 32. H4K14 acetylation in murine cells after H2O2 or nicotinamide 
treatment for one day 93 
Figure 33. H4K16 acetylation in murine cells after H2O2 or nicotinamide 
treatment for two hours 94 
Figure 34. Localisation changes for Sirt1 in murine normal and glioma 
astrocytes after two-hour H2O2 or nicotinamide treatment 95 
Figure 35. hSIRT1 localisation changes in SVG and primary glioma cells 0906 
after four-hour H2O2 treatment 97 
 x 
Figure 36. Altered localisation of SIRT1 with NAM or RES treatment 99 
Figure 37. Immunofluorescence of hSIRT1 in primary glioma cells after NAM 
treatment 101 
 Figure 38. Inhibition of Sirt1 affects mitochondrial mass in normal murine 
astrocytes under mild oxidative stress 103 
Figure 39. hSIRT1 is increased in the cytoplasm and associates with 
mitochondria under sub-lethal oxidative stress 105 
 
Tables 
Table 1. Patient data for human primary glioma cell lines  27 
Table 2. Primary antibodies used in Western blotting 34 
Table 3. Secondary antibodies used in Western blotting 34 
Table 4.  Primary antibodies for immunofluorescent staining  39   
Table 5.  Secondary antibodies for immunofluorescent staining  40 
Table 6.  Cell counts for sub-cellular localisation of hSIRT1 in primary glioma cells 
with and without NAM treatment  100 
  
  xi 
Abbreviations 
AKT Activated kinase  
AMP Adenosine monophosphate 
DMNQ 2,3, dimethoxy-1,4 naphthoquinone 
DMSO Dimethyl Sulfoxide 
EDTA Ethylenediaminetetraacetic acid 
FACS Fluorescent-activated cell sorting 
FBS Fetal Bovine Serum 
H4K16 Histone 4 lysine 16 
H4K16-ac Histone 4 lysine 16 acetylation 
HAT Histone acetyl transferases 
HDAC Histone deacetylase 
HEPES 4-(2-hydroxyethyl)-1 piperazineethanesulfonic acid 
mTOR Mammalian target of rapamycin 
MTT 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide 
NAM Nicotinamide 
NFκB Nuclear factor kappa B 
PGC1α Peroxisome proliferator-activated receptor gamma co-activator  
1-alpha 
PI Propidium Iodide 
PI3K Phosphoinositide 3-kinase 
IGF-1 Insulin-like growth factor 1 
IGF-1R Insulin-like growth factor 1 receptor 
IRS-2 Insulin receptor substrate 2 
RES Resveratrol 
RT Room temperature 
SDS Sodium dodecyl sulfate 
hSIRT1 Sirtuin 1 (human) 
Sirt1 Sirtuin 1 (mouse) 
SIRT1 Sirtuin 1 – used generically 
  
 xii 
 
  13 
Part 1:  Introduction 
1.1 Glioblastoma Multiforme (GBM) 
Brain tumours originating from glial cells are termed gliomas. Around 70% of 
gliomas originate from astrocytes (astrocytoma) and most of the remaining gliomas 
originate from oligodendrocytes (oligodendroglioma), with a small percentage a 
mixture of origin from astrocytes, oligodendrocytes and ependymal cells (Lino et al 
2010). The World Heath Organisation (WHO) classifies gliomas into grades I-IV. 
WHO Grade IV astrocytoma tumours are commonly known as glioblastoma 
multiforme (GBM) (Dunn et al 2012, Louis et al 2007).  
Glioblastoma is the most common and most aggressive primary brain tumour 
(Louis et al 2007), and even though progress has been made with diagnosis and 
enhanced understanding of the disease through research, patients still have a very 
poor prognosis with median survival between 12–15 months (Dubrow et al 2013). 
Recurrence is expected even after treatment. 
1.2 Treatment of GBM 
Treatment for this disease remains largely unchanged in a decade, where surgery is 
followed by radiation and temozolomide treatment therapy (Dubrow et al 2013).  
Much research into GBM to try to find better treatment options include identifying 
the cells from which recurrence occurs (“stem cells”) (Broadley et al 2011a) (Chen 
et al 2012a, Lim et al 2011), molecular and genetic markers (Dreyfuss et al 2009, 
Reynes et al 2011, Tafani et al 2011) (Liu et al 2006), immune therapy (Fadul et al 
2011, Hunn et al 2015), and aberrant signaling pathways (Fassl et al 2012, Lino et 
al 2010) (Lino & Merlo 2011) (Krakstad & Chekenya 2010). Epigenetics, the study 
of the natural control over the genome from DNA modulation by enzymes is a 
relatively new area of interest to GBM research with much potential (Allen et al 
2015, Clarke et al 2013, Rauscher 2005). 
All cells have highly complex cell signaling network systems and epigenetic 
responses, which respond to the changing microenvironment. Cells are designed 
to switch on or off genes in response to environmental changes, or to change the 
activity of molecules that are always present. Cancer cells have aberrant signaling 
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systems that are believed to arise mostly from genetic mutations, but can also 
come about from the stress to the cell for example through tissue damage (Wu et 
al 2010).  
1.3 Sirtuin Family of Histone Deacetylases 
Around twenty years ago, the first enzyme in the sirtuin family of histone 
deacetylases was discovered in yeast, Saccharomyces cerevisiae, and was called 
Sir2 (Sinclair & Guarente 1997). It was found to extend lifespan by repressing 
genome instability, and thence its name Silent Information Regulator (Kaeberlein et 
al 1999). Further research uncovered a family of highly conserved sirtuin genes 
that are found from bacteria to mammals and much interest was generated due to 
the link sirtuins have to longevity in yeast, worms and flies (North & Verdin 2004) 
(Tissenbaum & Guarente 2001) (Haigis & Sinclair 2010) (Rogina & Helfand 2004).  
In mammals seven sirtuins have been discovered, SIRT1-7, but research has 
failed to verify if any of them are specific regulators of aging, even though some 
research indicates a link with long-term survival and SIRT1 expression (Figarska et 
al 2013). All sirtuins have a highly conserved NAD+ binding domain, which 
characterises them to a different family of histone deacetylases (HDAC) from 
HDAC classes I, II and IV. Sirtuins have been classified as HDAC class III 
(Marmorstein 2001), and will be activated on nutrient deprivation or other stressors, 
such as heat shock and oxidative damage.  
All sirtuins require NAD+ cleavage in their reactions linking their activity to the 
metabolic state of the cell (Landry et al 2000). While not much is known about the 
different functions of each sirtuin – there are key differences. Some of them have 
mono–ADP-ribosyltransferase function instead of or as well as deacetylase 
function, they locate to different subcellular locations, have differing terminal 
segments and different substrates, albeit with some overlap (Carafa et al 2012, 
Haigis & Guarente 2006).  
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1.4 Sirtuin 1 (SIRT1) 
SIRT1 is the closest homologue to the prototype Sir2 in yeast, and is by far the 
most abundant and most studied member of the sirtuin family, to date. Unlike other 
sirtuins, it is functionally vital (Haigis & Sinclair 2010).  
SIRT1 deacetylates histones to silence DNA transcription in times of stress, and to 
allow for chromatin stabilisation or DNA repair (Blander & Guarente 2004, Imai et al 
2000). Histone acetylation is a reversible and highly dynamic modification process 
where histone acetyl transferases (HATs) and histone deacetylase enzymes 
(HDACs) alter chromatin structure thereby controlling transcription and assisting in 
DNA repair (Kurdistani & Grunstein 2003). A major substrate identified for SIRT1 is 
Histone 4 lysine 16 (H4K16). H4K16 is frequently acetylated – present in 
approximately 60% of total H4 in mammals – and represents a pattern of actively 
transcribed euchromatin distinct from other H4 lysine acetylation (Smith et al 2003) 
(Dion et al 2005) with a more specific role in cell cycle control compared to other 
histone acetylations (Megee et al 1995). SIRT1 deacetylates all four histones, but 
preferentially H4K16 where, in a co-ordinated process involving recruitment of other 
molecules, SIRT1 is directly involved in the formation of facultative heterochromatin, 
and indirectly in constitutive heterochromatin (Vaquero et al 2004, Vaquero et al 
2007). Research has also shown that SIRT1 deacetylates H4K16 specifically in 
relation to other deacetylase enzymes (Imai et al 2000), and has a direct effect to 
silence tumour suppressor genes in breast and colon cancer cells where silencing of 
SIRT1 changes phenotypic aspects of these cancer cells (Pruitt et al 2006). 
Furthermore, hypoacetylation of H4K16 has been observed in a number of human 
cancers (Fraga et al 2005), and HDAC inhibitors have been investigated in the 
treatment of a number of cancers, including glioblastoma (Egler et al 2008).  
Research has also revealed many substrates other than histones for SIRT1, a list 
that is still growing. The common thread for all SIRT1 activities is a response to 
stress in the cell to maintain cellular stability and homeostasis, or to switch the cell 
toward a death pathway through programmed cell death, apoptosis. In particular, 
SIRT1 is activated in response to metabolic and hypoxic or oxidative stress 
(Merksamer et al 2013, Salminen et al 2013, Yoon et al 2014). It also has influence 
on the immune and autophagic responses (Hou et al 2010, Lee et al 2008, Yang et 
al 2012, Yeung et al 2004, Yoshizaki et al 2009).  
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SIRT1 is found in the nucleus in most cell types at most times, but can be found in 
the cytoplasm under some conditions, in some cell types (Hisahara et al 2008, 
Sugino et al 2010, Tanno et al 2007). Research into localisation changes for SIRT1 
is relatively new.  
1.5 SIRT1 in metabolism and cell proliferation 
SIRT1 activity is intrinsically linked to the metabolic state of the cell because 
NAD+, a key metabolite, is a coenzyme in the deacetylase function of SIRT1. 
SIRT1 is activated when levels of NAD+ are high, and inhibited when levels of 
NADH are high (Saunders & Verdin 2007). Research evidence supports the theory 
that nutrient availability regulates SIRT1 expression and activity (Chalkiadaki & 
Guarente 2012b) (Kanfi et al 2008) (Rodgers et al 2005). 
SIRT1 deacetylates STAT3, FOXO1 and PGC1a to increase gluconeogenesis 
(Rodgers et al 2005) (Nie et al 2009), but SIRT1 can also down regulate expression of 
genes involved in gluconeogenesis under nutrient deprivation (Liu et al 2008) 
indicating SIRT1 activity is dependent on specific intracellular conditions.  
Additionally, increased SIRT1 activity has been shown to increase mitochondrial 
content, increase energy expenditure and protect against metabolic disease 
(Lagouge et al 2006).  
SIRT1 is implicated in cell proliferation. Most studies have involved cancer cells. 
For example down regulation of SIRT1 inhibits proliferation of breast cancer cells 
(Li et al 2012), and inhibition of SIRT1 blocks proliferation of chronic lymphocytic 
leukemia cells. Contrary to this, increased expression of SIRT1 after resveratrol 
treatment inhibits proliferation of osteoscarcoma and breast cancer cells (Li et al 
2009) (Lin et al 2010). 
Some studies looking at SIRT1’s role in non transformed cells have been done. In 
endothelial cells, SIRT1 promotes proliferation through targeting liver kinase B1 
(LKB1) (Zu et al 2010), and over-expression of SIRT1 increases muscle cell 
precursors proliferation (Rathbone et al 2009). However over-expression of SIRT1 
using resveratrol suppressed proliferation in microglia (Li et al 2015).  
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1.6 SIRT1 in oxidative stress 
There are many complex effects of intracellular reactive oxygen (ROS) species on 
SIRT1 activity and expression. Some well known actions of SIRT1 in oxidative 
stress environment are summarised in Figure 1. 
 
Figure 1. Simplified overview showing cellular substrates and pathways for SIRT1 under 
oxidative stress conditions 
Blue circles represent substrates; orange rectangles show major outcomes for the action of SIRT1 
deacetylation. Black arrows show where deacetylation activates the substrate, black T-lines show 
where deacetylation inhibits the substrate. Abbreviations: ROS = reactive oxygen species; ATM = 
ataxia telangiectasia mutated; Ku70= one part of the Ku heterodimer involved in DNA repair; NFκB 
= nuclear factor kappa B; FOXOs = forkhead box-O transcription factors; p53 = tumour suppressor 
transcription factor; PGC-1α = Peroxisome proliferator-activated receptor gamma co-activator 1-
alpha; P = phosphate. Asterisk* = cell death can occur on these pathways under specific conditions. 
The role of SIRT1 in conditions of oxidative stress is well studied. Central to SIRT1 
role in protection of cells against oxidative stress is the anti-apoptotic response. 
DNA damage or oxidative stress activates SIRT1 deacetylation and attenuates p53 
or Ku70 induced apoptosis (Cohen et al 2004, Kume et al 2006, Luo et al 2001). 
SIRT1 also deacetylates forkhead box-O transcription factors (FoxOs) –studied in 
a variety of cells – to resist oxidative stress by a number of mechanisms including 
increased antioxidant expression, promoting autophagy, diminishing pro-apoptotic 
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responses and increasing expression of DNA repair proteins (Wang et al 2015, 
Zhang et al 2015) (Hori et al 2013) (Brunet et al 2004) (Hariharan et al 2010).  
Under some forms of oxidative stress, SIRT1 inhibits the NFκB transcriptional 
signalling pathway, by deacetylating the p65/RelA component of the NFκB complex 
(Yeung et al 2004) (Liu et al 2011). Depending on the cellular environment, 
inhibition of NFκB can lead to polar opposite outcomes. For example, it can lead to 
reducing inflammatory responses and promote anti-apoptotic gene expression 
(Salminen et al 2008) for cell survival, or it can lead to increased pro-apoptotic 
gene expression and cell death (Kucharczak et al 2003) (Salminen et al 2013).  
SIRT1 expression under oxidative stress in endothelial cells was increased in a 
study where SIRT1, in part, induced cellular senescence (Ota et al 2008) and 
SIRT1 protein expression was increased in human renal cells exposed to H202 
(Hasegawa et al 2008). Oxidative stress can decrease SIRT1 expression in some 
brain cells (Wu et al 2006), and H202 induced a decay of SIRT1 mRNA by the 
Human antigen mRNA binding protein (HuR) in response to check point kinase 2 
(Chk2) (Abdelmohsen et al 2007). Furthermore, degradation or modification of 
SIRT1 is also reported under oxidative stress conditions (Caito et al 2010). Recent 
research shows that under inflammatory conditions, SIRT1 can be cleaved to 
reveal an enzymatically dysfunctional smaller protein which can relocate to 
mitochondria and block apoptosis (Oppenheimer et al 2012). 
Specifically in astrocytes, anti-oxidant neuroprotective functions for SIRT1 have 
been identified by repression of inflammatory cytokines, increased expression of 
anti-oxidants, and deacetylation of FoxO4 transcription factor (Cheng et al 2014).  
The cellular signaling pathways activated during oxidative stress are many and 
varied. Duration, level of exposure and different species of ROS will activate 
different responses in different cell types. Moreover, the signalling pathways that 
are activated or repressed will result in outcomes that affect each other in complex 
systems of cross-talk and feedback. SIRT1 is one of the key regulators involved in 
most, if not all of these pathways, and much is still unknown.  
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1.7 Control of SIRT1  
SIRT1 activity is controlled by the metabolic state of cells, as it requires NAD+ a 
vital metabolite for its enzymatic function (Borra et al 2004). Its own reaction 
product, nicotinamide (NAM) inhibits SIRT1 in a self-regulatory feedback loop 
(Bitterman et al 2002).  
Due to the non-competitive inhibiton of NAM and potent effect, it is used 
extensively to inhibit SIRT1 in experiments in vitro and in vivo (see Figure 2). 
However, its use is not specific. NAM inhibits other sirtuins, in particular SIRT2 
(Giammona et al 2009), and it also inhibits Poly (ADP ribose) polymerase (PARP) 
involved in DNA repair (Avalos et al 2005, Clark et al 1971). NAM also has other 
anti-inflammatory and antioxidative effects (Lappas & Permezel 2011). 
Figure 2. Efficacy of nicotinamide to inhibit SIRT1 activity 
Bar graph from an experiment by Bitterman et al, showing the efficacy of NAM inhibition in 
comparison to synthetic inhibitors sirtinol, splitomicin and M15. TSA is total serum albumin and is 
used as a control. From (Bitterman et al 2002). 
Additionally, SIRT1 is under transcriptional and translational control. The 
transcription factor E2F1 can induce SIRT1 expression, while deacetylation of 
E2F1 by SIRT1 can inhibit its activity (Wang et al 2006). The tumour suppressor 
transcription factor p53 also binds the SIRT1 promoter to decrease transcription 
where SIRT1 also deacetylates and decreases activity of p53, and can attenuate 
p53 transcription in feedback loops (Lynch et al 2010) (Lou et al 2015) (Luo et al 
2001). SIRT1 is reported to also bind to its own promoter to suppress its own 
transcription (Han et al 2010). 
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Changes in SIRT1 protein expression can be controlled in several ways. The micro 
RNA, MiR-34a, binds mRNA for SIRT1, to decrease its translation and expression. 
Additionally, increased MiR-34a will increase stabilization of p53, and p53 
expression can bind SIRT1 promoter to suppress transcription or bind the MiR-34a 
gene increasing transcription of that gene (Raver-Shapira et al 2007). The SIRT1 
transcript can be stabilised by mRNA binding protein HuR, which is disrupted by 
oxidiative stress in HeLa cells (Abdelmohsen et al 2007). 
Activate Regulator of SIRT1 (AROS) activates SIRT1, while Necdin and Deleted in 
Breast Cancer 1 (DBC1) inhibits SIRT1 by binding SIRT1 protein directly (Kim et al 
2007), (Hasegawa & Yoshikawa 2008, Kim et al 2008). Peroxisome proliferator-
activated receptor- γ (PPAR γ) which inhibits cellular proliferation, can bind SIRT1 
directly to suppress its activity or bind to the SIRT1 promoter to suppress 
transcription (Han et al 2010). Resveratrol, a natural compound found abundantly in 
the skins and seeds of grapes, activates SIRT1 when ingested and is used widely in 
experimentation to activate SIRT1 (Howitz et al 2003)} (Sulaiman et al 2010). 
However, it also has other actions within the cell that are not specific to SIRT1.  
In addition to transcriptional control, posttranslational changes to SIRT1 including 
phosphorylation, ubiquitination, and SUMOylation affect SIRT1 activity. There are 
several recognised phosphorylation sites on SIRT1 (Sasaki et al 2008) (Lau et al 
2014). Increased ROS conditions activate c-Jun kinase 1 (JNK1) which 
phosphorylates SIRT1 and activates it in the nucleus to specific target substrates 
(Nasrin et al 2009). However, persistent JNK1 activation in the liver led to 
ubiquitination and degradation of SIRT1 (Gao et al 2011) showing that cell types or 
micro-environmental changes are important to SIRT1 responses. SUMOylation of 
SIRT1 by SENP1 lessens deacetylase activity under stress conditions resulting in a 
lessening of SIRT1s anti-apoptotic response (Yang et al 2007). It may be that multiple 
PTMs on SIRT1 at any one time alters its function according to the microenvironment. 
SIRT1 can change subcellular localisation which also regulates its activity. 
Depending on cell type, state of stress or stage of development, SIRT1 can be 
found in the cytoplasm or nucleus to affect cellular responses for example 
apoptotic responses in response to oxidative stress or differentiation signals (Jin et 
al 2007) (Sugino et al 2010) (Hisahara et al 2008).  
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1.8 SIRT1 splice variants and cleavage products   
Only in the last ten years of research, cleavage and splice variants of SIRT1 have 
been revealed.  
There is little research into the activity of SIRT1 cleavage products. The C and N 
terminals of SIRT1 protein have different functional elements (Pan et al 2012), 
which would be disrupted after cleavage.  
Elevated levels of tumour necrosis factor alpha (TNFα) induces SIRT1 to cleave in 
chondrocytes and draining lymph node cells altering its function (Dvir-Ginzberg et 
al 2011) (Gardner et al 2015) and high fat diet induces cleavage of SIRT1 in 
adipose tissue contributing to metabolic dysfunction (Chalkiadaki & Guarente 
2012a). Altered gene expression was observed after SIRT1 cleavage (Dvir-
Ginzberg et al 2011). Cleaved SIRT1 75kDa fragment blocked apoptosis in 
osteoarthritic chondrocytes (Oppenheimer et al 2012), and cleaved SIRT1 moved 
to the cytoplasm from the nucleus in apoptotic HeLa cells (Ohsawa & Miura 2006). 
Cleavage of SIRT1 in endothelial progenitor cells mediated premature senescence 
(Chen et al 2012b). 
The first splice variant of SIRT1, SIRT1-Δ8, was reported five years ago in a range 
of human tissue indicating evolutionary conservation (Lynch et al 2010). SIRT1-Δ8 
showed altered function including association with p53. Interestingly, p53 controlled 
the expression of this variant isoform of SIRT1. A second splice variant of SIRT1, 
SIRT1-Δ2/9 was also found even more recently- also in a range of human 
tissue(Shah et al 2012). This variant also associated with p53 opposing the function 
of full-length SIRT1 indicating a role of SIRT1 in malignancy (Shah et al 2012). 
1.9 SIRT1 and cancer 
It remains unclear whether SIRT1 is a tumour suppressor or promoter. Much 
research into this area is being carried out recently due to the likelihood for a 
SIRT1 role in initiation and progression of cancer mainly due to its function to 
stabilise chromatin in times of DNA stress (Lee et al 1999, Martin et al 1999), but 
also due to SIRT1 involvement in apoptosis, autophagy and senescence (Broadley 
et al 2011a, Huang et al 2014, Luo et al 2001). Additionally, SIRT1 is involved in 
stress resistant pathways therefore it may be involved with maintaining cancer cells 
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under stress within the tumours and promoting drug treatment resistance. SIRT1 
plays a role in pathways central to cancer etiologies including glycolysis and 
differentiation (Tiberi et al 2012) (Ghosh et al 2010, Mantel et al 2008), and it binds 
to or deacetylates many molecules that are closely linked to cancer. 
However, research shows SIRT1 can be either promoting or suppressing cancer, for 
example, recent studies have shown a correlation with SIRT1 expression and poor 
disease prognosis in breast cancer (Cao et al 2015) and a high level of SIRT1 is 
seen as a negative prognosticator for pancreatic cancer (Stenzinger et al 2013); yet 
no correlation with SIRT1 expression is found in hepatocellular carcinoma or 
cholangiocarcinoma progression (Al-Bahrani et al 2015). SIRT1 expression is 
elevated in some cancers compared to the normal tissue, for example in acute 
myloid leukemia, primary colon cancer and non-melanoma skin cancers (Bradbury 
et al 2005) (Stuenkel et al 2007) (Hida et al 2007); yet SIRT1 expression is reported 
to be decreased in other cancers compared to normal tissues for example in bladder 
(Sanchez-Carbayo et al 2006), and ovarian cancers (Hendrix et al 2006). 
Moreover, SIRT1 expression data from different studies of the same cancer don’t 
always agree – in one prostate cancer study SIRT1 expression is elevated 
(Huffman et al 2007) and in another it is reduced (Lapointe et al 2004). SIRT1 
appeared benign in hepatocarcinoma progression in one study (Al-Bahrani et al 
2015) while other studies have shown that inhibiting SIRT1 and cortactin in 
prostate cells attenuated migration and metastasis (Nakane et al 2012) and 
transgenic overexpression of SIRT1 in mice with PTEN deficiency promotes thyroid 
carcinogenesis (Herranz et al 2013). It may be that SIRT1 has different roles at 
different stages of cancer. 
It is also unclear whether increased SIRT1 expression occurs before onset or as a 
consequence of malignancy. Examples include the overexpression of nicotinamide 
phosphoribosyltransferase (NAMPT) in prostate cancer which may increase SIRT1 
expression and activity (Wang et al 2011), and a study of lung cancer found SIRT1 
activity increased in airway epithelium of smokers but not in non-smokers, yet 
SIRT1 activity was significantly decreased in lung adenocarcinoma (Beane et al 
2012). This last example indicates a protective role of SIRT1 in lung cancer, and is 
reflected in another more recent study where repression of SIRT1 transcription 
contributes to lung cancer metastasis (Sun et al 2013). 
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1.10 SIRT1 in glioblastoma   
There is not much SIRT1 research in association with GBM, but in the last few 
years more research has looked into SIRT1 because treatment options for GBM 
have highlighted the need to target survival and apoptotic pathways (Krakstad & 
Chekenya 2010), which is central to the role of SIRT1.  
SIRT1 knockdown in glioma cell lines found inhibited growth and proliferation, and 
increased apoptosis strongly indicating a role of SIRT1 in progression of GBM, 
through the PTEN/PI3K/AKT signaling pathway (Qu et al 2012). FOXM 
transcription factor, reported to be a central regulator of glioma cell proliferation 
and tumour progression, was found to positively regulate SIRT1 expression in 
another study using glioma cell lines, suggesting SIRT1 plays a role in glioma 
tumour progression (Zhu et al 2014). 
SIRT1 is likely to play a role in GBM due to its importance in growth signaling (Lu 
et al 2013) in particular through activated PI3K/AKT signaling which is commonly 
abherently over-activated in GBM (Narayan et al 2013). This pathway involves five 
or six transcription factors all of which are substrates for SIRT1 deacetylation 
(Sundaresan et al 2011) (Ikenoue et al 2008). However, although SIRT1 
contributes to the activation of AKT signaling in some circumstances (Pillai et al 
2014), it can also ameliorate the effects of hyperactive signaling along this pathway 
(Salminen et al 2008), highlighting the need to elucidate the role of SIRT1 in GBM. 
Aerobic glycolysis, an alternative metabolic pathway, is often seen in cancer cells 
and is apparent in glioblastoma (Oudard et al 1996) (Zhou et al 2011). Additionally, 
glycolysis appears to support invasion in glioblastoma (Beckner et al 2005). 
However, there is some research to show that “stem cells”, the cells that 
regenerate tumours after treatment in glioblastoma, are not driven by glycolysis 
(Vlashi et al 2011). The role of SIRT1 in glycolysis is not determined.  
Radio-chemoresistant glioblastoma cell clones adapted metabolically to reduced 
glucose dependence had increased cellular NAD+ and SIRT1 expression (Ye et al 
2013), further indicating that SIRT1 may be involved in tumourigenesis in GBM. 
However another study found SIRT1 activation was in part responsible for the 
effective treatment of temozolomide’s anti-tumour effects on glioma cell lines 
(Jiang et al 2012).  
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Conflicting evidence for SIRT1 in cancer highlights the likely different activities of 
SIRT1 after different treatments, and probably for different stages or areas of the 
tumour. In fact it was found that glioblastoma cells categorised by the World Health 
Organisation (WHO) grade I-III have increased SIRT1 compared to normal brain 
tissue, however WHO grade IV had comparatively decreased SIRT1 (Annabi et al 
2012).  
1.11 Aims of this research 
Glioblastoma treatment options have remained limited for many years, with 
prognosis for patients very poor. Glioma cells remain resistant to treatment, and 
recurrence of the disease is usual. SIRT1 is a key regulator of stress response in 
cells, and intimately involved in metabolism, development, and the autophagic and 
apoptotic responses, while research into the role of SIRT1 in glioblastoma is very 
limited, it is likely to have a role in this disease. The aim of this research is to 
investigate the differences between glioma and normal astrocyte cells in a mouse 
culture model and primary human glioma compared to normal human astrocytes to 
look for differences in SIRT1 – in expression, activity, and under oxidative stress. 
The cell lines chosen for this research were the immortalised murine cell lines 
GL261, a glioma model cell line, which was compared to the immortalised normal 
murine astrocyte cell line, C8D1A. In the human model, cell lines established from 
cells taken during resection of tumours in patients with GBM WHO Grade IV, and 
results from these cells were compared to SVGp12, an immortalised human 
astrocyte cell line. 
Astrocytes are the most abundant cells in the central nervous system (Cheng et al 
2014) and are important in oxidative and cytotoxic stress conditions (Bresgen et al 
2006). Moreover, glioblastoma derives from astrocytes which is why astrocytes are 
the normal comparison cell used in this study. 
The focus has been threefold:  
1. Comparison of basal expression levels of SIRT1, localisation, and its 
deacetylation activity on histone 4 (H4K16) between  
a. Murine cell lines of glioma (GL261) compared to normal astrocytes 
(C8D1A) and; 
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b. Human primary glioma cells taken from patient tumours compared to 
the normal astrocyte cell line taken from embryonic origin (SVG p12) 
2. Investigating the role SIRT1 may have in proliferation for the same cells as 
stated above, and  
3. Investigating the role SIRT1 may have under oxidative stress in the same 
cells as stated above. 
For the purposes of this thesis, SVG p12 cells are referred to as SVG, hSIRT1 is 
used when referring to human cells, Sirt1 for mouse cells, and SIRT1 when 
discussing the enzyme generically. 
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Part 2:  Materials and Methods 
2.1 Cell culture 
2.1.1 Cell lines  
Murine cell line C8D1A, the human cell lines SVGp12 and the human glioblastoma 
cell line LN18 were obtained from the American Type Culture Collection, 
(Rockville, MD, USA), http://www.atcc.org/. HeLa cells were a kind gift from An 
Tan, Malaghan Institute of Medical Research The murine glioma cell line, GL261, 
was obtained from DTTD Tumour Repository, National Cancer Institute (National 
Institute of Health, USA). 
Human primary cells were from glioblastoma tumour tissue obtained under 
informed consent and isolated as described by Broadley et al (Broadley et al 
2011b), approved by Central Regional Ethics Committee, Ministry of Health from 
patients, CEN/09/06/037, 2009. Patients were all diagnosed with glioblastoma 
(GBM WHO Grade IV), both male and female, aged 34–77 years. Available patient 
data is presented in Table 1.   
Table 1. Patient data for human primary glioma cell lines  
 
Human	primary	
glioma		
cell	line	
	
Age	at	
resection	
(years)	
	
Gender	
	
Survival	
(months)	
705	 34	 F	 34	
902	 38	 M	 26	
1005	 42	 M	 16	
813	 47	 M	 34	
903	 47	 F	 -	
906	 57	 F	 8	
804	 61	 M	 10	
804	 61	 M	 10	
711	 62	 M	 13	
905	 64	 F	 17	
713	 65	 M	 33	
816	 65	 M	 23.5	
803	 67	 F	 5	
708	 70	 M	 10	
907	 77	 F	 12.5	
801	 	 	 10	
815	 	 	 26	
817	 	 M	 16	
1011	 	 	 12	
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2.1.2 Cell culture hardware 
Cells were grown in T25 and T75 flasks, 150 mm tissue culture dishes and 6-, 12- 
and 96-well plates supplied by Falcon (BD Biosciences, San Jose, CA). Serological 
pipettes were from by BD Biosciences. Pipette tips (Axygen, Union City, CA) were 
sterilised by autoclaving at 121°C for 20 min.  
2.1.3 Cell culture media 
Human primary glioma and SVG cells were grown in RPMI-1640 (Invitrogen, 
Carlsbad, CA) supplemented by 10% heat inactivated foetal bovine serum (Sigma 
Aldrich, St Louis, MO), 100 Units/mL penicillin, 100 μg/mL streptomycin (supplied as 
a combined supplement by Gibco (Invitrogen). Murine cell line C8D1A was grown in 
DMEM with 10% heat inactivated FBS (Sigma Aldrich) and GL261 were grown in 
both 10% and 20% FBS separately. Both murine cell lines were supplemented by 
penicillin/streptomycin in the same way as for the human cell cultures.  
2.1.4 Cell culture 
All cells used in this study grew as adherent cultures. 
Cells were passaged between 70–90% confluency, with passage number not 
exceeding 25. To passage cultures, cells were rinsed with phosphate buffered 
saline (PBS) (Invitrogen) incubated at 37°C with trypsin-EDTA (0.05%, Invitrogen) 
for 3–10 min, followed by resuspension of a reduced number of cells in media – 
unless more culture dishes were needed – where cells were plated back out into 
several culture dishes. All cultures were grown in HERAcell incubators (Thermo 
Scientific, Waltham, MA) at 37°C, in humidified air with 5% CO2. Handling of cells 
for culture and treatment was performed under sterile conditions in a Class II 
Biological Containment Hood (Herasafe, Heraeus, Germany). Cell counting was 
performed using trypan blue with a Neubauer heamocytometer (Weber Scientific, 
Hamilton, NJ). Regular checks were made to ensure cultures were mycoplasma 
free using e-Myco mycoplasma PCR detection kit (iNtRon Biotech, Korea). All 
cells were harvested in the log phase of growth. 
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2.1.5 Storage of cells 
For long-term storage, cells were stored in cryotubes (Greiner Bio-one, Belgium) 
with 10% v/v dimethylsulfoxide (Sigma Aldrich)/media in the vapour phase of liquid 
nitrogen. Cells were slowly cooled using a controlled rate cooler to -80°C then 
transferred to liquid nitrogen. To recover cells from liquid nitrogen, cells were 
thawed in a 36°C waterbath, transferred to pre-warmed media for one day, and 
then the media was replaced. 
2.1.6 Cell harvesting  
To harvest cells, media was removed, cells were rinsed with PBS and trypsin-
EDTA (0.05%) was applied. Cells were incubated with trypsin-EDTA for a few 
minutes until cells lost their adhesion to the plate, then media was added to reduce 
the concentration of trypsin-EDTA, followed by centrifugation at 736 g for 5 min, 
then rinsed and resuspended in PBS and centrifuged again as before. 
2.2 Protein extraction and western blotting 
2.2.1 2.2.1 Whole cell extraction 
For whole cell extraction, at least 1x106 cells were rinsed with PBS, released from 
culture dishes with trypsin-EDTA, and washed twice with PBS. Centrifuge and 
microcentrifuge speeds and times for the washing steps were 736 g for 5 min, and 
1,073 g for 4 min respectively. PBS was removed by pipette and 20-70 μL Lysis 
Buffer (see Section 2.3.1) and Protease Inhibitor – either Roche Diagnostics 7x 
(Basel, Switzerland Product no.04693159001), or HaltProtease inhibitor Cocktail 
100x (Thermo Scientific Product No. 78410) was added to the pellet and pipetted 
up and down for at least 20 times. Following incubation in Lysis Buffer for 1 h on 
ice, the lysate was centrifuged at 11,337 g for 5 min and the supernatant carefully 
removed with a pipette and transferred to a clean microfuge tube. 
The protein yield was measured using a Bradford DC protein Assay Kit (Bio-Rad, 
Hercules, CA) with absorbances measured at 750 nm (Versamax MicroPlate reader, 
Molecular Devices Pty Ltd, with SOFTmax PRO 4.0 software) against a standard 
curve generated from bovine serum albumin (BSA). Lysates were suspended in 2x 
or 6x sample loading buffer depending on how much quantity was extracted before 
heating to 90°C or 35°C for 5 min and then stored at -80°C. The different 
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temperatures were used as it was found 90°C affected the quality of SIRT1 protein. 
Unless stipulated in Figure legends, the temperature used was 35°C. 
2.2.2 Histone extraction 
At least 2x106 cells were washed with ice cold PBS, released from the culture dish 
by trypsin-EDTA and washed with PBS. PBS was pipetted off the cell pellet 
followed by resuspension of cells in 1mL ice-cold Histone Extraction Buffer 
(Section 2.3.2) and centrifuged at 2000 g for 15 min. The buffer was removed and 
the pellets were washed four times by resuspending in Histone Extraction Buffer 
and centrifugation. The washed pellet containing nuclei was resuspended in 100 
μL Tris-EDTA solution (0.01 M Tris-HCl, 0.13 M EDTA, pH 7.4), with addition of 1.1 
μL/100 μL H2SO4 (BDH Aristar ® Plus, BDH Chemicals, Radnor, PA) followed by 
vortexing and incubation for 3 h at 4°C. Supernatant was collected after a 15 
minute centrifugation at 11,337 g followed by addition of 1 mL acetone and 
incubation at 4°C overnight. Precipitated material was collected by centrifugation at 
11,337 g for 15 min, and washed once in 1 mL acetone. Acetone was completely 
removed and the powder was air dried for 5 min, then resuspended in 20-50 μl TE 
buffer (0.028 M Tris, 0.037 M EDTA, pH 6.9). Protein was measured as described 
in Section 2.2.1, then 2x or 6x loading buffer was added before heating at 95°C for 
5 min and storage at -20°C. 
2.2.3 Nuclear and cytoplasmic extracts 
Nuclei- and cytoplasm-enriched fractions were isolated using two methods. Both 
fractions were expected to be partial purifications, contaminated by other 
organelles. Measurements for purity were included.  
Method one 
After Andrews and Faller, 1991 Premade buffers A and B were stored at 4°C 
(Section 2.3.6). Protease Inhibitor 7x (Roche Diagnostics) or 100x (Thermo-
Fisher), and Triton X-100 (for Buffer B) were added on the day of extraction. At 
least 3 x 106 cells were washed once with ice cold PBS, and then harvested by the 
standard method (Section 2.1.6). Between 0.2-1 mL Buffer A (for 1-8 x 106 cells) 
was added to the cell pellet and pipetted up and down gently, and left at room 
temperature (RT) for 10 min. A cytosolic fraction was collected as the supernatant 
after centrifugation at 11,337 g at 4°C for 6 min, and kept on ice before protein 
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quantification and storage. Between 50-300 μL (1-8 x 106 cells) Buffer B was then 
added to the remaining pellet, and resuspended thoroughly by pipette, followed by 
vortexing for 10 sec. The pellet was continuously rotated at 4°C for 20 min. The 
nuclear fraction was collected in the supernatant after centrifugation at 11,337 g at 
4°C for 10 min.  
Method two 
NE-PER® Nuclear and Cytoplasmic Extraction Kit (Pierce, Thermo-Scientific) 
The manufacturer’s instructions were followed. Briefly, at least 2 x 106 cells 
harvested using trypsin-EDTA were washed twice with PBS and after 
centrifugation at 736 g for 5 min, PBS was removed carefully, and for each 40 μL 
packed cells, 200 μL ice-cold CER I solution was used to resuspend the pellet, 
followed by vortexing and incubation on ice for 15 min. Next, 11 μL ice-cold CER II 
was added followed by vortexing and incubation on ice for 1 min. Then, vortexing 
followed by centriguation at 16,000 x g the supernatant (cytoplasmic fraction) was 
removed and stored on ice. The pellet was rinsed in PBS twice, then resuspended 
in ice-cold 100 μL NER, vortexed and held on ice for 10 min. This was repeated 
four times, followed by centrifugation at 16,000 x g for 15 min to obtain the nuclear 
fraction in the supernatant. Where fixation of cells was used before extraction, cells 
were fixed in 1% v/v formaldehyde in the culture dish at RT for 10 min and 0.125 M 
glycine was then added and left for 5 min, followed by washing with PBS two times.  
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2.2.4 SDS electrophoresis 
Ten percent acrylamide SDS gels were used for electrophoresis of non-histone 
proteins, 15% acrylamide SDS gels were used for electrophoresis of histones. 
Each gel was made with a 4% resolving gel. The reagents and solutions were: 
10% SDS acrylamide running gel  
0.454 M Tris pH 8.8 
 0.347 M SDS 
10.5% acrylamide solution (N,N’methyl acrylamide) electrophoresis reagent, (BioRad)  
2.2 mM ammonium persulphate  
0.05% v/v TEMED (BioRad) 
15% SDS acrylamide running gel 
0.454 M Tris pH 8.8,  
0.347 M SDS,  
15% acrylamide solution 
2.2 mM ammonium persulphate 
0.05% v/v TEMED 
Resolving gel 
0.125 M Tris pH 6.9 
6.9 mM SDS 
3.9% acrylamide solution 
2.2 mM ammonium persulphate 
0.1% TEMED 
Gels were mounted into a Bio-Rad Mini-PROTEAN Tetra Cell gel box, and cold 
Running Buffer (Section 2.3.4) was added to the chamber. Between 25-100 μg 
whole cell lysate, 2-5 μg histone, and 10-15 μg nuclear and cytoplasmic fractions 
were loaded into each well. Unless stated in figure legends, equal amounts of 
protein was loaded into each well for the same blot. Precision Plus Protein™ All 
Blue standard (Bio-Rad) or PageRuler™ Prestained Protein Ladder (Thermo 
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Scientific) were used for molecular weight markers. Electrophoresis was at 190 V 
for 1 h.  
2.2.5 Western blot transfer 
After gel electrophoresis, the protein was transferred to polyvinylidene difluoride 
(PVDF) (BioRad) using a BioRad Criterion™ Blotter gel box. PVDF membrane was 
hydrated with 100% methanol and then equilibrated in freshly made chilled Transfer 
Buffer (Section 2.3.5) for 5–10 min. Gels were equilibrated in cold Transfer Buffer 
also, and then the gels were covered with PVDF, placed between sponges and filter 
paper which had been fully pre-soaked in Transfer Buffer, and sandwiched tightly in 
a cassette. The transfer was for 2 h at 300 mA. PVDF membranes were dried and 
stored at RT, or used immediately for antibody probing. 
2.2.6 Antibody probing 
After transfer, PVDF membranes were rehydrated and blocked for 1 h by rocking at 
RT in either 3% w/v non-fat milk (Anchor, New Zealand) dissolved in PBS. 
Following blocking, membranes were rocked for 1.5 h at RT, or overnight at 4ºC in 
a milk/PBS solution containing the primary antibody (Table 2). The membrane was 
then washed three times in PBS, and left to soak in PBS for five min, after which 
the membrane was rocked in a milk/PBS or BSA/PBS solution containing 
secondary antibody conjugated to horseradish peroxidase (Table 3) for 1.5 h at 
RT. Following the secondary antibody probe, membranes were washed three times 
with PBS and left to soak in PBS with 0.02% Tween 20 for 5 min, and rinsed three 
more times with PBS.  
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Table 2. Primary antibodies used in Western blotting 
Table 3. Secondary antibodies used in Western blotting 
 
2.2.7 Amido Black staining, Stripping Buffer, and chemiluminescence 
Amido Black solution 
Amido Black staining (0.1 g/mL Naphthol Blue Black, 7.5% v/v glacial acetic acid, 
20% v/v methanol) of PVDF membranes was used as a protein loading measure 
during histone acetylation analysis. Membranes were rocked with Amido Black 
solution for 2 min, rinsed in ethanol and left to dry before scanning to make an image. 
Antibody  Source and type Concentration used 
Anti-SIRT1 H(300)  
SC 15404 
Santa Cruz Biotechnology 
(Dallas, TX) 
Rabbit, polyclonal 
IgG 
0.2-0.4 g/mL 
Anti-SIRT1 [SIRII] 
ab 50517 
 
Abcam (Cambridge, UK) 
Sapphire Biosciences,  
Mouse, monoclonal 
C terminal aa 722-737 
 
0.575 g/mL 
Anti--actin 
A5441 
Sigma-Aldrich 
Mouse monoclonal 
1:100,000 
 
Anti-Lamin A/C 
orb18081 
Biorbyt 
(Cambridge, UK) 
Rabbit polyclonal 
1 g/mL 
-tubulin 
SAB4500087  
Sigma-Aldrich 
Mouse monoclonal 
1:5000 
 
Anti-acetyl-Histone  
H4 (Lys 16) 
07-329 
Merck Millipore 
(Billerica, MA) 
Rabbit polyclonal 
0.75 g/mL 
Antibody  Source and type Concentration used 
Goat Anti-rabbit HRP 
Sc 2004 
Santa Cruz Biotechnology  
IgG 
0.25 g/mL 
Goat Anti-mouse HRP 
Sc 2005 
Santa Cruz Biotechnology  
IgG 
0.25 g/mL 
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Chemiluminescence  
Enhanced Chemiluminscence (ECL) Western Blotting Substrate (Pierce, Thermo 
Scientific) was used to detect horseradish peroxidase activity, which corresponds 
to quantity of antibody bound to the membrane and therefore protein levels in the 
lysate. Where there were low levels of protein, Western Lightning Ultra (Perkin 
Elmer, Waltham, MA) was used. 
Stripping Buffer  
When stripping of membranes was required, membranes were rocked at RT in 
stripping buffer (Restore™Western Blot Stripping Buffer) (Thermo Scientific) for 
10–15 min. 
2.2.8 Western blot imaging 
Scanned images from film developed using a Kodak X-OMAT 1000 film processor, 
or a GelLogic 4000 Pro imaging system (with Carestream software) were analysed 
using Image J software (Schneider et al 2012). To adjust for loading differences, a 
housekeeping protein, β-actin, was used for whole cell extracts and lamin B or 
lamin A/C and α-tubulin were used for nuclear/cytoplasmic extracts, respectively. 
Image J ‘gel analysis’ was used to measure the area under the curve generated 
from the electronic measurement of band density. Where measurements across 
different gels were made, one sample was used for the reference point. This 
sample was used across the gels and adjusted to 1, and other bands from samples 
were expressed as a fraction of this (Figure 3). 
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Figure 3. Example of analysis of protein bands using Image J analysis 
(A) Electronic image from HRP- generated fluorescence using a membrane immunoblotted with 
SIRT1 and -actin. (B) Image J gel plots of bands shown in A. (C) Tabulated measurement of area 
under the curves in B, measured in Image J. All measurements used in analysis were adjusted to 
take into consideration of loading differences.  
 
2.3 Buffers  
2.3.1 Lysis Buffer 
0.14 M NaCl  
0.05 M Tris  
1% v/v Triton X-100  
0.1% w/v SDS  
pH 8.5  
7x Protease Inhibitor (Product No. 78430) (Thermo-Fisher Scientific)  
 
  Full-Length 
SIRT1 
Full-Length  
SIRT1 adjusted 
β-actin β-actin 
adjusted 
Relative  
difference 
1 3785 1 2842 1 1 
2 1173 0.31 2800 0.99 0.32 
3 2257 0.60 1900 0.67 0.89 
A B 
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2.3.2 Histone Extraction Buffer 
0.01 M Tris 
0.023 M MgSO4.6H2O  
0.25 M sucrose  
0.05% v/v Triton X-100 
2.3.3 Sample Loading Buffers (Laemmli Buffers) 
SDS Sample Buffer 2x 
0.124 M Tris-Cl pH 6.8  
20% v/v glycerol  
4% w/v SDS  
0.2% v/v 2-mercapthoethanol  
0.05% w/v bromophenol blue 
SDS Sample Buffer 6x  
0.375 M Tris-Cl pH 6.8 
60% v/v glycerol  
12% w/v SDS 
9.3% w/v dithiothreitol (DTT)  
0.06% w/v bromophenol blue  
2.3.4 2.3.4 SDS gel electrophoresis Running Buffer 
0.025 M Tris 
0.192 M glycine 
0.0173 M SDS 
pH 8.3 
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2.3.5 Western blot Transfer Buffer 
0.025 M Tris 
0.192 M glycine 
10% v/v methanol  
2.3.6 Nuclear cytoplasmic Extraction Buffers 
Buffer A 
10 mM HEPES (pH 7.9)  
10 mM KCL (Scharlab, Spain) 
0.1 mM EDTA 
7x protease inhibitor (Roche Diagnostics) 
Buffer B 
20 mM HEPES (pH 7.9)  
0.4 M NaCl  
1 mM EDTA 
10% v/v glycerol 
2.3.7 Flow Cytometry (FACS) Buffer 
HBSS buffer (Gibco) 
2% v/v heat-inactivated FBS 
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2.4 Immunofluorescent staining 
2.4.1 Fixation and staining 
Cells were seeded on sterile Lab-Tek 8-well chamber slides at a density of  
6-8,000 cells per well, with 300 μL media, and left for 48 h before treatment or fixation.  
Fixation of cells was preceded by removal of media followed by two gentle washes 
with warmed PBS, and then drained well. Freshly made paraformaldehyde (PFA) 
(see Section 2.4.3) was applied to cover the cells, and left at RT for 10 min. Cells 
were washed twice with PBS, followed by permeabilisation using PBS with 0.2% 
Triton X-100 (Sigma-Aldrich) for 3 min at RT. Cells were then rinsed four times 
over 5 min with PBS, and incubated for 1 h with primary antibody buffered in 3% 
w/v bovine serum albumin in PBS solution, with enough liquid to cover the cells. 
After incubation with the primary antibody, cells were washed with PBS two times, 
and once with PBS/0.02% Triton X-100 over five min. Cells were then incubated 
with fluorescent-labelled secondary antibodies in 3% w/v BSA in PBS at RT, in the 
dark, for 40 min, followed by two rinses with PBS and one rinse with PBS/Triton  
X-100 over 5 min. Isotype or secondary-only controls were included (Tables 4–5).  
Table 4. Primary antibodies for immunofluorescent staining 
 
Antibody Source and Type Concentration Used 
Goat anti-Sirtuin 1 
EB10826 
Everest Biotech 
(Ramona, CA) 
Aa 577-590 
10 g/mL 
Anti-SIRT1 [SIRII] 
ab 50517 
Abcam 
Sapphire Biosciences,  
Mouse monoclonal, IgG 
aa 722-737 
4.6 g/mL 
Anti-SIRT1 H(300) 
SC 15405 
Santa Cruz Biotechnology 
Rabbit polyclonal, IgG 
Aa 448-747 
4 g/mL 
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Table 5. Secondary antibodies for immunofluorescent staining 
 
2.4.2 Microscopy 
Microscopy was carried out using an Olympus BX51 immunofluorescence 
microscope (Olympus Optical Co. Ltd, Tokyo, Japan,) with an Olympus DP70 
camera and Olympus LS Research software. 
2.4.3 Paraformaldehyde solution 
4% w/v paraformaldehyde  
1x PBS 
The above reagents were added to a conical flask with a few drops of 5 M NaOH, 
vortexed and fully dissolved in a water bath at 55-65°C for 30 min or until clear. 
The solution was left to adjust to RT before using. 
2.5 Mitochondrial staining  
MitoTracker ® Green FM (Invitrogen) was dissolved in anhydrous dimethyl 
sulfoxide to a concentration of 1 mM. A solution of 150 nM MitoTracker ® Green 
FM in media was applied to cells and left for 1.5 h at 37°C. 
Antibody Source and type Concentration used 
Goat anti-rabbit Alexa 
Fluor 488  
A11608 
Invitrogen 
IgG 
10 g/mL 
Goat anti-mouse Alexa 
Fluor 488 
A11001 
Invitrogen 
IgG 
10  g/mL 
Goat anti-rabbit Alexa 
Fluor 647 
A21244 
Invitrogen 
IgG 
10  g/mL 
Goat anti-mouse Alexa 
Fluor 647 
A21235 
Invitrogen  
IgG 
10  g/mL 
Rabbit anti-goat  
CF488A 
Biotium  
(San Francisco, CA) 
IgG 
10  g/mL 
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2.6 Intracellular staining and measurement by flow cytometry 
To measure levels of SIRT1 by flow cytometry, intracellular staining was 
performed. Approximately 1x106 cells were harvested as described in Section 
2.1.6. Cells were transferred to a round-bottom 96-well plate and rinsed once in 
PBS (200 μL per well), followed by centrifugation at 2080 x g for 2 min. To remove 
fluid from wells after centrifugation, plates were flicked once and fluid was removed 
by inversion of the plate. Cells were resuspended in the viability dye, LIVE/DEAD® 
Fixable Blue (Invitrogen), using a dilution of 1:500 in PBS (50 μL per well), and 
incubated on ice in the dark for 20 min. Cells were centrifuged and rinsed twice 
with PBS. Fixation and permeabilisation was carried out using BD 
Cytofix/Cytoperm™(BD Biosciences). All antibodies were diluted in Perm/Wash 
Buffer. SIRT1 primary antibody, Sc15404 (see Table 2, Section 2.2.6), was used at 
a concentration of 0.4 μg/mL and incubated on ice, in the dark, for 20 min, followed 
by two washes with Perm/Wash Buffer. The secondary antibody, goat anti-rabbit 
(Alexafluor ® 647, A21244) (Table 5, Section 2.4.1), was used at a concentration 
of 5 ng/mL and incubated on ice, in the dark, for 30 min, followed by two washes 
using 1x Perm/Wash.  
Cells were suspended in a FACS buffer (Section 2.3.7) acquired using a BD LSR-II 
and FACSDiva software. Between 5,000–10,000 cells were collected. Data were 
analysed using FlowJo 9.5.2 software (Tree Star). Background fluorescence, 
compensation and non-specific binding were controlled for using the isotype 
control anti-dansyl rabbit IgG antibody (A-6398, Invitrogen). 
2.7 MTT Assay 
In this assay, the yellow tetrazole, MTT (3-(4,5-dimethylthiazol-2-yl)-2,5–
diphenyltetrazolium bromide), is reduced to a purple formazan in living cells. The 
formazan is insoluble, and therefore an SDS Lysis Buffer (10% w/v sodium dodecyl 
sulphate (SDS), 45% v/v N-N-dimethylformamide, adjusted to pH 4.7 using glacial 
acetic acid) is used to dissolve these crystals so that an absorbance reading can 
be made. The reduction of MTT depends on the presence of active reductase 
enzymes so the results reflect metabolic activity of the cells (Berridge & Tan 1993).  
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Cells were seeded at 5000 cells per well in 100 μL of media, in 96-well plates. After 
24 h, cells were treated with fresh media with appropriate concentrations of 
treatment chemicals prepared in media en masse. The media was also replaced 
for untreated control cells. Control wells with media alone, or media with treatment 
alone, were included. At 48 h after seeding (day one of treatment) and 96 h (day 
3), MTT was added at 2.5 mg/mL suspended in HBSS buffer (Gibco). After 2 h 100 
μL SDS Lysis Buffer was added to every well. When the wells had no bubbles, 
absorbances were measured at 570 nM using a FLUOstar OPTIMA Microplate 
Reader (BMG LABTECH, Ortenberg, Germany). Control absorbance values for 
media with or without treatment were subtracted from values for the equivalent 
wells with cells. 
2.8 Oxidative stress 
2.8.1 Hydrogen peroxide 
The concentration of the stock hydrogen peroxide (AnalaR grade, BDH/Merck, 
Poole, England) was determined by spectrophotometry at 240 nm using a molar 
extinction coefficient of 43.6 M-1cm-1. Cells were seeded and left for 24 h before 
treatment. For treatment, media was removed and replaced with fresh media with 
H2O2 at the desired concentration, and this remained until cells were harvested. 
Concentrations of H2O2 used for each cell line were determined by establishing 
viability titration curves and propidium iodide exclusion assay (Section 2.10). 
Untreated control cells were always measured at the same time as treated cells. 
2.9 Inhibition and activation 
2.9.1 Inhibitor 
Nicotinamide (NAM) (Sigma Aldrich) at concentrations of 1 and 10 mM was used 
as an inhibitor for SIRT1. After leaving cells for 24 h after seeding, the desired 
concentration of NAM was added to cultures and remained until cells were 
harvested.  
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2.9.2 Activator 
Resveratrol (RES) (Sigma Aldrich) at concentrations of 10, 25 and 50 μM was used 
as an activator for SIRT1. Working stock of RES was dissolved in 100% ethanol 
and stored for up to 6 weeks. After leaving cells for 24 h after seeding, the desired 
concentration of RES was added to cultures, which remained until cells were 
harvested.  
2.10 Measurement of cell death  
To measure cell death, a propidium iodide (PI) (BD Biosciences) exclusion assay 
was used. Cells were grown for 24 h before treatment, and harvested when they 
were in exponential growth (untreated cells 60-85% confluence). All cells were 
collected and subjected to the standard wash (Section 2.1.6). A concentration of 
0.5 μg/mL PI suspended in FACS Buffer (Section 2.3.7) was added to the cell 
pellets and, after 15 min incubation, PI exclusion was measured by flow cytometry. 
Between 5,000–10,000 cells were analysed using BD FACSCalibur (BD 
Biosciences), and CellQuest Pro software (BD Biosciences). Data were analyzed 
using FlowJo 9.2 software (Tree Star, Ashland, OR). 
2.11 Statistical Analysis 
All statistical analysis was performed using Prism Graphpad version 5.0 and 6.0 
software (CA, USA). P values were generated using linear regression, one-way 
ANOVA with Tukey or Sidak’s multiple comparison post test, unpaired Student t-
test and values of P < 0.05 were considered significant. 
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Part 3:  Results – Basal Levels 
Exploring the potential role of SIRT1 in untreated glioma and normal 
astrocyte cells  
It has not been established if SIRT1 acts as a tumour promoter or tumour 
suppressor in glioblastoma. In this study, C8D1A and GL261 murine astrocyte cell 
lines were used as a model for glioblastoma. GL261 cells lines are a transformed 
cell line used as a model for glioblastoma, as it closely resembles the pattern of 
human glioblastoma when implanted in the brain of a mouse (Newcomb 2009), 
while C8D1A cells are used as the normal murine astrocyte comparison cell line. In 
the human model, SVG – a normal human astrocyte cell line was used as a 
comparison to primary glioma cells obtained from patient tumours.  
To begin investigating the role of SIRT1 in glioblastoma, basal levels of SIRT1 
were measured by Western blotting.  
3.1 SIRT1 levels in murine and human glioma and normal 
astrocyte cells 
3.1.1 Levels of Sirt1 in untreated murine C8D1A and GL261 cell lines 
To begin the comparison of Sirt1 in normal astrocytes versus glioma cells, basal 
levels of Sirt1 were measured using Western blotting, for untreated C8D1A and 
GL261. To investigate the levels of hSIRT1 in human primary glioblastoma cells, 
whole cell lysis followed by SDS PAGE and Western blotting for Sirt1 was 
performed. 
Immunoblotting using a C-terminus monoclonal antibody revealed a trend for 
greater Full-Length Sirt1 (FL-Sirt1) in GL261 compared to C8D1A (Figure 4), but 
the difference was not significant for six independent experiments (p > 0.05). A 
rabbit polyclonal antibody used for Western blotting but designed to recognise 
human SIRT1 was used while optimising experimental procedures. This 
experiment, performed once, showed FL-Sirt1 but also some second protein bands 
running at about 75 kDa, which may or may not be Sirt1 variants (Figure 4 C). 
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Figure 4. Sirt1 levels were not significantly different between C8D1A and GL261 cell lines 
Representative Western blot images from untreated C8D1A and GL261 cells in exponential growth 
phase at approximately 70% confluence. (A) Western blot image for Sirt1. The monoclonal antibody 
Ab50517 recognising C-terminus amino acids 722-737 of mouse Sirt1 was used, with -actin as a 
loading control. FL-Sirt1 was 120 kDa in these cells; (B) Relative abundances of FL-Sirt1 in C8D1A 
and GL261 cells. Measurements were ratios of FL-Sirt1 to -actin, n=6 for each cell line, (p > 0.05 
Student’s t-test, error bars representing SEM). Measurements taken from immunoblots using Image 
J analysis with adjustment for actin were done using the antibody specified above; (C) Immunblot 
image taken using antibody designed to recognise human hSIRT1, sc15404 recognising C-terminus 
amino acids 448-747 was used. HeLa is a human epithelial adenocarcinoma cell line and LN18 is a 
human glioma cell line.  
C 
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3.1.2 hSIRT1 levels in human primary glioblastoma cells and SVG, a human 
astrocyte cell line 
To investigate the levels of hSIRT1 in human primary glioblastoma cells, whole cell 
lysis followed by SDS PAGE and Western blotting for hSIRT1 was performed. The 
antibody used was a polyclonal hSIRT1 antibody that recognised the C-terminus 
region (aa 448-747). We compared levels of hSIRT1 in astrocyte cell line, SVG, to 
primary cells taken from glioblastoma tumours and adjusted to β-actin on 
quantification using Image J software. 
Primary glioblastoma cell cultures were established from tumours taken from 
patients as described by Broadley et al, (Broadley et al 2011b). Some clinical data 
was available for these patients, which are described in the methods section. 
Primary cells from the tumours were used at as early a passage as possible in an 
attempt to avoid cells transforming in culture. Some primary cells grew more 
quickly than others, and some stopped growing and appeared to enter senescence 
during the course of the experiments, hence not all experiments have data from the 
same panel of primary cells.  
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Figure 5. Comparison of FL-hSIRT1 and hSIRT1 smaller species in human glioma and 
normal SVG astrocyte cell line and the relationship to patient survival 
SVG cell line and 12 primary glioma cell cultures were grown to 70% confluency before extraction 
and western blotting for hSIRT1 was performed. (A) Western blot image for SVG and human 
primary gliomas after probing for hSIRT1 and β-actin (B) Histogram showing relative levels of FL-
hSIRT1 after adjusting to β-actin loading control levels, SVG set to one, and correlation plot 
showing glioma primary cell line hSIRT1 levels against patient survival; (C) as in B, but for the 
hSIRT1 fragment at about 75 kDa; (D) as in B but for the ratio of hSIRT1 75 kDa fragment over FL-
hSIRT1.Note B, C and D have different y-axes for ease of visual comparison. Linear regression 
analysis was performed using Prism 6 software. Data used from a single Western blot experiment. 
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Results showed a prominent band at around 120 kDa, which is full-length hSIRT1 
(FL-hSIRT1). This was present in all primary glioma cells in varied amounts, and in 
SVG (Figure 5 A). The second most prominent band ran at about 75 kDa, which 
was present in all the primary cells tested and in SVG. There was also a third band 
present in many, but not all of the primary cells, at 90 kDa. However, in the SVG 
cell line, there were more than two bands consistently present, while the primary 
glioma cells had only two or three bands (120, 90, and 75 kDa).  
Without using sequencing or mass spectrometry, it is not possible to identify the 
smaller bands, but based on the recent literature it is likely that at least some of 
them are hSIRT1 variants (Chalkiadaki & Guarente 2012a, Chen et al 2012b, Dvir-
Ginzberg et al 2011, Shah et al 2012). However, a hSIRT1 variant running at 75 
kDa on Western Blot has been listed on the NCBI BioSystems database and is an 
accepted isoform of hSIRT named SirT1 75 kDa fragment. Thus, in this study, the 
band seen at approximately 75 kDa was thought to be this isoform, and has been 
labelled 75 kDa SIRT1 in the results.  
Overall, these results suggest there was less FL-hSIRT1 in all the human primary 
cell lines measured in this assay compared to SVG (Figure 5 B). However, a third of 
the primary cell glioma cell lines had increased 75 kDa hSIRT1 compared to SVG 
(Figure 5 C), and interestingly, when the ratio of the 75 kDa fragment against FL-
hSIRT1 was measured, all the primary glioma cells exceeded that of the normal cell 
line (Figure 5 D). To gain more understanding for the role of hSIRT1 in GBM, linear 
regression using survival data and FL-SIRT1 and 75kDa hSIRT1 was assessed 
(Figure 5 B and C). No significance was found in these analyses. Repeated 
measurements of hSIRT1 from more patient samples would be more informative.  
Of note, 0903 has a different hSIRT1 Western blot profile to the other primary cells 
extracted, with a second band at around 90 kDa, as in the normal SVG profile. 
Curiously, only this patient survived long-term, at least 60 months with no sign of 
disease recurrence.  
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3.1.3 Intracellular staining verifies SIRT1 levels in glioma primary cells is 
less than in SVG astrocytes 
To further examine the difference in hSIRT1 levels in glioma cells compared to 
normal cells, SVG and a panel of glioma primary cells were fixed and 
permeabilised, stained with hSIRT1 or an isotype control, and a secondary 
antibody, Alexafluor 647. Cells were analysed by flow cytometry, after gating out 
doublets and dead cells using LIVE/DEAD Fixable Blue, to determine cellular 
hSIRT1 levels, using a different method to extraction and Western blotting. 
These results agreed with the Western blot data, where levels of hSIRT1 were 
mostly decreased in primary cells compared to the normal astrocyte cell line, SVG. 
While overall levels of hSIRT1 were decreased (Figure 6 B), intracellular staining 
data showed higher levels of hSIRT1 in glioma cells than in the results from Western 
blotting. This is most likely because the intracellular staining does not differentiate 
between different hSIRT1 isoforms, Alternatively it could be due to differential 
sensitivities of the techniques. There was a positive trend for increased survival and 
greater levels of hSIRT1 (Figure 6 C), but this did not reach significance. 
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Figure 6. Intracellular staining analysis of hSIRT1 protein levels in SVG normal astrocyte 
cell line and primary glioma cells  
Primary glioblastoma and normal astrocyte SVG cells were cultured to reach 70% confluency, then 
fixed, permeabilised and stained with hSIRT1 or an isotype control, and secondary antibody, 
Alexafluor 647. Levels of hSIRT1 were measured by flow cytometry. (A) Flow cytometry gating 
strategy – gating out doublets and dead cells, and histogram showing how isotype and secondary 
only controls show higher fluorescent intensity compared to unstained cells; (B) histogram showing 
relative MFI of hSIRT1/isotype control in 10 human primary GBM cell lines and SVG normal 
astrocytes; (C) Plot to show linear regression of GBM primary cells in relation to patient survival. 
n=1, using triplicate flow cytometry measurements from the same experiment. 
3.2 Acetylation for H4K16 showing SIRT1 activity in normal and 
glioma cells 
H4K16-ac was measured to assess SIRT1 activity on this nuclear substrate. 
Hypoacetylation is seen as a hallmark in a panel of cancer cell lines including lung, 
neuroblastoma, testis, prostrate, osteosarcoma, lymphoma, breast and colon with 
specific H4K16-ac loss occurring early on and accumulating during the 
tumourigenic process (Fraga et al 2005). As previously mentioned, H4K16 is a 
well-known substrate for SIRT1, and relatively specific for SIRT1 in relation to other 
deacetylase enzymes (Imai et al 2000). SIRT1 deacetylation of this substrate is 
linked to breast and colon cancer because it silences tumour suppressor genes 
(Pruitt et al 2006) and acetylation of this residue on H4 is associated with cell cycle 
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control more specifically than other residues on histone 4 (Megee et al 1995). 
Together, these reasons make H4K16 a good substrate to measure in this study 
looking at differences between normal and glioma cells.  
The activity of SIRT1 is not necessarily directly related to levels of protein seen on 
Western blots, because SIRT1 activity can be influenced by other modifications, 
such as phosphorylation, binding to other proteins, and localisation. Results for 
H4K16-ac is one of many substrates for SIRT1. 
Histone extraction and Western blotting for H4K16-ac were performed on murine 
C8D1A and GL261, then followed by a comparison between H4K16-ac on human 
SVG normal astrocytes and a panel of primary glioblastoma cells. Decreased 
acetylation on H4K16 indicates more SIRT1 activity as it is a deacetylase enzyme. 
3.2.1 Acetylation of H4K16 in C8D1A and GL261 cell lines 
To determine Sirt1 activity in murine cell lines, histones were extracted from control 
untreated C8D1A and GL261 cells and probed for H4K16-ac.  
The results showed a greater acetylation for GL261 on H4K16 compared to C8D1A, 
which did not reach significance (Figure 7). Hyperacetylation was unexpected 
because hypoacetylation at this residue is common in other cancers (Fraga et al 
2005). 
 
Figure 7. H4K16 acetylation in GL261 and C8D1A cells 
(A) Representative Western blot images of 2.5 μg protein histone extracts from C8D1A and GL261 
cells in exponential growth phase at approximately 70% confluence. Top panel shows the acetylation 
of H4K16; bottom panel shows the H4 loading control achieved using amido black staining showing 
H4 at expected location (indicated by arrow). (B) Analysis of H4K16-ac relative to loading control. n=7 
C8D1A; n=8 GL261. The difference was not significant (ns) p > 0.05, Student’s t-test. 
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3.2.2 Histone 4 lysine 16-acetylation is variable in primary glioblastoma cells 
The results showed half of the primary glioblastoma cell lines extracted had 
reduced H4K16-ac compared to SVG, with the other half having greater acetylation 
compared to SVG (Figure 8 A and B), showing a variation in H4K16-ac states 
between patients. Statistics showed no significant correlation between survival and 
H4K16-ac, using linear regression analysis (Figure 8 C). Finally, repeat extractions 
for H4K16-ac were made to investigate variation for acetylation status in primary 
cell cultures for each patient. This showed that there was not a great variation in 
acetylation status between extractions of the same cells – with one or two 
exceptions (Figure 8 E). SVG was not included in this repeat analysis, however, so 
averages were not used for regression analysis.  
A linear regression analysis was also made between FL-hSIRT1 expression levels 
and H4K16-ac, to see if there was a relationship between these two variables. 
While there was no statistical correlation found in this analysis, unexpectedly a 
trend for greater acetylation levels (that is, less SIRT1 activity) with increased 
hSIRT1 levels was observed (Figure 8 D). Either the hSIRT1 is deacetylating 
another nuclear substrate, or perhaps FL-hSIRT is not predominantly localised in 
the nucleus in primary glioblastoma cells, as seen with murine glioma cells.  
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Figure 8. H4K16-ac in human primary glioblastoma cells 
Cells were grown for one day, and then histone extraction was performed, followed by Western 
blotting for H4K16-ac. These results are from two separate extractions each time using SVG cells 
extracted at the same time as a control measure – adjusted to one (A) Images from Western blot of 
SVG and 12 human primary glioma cells from two extractions; (B) Histogram showing results of 
Western blot for H4K16-ac as in A, after adjustment for amido black loading control, and setting SVG 
to one, using Image J software; (C) Linear regression plot for H4K16-ac in the primary glioblastoma 
cells in A, against survival in months for patients; (D) Linear regression plot for relative H4K16-ac 
against relative FL-hSIRT1 levels in primary glioblastoma cells, n=1; (E) Histogram showing variation 
in relative H4K16-ac across a panel of glioblastoma cells. These were not measured against a 
standard SVG, but against each other, after adjustment to loading control. Repeats are as follows: 
0708:2, 0804:5, 0903:2, 0705:3, 0711:2, 0713:2, 0902:2, 1011:3, 0813:5, 1005:4, 0906:5. Bar 
represents mean with standard error of the mean. 
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3.2.3 FBS concentrations in media affect histone acetylation in GL261 
cultured cells but not FL-Sirt1 levels 
A recent publication showed there was aberrant Sirt1 localisation in cancer cells 
versus normal cells, due to increased protein stability in the cytoplasm, and was 
regulated by P13K/IGF-IR signaling (Byles et al 2010).  
In this research, C8D1A cells were routinely cultured in DMEM with 10% FBS, 
while GL261 cells were grown in 20% FBS (as recommended by suppliers). It was 
therefore questioned whether the altered histone acetylation was due to the higher 
levels of growth factors when 20% FBS was used. Changes in serum levels of FBS 
are known to alter insulin related cell signaling pathways (Berenguer et al 2010). 
To investigate this, GL261 cells were grown in 10% FBS supplemented media for 
five passages, and then immunoblotted for Sirt1 and H4K16-ac. Comparison was 
made with C8D1A and GL261 cells grown in 10% and 20% FBS. 
Figure 9. Neither FL-Sirt1 expression levels nor activity showed any significant change 
when FBS levels were altered 
(A) Immunoblot for Sirt1 with histogram showing quantification; (B) immunoblot and control amido 
black images for H4K16-ac and H4 in C8D1A cells, and GL261 cells grown in 10% or 20% FBS, 
and histogram showing quantification. The loading controls were β-actin for Sirt1, and amido black 
staining of the H4 region for H4K16-ac. Lysate was heated to 90°C. One-way ANOVA analysis was 
carried out on the images, ns= not significant p > 0.05. Error bars represent mean  s.d for the three 
independent experiments. 
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These results showed no statistical significance between the Sirt1 or H4K16-ac 
levels for GL261 grown in 20% FBS compared to C8D1A and GL261 grown in 10% 
FBS. While there was no significance in the results, there was a tendency for 
greater levels of H4K16ac in GL261 cells grown in 10% FBS compared to the 
same cells grown in 20% FBS, or C8D1A cells grown in 10% FBS. This needs 
further research, but if further repeats showed a significant difference in Sirt1 
activity on H4K16, it would indicate that increased FBS levels would also increase 
Sirt1 activity on this substrate. There were extra bands seen for some of the 
C8D1A Sirt1, which was thought to be related to the lysate being heated to 90°C. 
Temperatures were kept lower in other expermiments. This was no evidence to 
suggest this was related to FBS levels. 
3.3 Subcellular localisation for SIRT1 – immunofluorescent 
microscopy 
Deacetylation of H4K16 requires nuclear localisation; a possible explanation for 
different acetylation states on H4K16 could be explained by different localisation. 
Therefore, localisation of SIRT1 was next investigated. Control untreated cells were 
fixed in 4% paraformaldehyde solution and permeabilised with 0.2% Triton X-100, 
both in PBS, followed by immunofluorescent staining for SIRT1 (Section 2.4) 
3.3.1 Sirt1 is aberrantly localised to the cytoplasm in GL261 cells 
As expected, Sirt1 was predominantly localised to the nucleus in C8D1A normal 
astrocyte cells, however Sirt1 was seen localised to the cytoplasm and nucleus in 
GL261 cells strongly contrasting to the pattern seen in C8D1A (Figure 10). This 
general observation was seen consistently, however both cell lines showed variation 
in the localisation of Sirt1, suggesting Sirt1 is mobile in both these cell lines, and 
depending on the environment or conditions, Sirt1 localisation can change. For 
example, when cells were bunched together, Sirt1 would appear much more 
cytoplasmic in the normal cell line, C8D1A, than in single cells spaced apart from 
each other. 
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Figure 10. Aberrant cytoplasmic localisation of Sirt1 in GL261 cells 
C8D1A and GL261 cells were grown on coverslips for two days before fixation of cells with 
paraformaldehyde, incubation with mouse monoclonal anti-Sirt1 (Ab50517) then secondary 
antibody rabbit anti-mouse IgG H&L (Alexa Fluor® 488). Top panel shows Sirt1 (green); bottom 
panel DAPI staining of nuclei (blue). Scale bar is 100 m, and is relevant for all images. Arrows 
show examples where Sirt1 was absent in the nucleus of GL261 cells.  
Aberrant cytoplasmic localisation of Sirt1 has been reported in cancer cells 
compared to normal tissue from breast, prostate and lung cells (Byles et al 2010) 
but it has not been reported in glioma cells.  
3.3.2 hSIRT1 is aberrantly localised to the cytoplasm in human 
glioblastoma cells compared to the SVG normal astrocyte cell line 
In the mouse model of glioblastoma, aberrant Sirt1 cytoplasmic localisation in 
cancer cells was found. In the human primary GBM cells, more FL-hSIRT1 tended 
to show more H4K16-ac, a key substrate in the nucleus for hSIRT1, indicating a 
possible cytoplasmic localisation for hSIRT1 in these cells also. To investigate 
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intracellular localisation of hSIRT1 in human primary glioblastoma cells compared 
to SVG normal astrocytes, paraformaldehyde fixation followed by intracellular 
immunofluorescent staining for hSIRT1 was performed for SVG and a panel of 
primary GBM cells.  
Fluorescent microscopy revealed that in SVG cells, hSIRT1 was found mostly in 
the nuclei, with a small amount in the cytoplasm in clearly defined areas (Figure 11 
top panel). hSIRT1 in glioblastoma primary cells was also seen in nuclei but with a 
greater amount seen in the cytoplasm compared to SVG, and was more diffuse 
compared to cytoplasmic hSIRT1 in SVG (Figure 11 panels below first panel). 
Each primary glioblastoma has an apparent different level of cytoplasmic hSIRT1 
relative to nucleic hSIRT1. On analysis of immunofluorescent photographs, 
however, the pattern of cytoplasmic SIRT1 was diffuse, with some exceptions, 
notably 0814 (see Figure 11 B). While SVG cytoplasmic hSIRT1, even though it 
was minimal, was more defined to filamentous structures not far away from the 
nucleus compared to more diffuse cytoplasmic hSIRT1 seen in primary glioma 
cells (Figure 11 B). As confocal microscopy was not available, hSIRT1 localisation 
could not be quantified.  
 
 
 
Figure 11. hSIRT1 is found aberrantly in cytoplasm of primary glioblastoma cells 
compared to SVG normal astrocytes 
(Facing page) 
SVG astrocyte cell line and a panel of glioma primary cells were grown on 8-chamber well slides for 
two days, then fixed with paraformaldehyde and incubated with SIRT1 antibody, Alexafluor 488 
(green fluorescent) secondary antibody, and DAPI for nuclei staining. Microscopy with a camera 
attached was used to visualise results and to take electronic images for analysis. (A) Images of 
hSIRT1 (green) and nuclei (blue) in SVG and five primary glioma cell lines. Scale bar: 100 μm; (B) 
Enlarged pictures, or larger scale images showing SVG with predominantly nucleic with some 
cytoplasmic hSIRT1 with filamentous structures, and primary glioblastoma cells with more diffuse 
cytoplasmic SIRT1 (0713, 0907, 0906). Except for 0814 DAPI is excluded in these larger images to 
show more clearly differences in hSIRT1 between SVG and primary glioma cells. Scale bars shown 
for individual photos. 
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3.4 Subcellular localisation for SIRT1 – Western blotting 
Next, verification for the aberrant localisation by Western blotting of nuclear and 
cytoplasmic fractions for glioma and normal astrocytes was sought. Nuclear and 
cytoplasmic extracts were prepared by homogenisation and centrifugation. A 
variety of methods were used. 
3.4.1 Western blot nuclear/cytoplasmic fractionation using NE-PER Extraction 
 
Figure 12. Nuclear/Cytoplasmic fractionation and immunoblotting of C8D1A and GL261 cell 
lines.  
Top panel: immunoblot for Sirt1 using mouse monoclonal antibody ab50517. Middle panel shows 
immunoblot for the nuclear protein lamin B, and bottom panel shows immunoblot for α-tubulin, a 
cytoplasmic marker, n=1. 
Using this fractionation process, Sirt1 was observed predominantly in the 
cytoplasm of all extracts, with very little in the nuclear fraction (Figure 12), unlike 
the distribution observed using immunofluorescent staining using the same 
antibody which showed predominantly nuclear Sirt1 in C8D1A cells and a 
significant proportion of nuclear Sirt1 in GL261 cells. Although lamin B was 
detected only in the nuclear fraction, as expected, the nuclear extracts also 
contained α-tubulin indicting contamination by this cytoskeletal protein. This result 
could be partly explained by cross-contamination of the subcellular fractions, as 
cytoplasmic fractions could have nuclear content, showing a false high level of 
Sirt1 in the cytoplasm. However, the relative absence of Sirt1 in the nuclear 
preparation was puzzling.  
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3.4.2 Nuclear/Cytoplasmic fractionation and Western blotting of C8D1A and 
GL261 cells after fixation 
To attempt to retain Sirt1 in the nucleus during subcellular fractionation, cells were 
fixed in formaldehyde prior to fractionation.  
Fixation of cells followed by extraction using NE-PER Thermo-Scientific nuclear 
and cytoplasmic reagents was performed followed by Western blotting. Results 
showed a sub-cellular distribution of Sirt1 agreeing with results using microscopy 
with immunofluorescent staining, where there was greater levels of cytoplasmic 
Sirt1 in GL261 cells compared to C8D1A cells (Figure 13 A, B and C). For GL261 
cells grown in either 10% or 20% FBS, there was no difference in 
nuclear/cytoplasmic ratios, but an overall increase in Sirt1 expression was seen in 
cells grown in increased FBS. This was unexpected, as other studies show 
increased SIRT1 expression in a variety of cells with nuturient or serum deprivation 
(Alcendor et al 2007, Kanfi et al 2008), suggesting unusual activity for Sirt1 in 
glioma cells compared to other cells. Crosslinking the cytoskeleton together made 
it difficult to use lamin or tubulin as controls, so other proteins would be required to 
confirm the fractionation purity levels. Further experiments are required for 
validation. However, these results, taken together with those using IF and 
microscopy, indicated that the localisation of Sirt1 is more cytoplasmic in the 
glioma murine cell line, GL261 compared to the normal astrocyte comparison cell 
line, C8D1A. There appeared to be no effect of FBS level on cytoplasmic to 
nuclear Sirt1 ratio.  Both the crosslinking experiment shown here, and the 
acetylation of H4K16 in 3.2.3 indicated that nuclear Sirt1 was not altered with 
different FBS.  
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Figure 13. Nuclear/cytoplasmic extraction of C8D1A and GL261 cells after fixation  
C8D1A cells and GL261 cells were grown for one day and nuclear/cytoplasmic extraction was 
performed after crosslinking proteins with formaldehyde as described in methods section. GL261 
cells were grown in media supplemented with 10% or 20% FBS. At least five passages of growth in 
either culture was established before extraction. (A) Western blot image of nuclear and cytoplasmic 
fractions of cells. Note less C8D1A was available to load, due to poor extraction yield for these 
cells, and there is no loading control; (B) histogram showing relative Sirt1 levels for each 
compartment. C8D1A levels were doubled to adjust for a known deficit in loading due to a poor 
extraction yield of C8D1A fractions; (C) histogram-showing relative amounts in the nucleus relative 
to the cytoplasm. Abbreviations: N = nuclear extraction, C = cytoplasmic extraction. n=1 
3.4.3 Extraction of Cytoplasm and Nuclear Fractions of SVG astrocyte cells 
To confirm hSIRT1 localisation differences between nucleus and cytoplasm, 
nuclear/cytoplasmic extractions were carried out. Using only SVG cells initially, 
nuclear and cytoplasmic fractions were isolated using extractions using Buffers A 
and B as described in methods section and described in Andrews and Faller 
(Andrews & Faller 1991). Western blotting was then performed. 
Results using this process showed that the extractions for different compartments 
were reasonably pure, and yet there was more cytoplasmic hSIRT1 compared to 
nuclear hSIRT1 (Figure 14 B). This did not correspond to the immunofluorescent 
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photographs that were obtained earlier (Figure 14 A), and was the same 
inconsistency as was seen with the murine cells after extraction. 
An alternative method using an extraction kit purchased from Thermo Scientific 
was then used (NE-PER). Results from extraction using this kit resulted in a 
cleaner compartmental extraction, cytoplasmic hSIRT1 was still predominant, and 
nucleic hSIRT1 was minimal (figure 14 C). This could have been due to poor 
nucleic yield, or nucleic hSIRT1 being lost during the extraction process either by 
degradation or movement out of the nucleus. These results were similar to the 
nuclear/cytoplasmic extractions for the murine cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. Nuclear/cytoplasmic extraction for untreated SVG cells – using different 
processes 
 (A) Intracellular immunouorescent staining for SVG cells showing SIRT1 (green) and DAPI, 
staining nuclei (blue); (B) Nuclear/cytoplasmic extraction using buffers A and B made in the lab. 
Cells were grown for one day to approximately 70% confluency before extraction was performed. 
Alpha-tubulin and lamin A/C were used to check for purity of cytoplasm and nucleic extraction 
respectively; (C) As for B, but using NE-PER extraction kit; (D) As for B, but using a mild fixative 
agent, before using the NE-PER extraction kit. Arrows point to a smaller labile form of lamin A that 
is only found within the nucleus. Abbreviations: N = nuclear extraction, C = cytoplasmic extraction.  
h 
h 
h 
h 
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Finally, a third extraction technique using mild crosslinking fixative used before 
using the commercial nuclear/cytoplasmic extraction kit, as for the murine cells in 
Section 3.4.2. Results showed that hSIRT1 was predominantly nuclear, with a 
small portion in the cytoplasm (Figure 14 D). Measuring purity of compartmental 
extraction was difficult due to crosslinking and α-tubulin was seen in both 
compartments. However a small isoform of lamin A/C known to be more labile and 
nucleic only, was seen in the nuclear lysate only (Figure 14 D arrows), indicating 
separation of compartments may have been successful. However, the size of 
hSIRT1 seen in the extraction was smaller than in the other extractions. The 
reason for this was not understood, and highlighted the difficulty in studying a 
molecule responding to cellular stress and which may localise differently 
depending on micro-environmental conditions. 
Given that the results for the extraction process using mild fixation agreed with the 
results seen in immunofluorescent experiments, extraction using this method 
followed by Western blotting was repeated using SVG and human primary glioma 
cell line, 0906. 
 
Figure 15. Nuclear/cytoplasmic extraction for SVG and 0906 cells using formaldehyde 
fixation 
Cells were grown for one day to approximately 70% confluency before extraction was performed, 
using a mild fixative before using the NE-PER extraction kit, and immunoblotting for hSIRT1 for (A) 
SVG and (B) 0906. Purity and loading controls were not included, n=1. 
Results for these cells also agreed with the immunofluorescent staining 
experiments, with more cytoplasmic hSIRT1 seen with the 0906 primary cells while 
more nuclear hSIRT1 was seen in SVG cells (Figure 15). As in the preliminary 
experiment (shown in Figure 14 D), FL-hSIRT1 appeared to be lost. The second 
protein band, running at about 75 kDa was present, however. This experiment did 
not have control antibody bands, so the result needs verification using controls.  
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3.4.4 Changes in hSIRT1 levels before and after primary cell line 0906 
immortalisation 
Sirt1 protein, but not mRNA levels was found to decrease with increasing serial 
passage in mouse embryonic fibroblast (MEF) cells undergoing premature 
senescence, however when these cells spontaneously immortalised, Sirt1 levels 
were returned to the higher level seen with faster proliferating cells (Pelicano et al 
2006). Further investigation by Sasaki et al using MEFs and human lung fibroblast 
cells show Sirt1 levels increased with increased mitotic activity and decreased with 
replicative senescence.   
During culturing, some primary glioma cells entered senescence. One primary cell 
line, 0906, transformed between passage 8 and passage 16, and emerged from 
senescence with a smaller and different morphological shape, less spread out on 
the culture dish and replicating more quickly (Figure 16 A). It was assumed they 
had become immortalised. To find out if hSIRT1 levels changed after 
immortalisation of human primary cells, whole cell extraction of 0906 cells before 
and after transformation, followed by immunoblotting for hSIRT1 was performed. 
 
 
Figure 16. Human primary 0906 cells spontaneously immortalised in culture 
(A) Photograph from a light microscope showing 0906 human primary glioma cells before (P8) and 
after (p15) immortalisation, scale bar 200 μM; (B) Western blot images for hSIRT1 in SVG and 0906 
in cells before and after immortalisation. Images representative of three independent extractions. 
Passage	15	
(P15)	
Passage	8	
(P8)	
P	8	 P	15	
hSIRT1		
	
β-ac n	
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Results showed that hSIRT1 and 75 kDa SIRT1 were increased after human 
primary 0906 cells became immortalised in culture to be similar to levels seen in 
the  SVG imortalised cell line (Figure 16 B).  
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Part 4:  Results – Cell Proliferation 
Exploring the potential role of SIRT1 in glioma cells in cell proliferation 
Minimal research has been done to investigate the role of SIRT1 in the proliferation 
of glioma cells. A recent study showed SIRT1 knockdown significantly delayed 
mitotic entry in a panel of glioma cell lines, inhibited growth and proliferation, and 
promoted apoptosis (Annabi et al 2012). No reports into the role of SIRT1 with 
respect to proliferation in primary glioma cells could be found in the literature at the 
time of writing this thesis. As SIRT1 is a key regulator of longevity in yeast, worms 
and flies (Kaeberlein et al 1999) (Tissenbaum & Guarente 2001) (Rogina & 
Helfand 2004), and deacetylates key proteins involved in metabolic function and 
energy homeostasis in many cell types (Brooks & Gu 2009), it is likely to be 
involved in proliferation and viability of cells in glioblastoma.  
4.1 Proliferation measures for murine and human glioma and 
normal cells using MTT reduction assay 
As previously described (Section 2.7), MTT reduction measures metabolic activity 
but is used widely as a viability assay, and as an indication of proliferation of cells. 
MTT reduction is a measurement of metabolic activity, and for this study, 
differences between one and three days were used as a reflection of cell 
proliferation. Proliferation rates were measured for murine and human glioma cells 
and compared to the normal astrocyte cell lines, and also compared to SIRT1 
levels. 
4.1.1 Cell proliferation for murine and human normal and glioma cells 
compared to full-length SIRT1 levels 
C8D1A and GL261 cells (either with 10% or 20% added FBS), SVG and two 
primary glioma cell lines were grown in 96-well plates, as described in the methods 
(Section 2.7). MTT reduction was measured at day one and day three and the 
differences between measurements were analysed (“proliferation”). Additionally, 
proliferation was measured for a panel of human primary glioma cells, and this was 
analysed against FL-hSIRT1 levels measured by Western blot (taken from an 
earlier experiment) to find out if there was a relationship between the two.  
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Figure 17. Cell proliferation in murine and human glioma and normal astrocytes compared 
to FL-SIRT1 
(Facing page) 
Cells were grown in triplicate in 96 well plates with MTT reduction measured at one and three days. 
MTT values are amounts of MTT reduced in a 2 hr assay. Proliferation was the average MTT value 
day three minus average MTT value at day one. Relative FL-SIRT1 was a measure of protein 
quantity in relation to β-actin after adjustment for loading. (A) MTT values for murine cell lines – with 
GL261 grown in two levels of FBS, n=3 (B) Bar graph showing triplicate measurements of FL-Sirt1 
in murine cell lines from Western blot measurements from previous extractions (Section 3.4), n=3. 
(C) MTT values for human cell line SVG, and human primary cell lines 0713 and 0906. The 0906 
cells were measured before and after immortalisation as described in Section 3.14, n=3.(D) Bar 
graph of hSIRT1 levels in Western blot experiments done previously, n=2; (E) MTT values from 18 
primary gliomas and SVG normal astrocyte cell line. (F) Graphic representation of FL-hSIRT1 levels 
taken from single Western blot extractions done previously for each primary cell line (Section 3.9). 
The 0906 cell line is taken from cells after immortalisation. (G) Linear regression of proliferation 
values against FL-hSIRT1 values of 12 primary gliomas. Student’s t-test: ns = not significant; *** p < 
0.001; **** p < 0.0001  
The murine glioma cell line GL261, grown in either 10% or 20% FBS, had a 
significantly higher proliferation rate compared to normal C8D1A astrocytes (black 
bars, Figure 17 A). There was no significant difference in proliferation between 
GL261 cells grown in 10% or 20% FBS. FL-Sirt1 levels did not change significantly 
between untreated C8D1A and GL261 (Figure 17 B), suggesting FL-Sirt1 expression 
was not linked to the differences in proliferation seen in the murine MTT results. 
Results for the human SVG cells and primary glioma cells showed there was a 
significant difference in the proliferation rate between 0906 primary glioma cells 
pre- and post-immortalisation (p < 0.005) (Figures 17 C and D). SVG has 
proliferation higher than the glioma cells. This result could be a reflection of a 
comparison between primary cells and an immortalised cell line, but needs 
confirming. A panel of 12 glioma primary cell lines were analysed for hSIRT1 levels 
against proliferation, and while there was a positive trend for more hSIRT1 with 
higher proliferation it did not reach significance (Figure 17 G). It is understood that 
linear regression analyses usually require at least 25 sample data to give 
meaningful relevance, and the correlation here and the ones in other sections are 
understood to be trends that need investigating with more patient data. The 
immortalised 0906 cells had significantly increased proliferation compared to pre-
immortalised 0906 cells and there was also an increase in hSIRT1 seen on the 
Western blot but it did not reach significance. As described in the previous section, 
it is likely that cells in GBM tumours have transformed to become proliferative and 
invasive – different to the normal astrocyte cells. There is also evidence in the 
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literature for immortalisation of glioma cells in tumours (Hiraga et al 1998, 
Kheirollahi et al 2013, Nakatani et al 1997). In these studies, increased telomerase 
is found in cells from GBM tumours – and there is recent research to suggest 
SIRT1 directly regulates telomerase expression (Zhang et al 2014). 
4.1.2 MTT reduction in human primary glioma cells in relation to survival 
statistics 
To gain a preliminary indication of any relationship between MTT measurements 
and patient survival, linear regression analyses were made.  
Figure 18. Relationship between MTT reduction, hSIRT1 and patient survival 
Linear regression plots for (A) Cell proliferation (measured from the difference of MTT value 
between day one and day three) and patient survival taken from a panel of 16 primary glioma cells; 
(B) MTT reduction measurement taken from day one and patient survival for 16 primary glioma 
cells; (C) MTT taken from day one and levels of FL-hSIRT1 for 15 primary glioma cells measured 
from a single extraction and compared to SVG from the same blot (set at 1). 
Linear regression analysis revealed that while cell proliferation did not correlate with 
patient survival, there was a positive trend (Figure 18 A). Unexpectedly, there was a 
statistically significant correlation (p < 0.001) between MTT values taken at day one 
and survival (Figure 18 B) and yet no significant correlation with FL-hSIRT1 and 
MTT reduction at day one (Figure 18 C). MTT reduction reflects cell metabolic 
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activity in the cell, and because cancer treatment targets cells with high metabolic 
rate, this result may be because those cells with higher metabolic rate are more 
susceptible to radiation and chemotherapy, and the patients who donated these cells 
had been undergoing treatment, and treatment probably prolonged survival.  
4.1.3 Acetylation of H4K16 in relation to MTT reduction  
To assess if hSIRT1 activity, rather than FL-hSIRT1 expression, may be linked to 
metabolic rates or proliferation rate in human glioma cells, levels of H4K16-ac were 
analysed. 
Histone extraction from 11 primary glioblastoma cell lines was performed followed 
by Western blot for H4K16-ac. The level of histone acetylation was compared with 
MTT measured after 1 d, and with cell proliferation rate calculated as the 
differences of MTT reduction between day one to day three. 
Figure 19. Relative H4K16 acetylation across a panel of human primary glioma cells in 
relation to MTT reduction 
Histone extraction after growing cells for one day, followed by Western blotting, and probing for 
H4K16-acetylation was performed on 11 human primary glioma cell lines as described in Section 
3.5. (A) Linear regression for H4K16-ac plotted against cell proliferation rate for human primary 
glioma cells; (B) linear regression for H4K16-ac plotted against MTT values at day one. n=1 H4K16-
ac extraction, n=3 MTT reduction.  
There was no significant correlation between cell proliferation and H4K16-ac, or 
MTT reduction at day one (Figure 19 A and B) although there was a positive trend 
between acetylation and proliferation.  
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4.2 SIRT1 activation and inhibition effects on cell proliferation 
rates in glioma and normal cells 
To examine the potential role of SIRT1 activity in cell proliferation of glioma 
compared to normal cells, a SIRT1 inhibitor, nicotinamide (NAM) or a SIRT1 
activator, resveratrol (RES), was added to cultures after one day of plating out and 
MTT reduction was measured on day three and the proliferation measurements 
were compared to untreated cells. NAM is known to be an effective inhibitor of 
SIRT1 (Bitterman et al 2002), and RES is a known activator of SIRT1 (Howitz et al 
2003). The GL261 cells were grown in either 10% or 20% FBS supplemented 
media to assess the effect of the growth factor, to continue the assessment made 
in previous experiments.  
4.2.1 Assessing the role of Sirt1 activity on proliferation rate for murine 
normal astrocyte cell line C8D1A and glioma cell line GL261  
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Figure 20. Proliferation in murine astrocyte normal and glioma cell lines with Sirt1 
inhibition and activation  
(Facing page) Cells were grown in 96 well plates for one day before treatment with or without 
inhibitor of Sirt1, nicotinamide (NAM) dissolved in water, or resveratrol (RES) dissolved in diluted 
ethanol. MTT reduction was measured on day one and three after treatment in (A) normal murine 
astrocyte cell line, C8D1A. (B) murine glioma cell line, GL261, grown in 20% FBS; (C) murine 
glioma cell line, GL261, grown in 10% FBS. The difference of MTT reduction between day one and 
day three was used as a measure of proliferation. * p < 0.05 , ** p <0.01 ***p < 0.001, **** p 
<0.0001, ns = not significant, by one way ANOVA and Tukey multiple comparison post-test, n=3 for 
each cell line. Vehicle EtOH was used at 0.1% concentration. Note the y-axis have different scales to 
make visual comparison easier. 
 
Treatment with the Sirt1 inhibitor NAM decreased proliferation in all cell lines 
(Figure 20), and the Sirt1 activator RES increased proliferation at the highest 
concentration 50 μM, which suggested that Sirt1 was involved in the proliferation 
rates for these cells. There was a significant negative effect of 10 mM NAM on 
proliferation of C8D1A cells (p < 0.05) (Figure 20). The significance between the 
GL261 untreated and NAM treated cells was greater than for C8D1A cells, 
indicating that the faster proliferating cells are more influenced by NAM. Increased 
FBS supported this as the untreated GL261 cells grown in 20% FBS were more 
proliferative than the 10% FBS-grown cells, and had significantly greater inhibition 
from NAM (p < 0.01 10% FBS cultures, p < 0.00001 20% FBS cultures) (Figure 20 
A, B and C, green bars). 
RES increased proliferation significantly only in GL261 cell lines, at either 10% or 
20% FBS (Figure 20 A, B & C pink, purple and red bars). Interestingly, the vehicle 
control ethanol negatively affected proliferation for all cell lines. Ethanol was used 
at 0.1% final concentration in the culture media which was the amount used with 
50 μM RES treatment, yet the effects of the higher concentration of RES appeared 
to overcome the toxic effect, making interpretation difficult. 
4.2.2 Assessing the role of hSIRT1 on proliferation of human normal 
astrocyte cell line SVG compared to two primary glioma cell lines  
MTT reduction was also used to measure proliferation rate in human normal 
astrocyte and primary glioma cells with and without NAM or RES treatment, as 
described in the previous section.  
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Figure 21. Proliferation for human astrocyte SVG and primary glioma cell lines with hSIRT1 
inhibition and activation 
Cells were grown in 96 well plates for one day before treatment with or without, nicotinamide (NAM) or 
resveratrol (RES). MTT reduction was measured on day one and day three after treatment in (A) 
normal human astrocyte cell line, SVG; (B) human primary glioma cell line 0713; (C) human primary 
glioma cell line 0906, before immortalisation as explained in Section 3.14; (D) human primary glioma 
cell line 0906 after immortalisation. Results are expressed as. * p < 0.05, ** p < 0.01 ***p < 0.001, **** 
p < 0.0001, ns = not significant, by one way ANOVA and Tukey multiple comparison post-test, n=3 for 
each cell line. Vehicle EtOH was used at 0.1% concentration. 
As in the murine cell lines, NAM treatment decreased proliferation in all cells 
tested, but RES had different effects. This suggested RES may have been acting 
on non-hSIRT1 effects in at least some of these cells.  NAM had a greater effect 
decreasing proliferation in the primary glioma cell lines compared to the normal cell 
line SVG, with a significant difference obtained using 10 mM NAM on the 0713 
primary glioma cell line (Figure 21, green bars). RES increased proliferation for 
0713 cells, and 0906 cells pre-immortalisation, but appeared to decrease 
proliferation for SVG cells and post-immortalised 0906 cells, reaching significance 
in SVG cells for 25 or 50 μM RES (Figure 21, pink, purple and red bars). However, 
ethanol had varying effects as the 0713 cell line showed decreased proliferation 
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with ethanol, similar to the murine cell lines, while the other three cell lines 
apparently did not show these effects. 
Taken together with the murine cell lines, these results showed that NAM and RES 
treatment generally had opposing affects on proliferation, which could indicate a role 
of SIRT1 in cancer and normal astrocyte cells. NAM apparently had greater effect on 
the primary glioma cells than on the normal cell line. As NAM and RES both have 
effects on cell signalling that are not directly related to SIRT1, more specific ways to 
investigate SIRT1 involvement are needed to examine these results.  
4.2.3 Nicotinamide significantly affected proliferation of human primary 
glioma cells 
To investigate whether NAM was generally effective in decreasing proliferation of 
primary glioma cells, a panel of 18 primary glioma cells was used. 
The greatest effects of NAM on proliferation were observed in cells with the 
greatest untreated proliferation rates (Figure 22 A). When averages of the 
triplicates were measured in a cohort, NAM significantly reduced proliferation 
across the panel of primary glioma cells (Figure 22 B) (p < 0.01).  
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Figure 22. Effect of hSIRT1 inhibition on proliferation in a panel of primary glioma cells  
(A) Bar graph showing proliferation for a panel of primary glioma cells grown in triplicate in 96 well 
plates, with and without 10 mM NAM. Proliferation is taken as the difference between day one and 
day three MTT reduction, and where cells MTT values were less on day three compared to day two, 
the proliferation is shown as negative. 2-way Anova with Sidak’s multiple comparison post-test, * p 
< 0.05, ** p< 0.01, *** p < 0.005. **** p < 0.001; (B) Bar graph showing the average proliferation of 
untreated primary glioma cells compared to NAM treated cells from the same MTT experiment 
shown in A. Student’s t-test ** p < 0.01.  
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4.3 Effects of nicotinamide and resveratrol treatments on SIRT1 
protein 
At the highest concentration used in this study (50 μM), RES unexpectedly 
decreased proliferation in the normal SVG cell line. To investigate if changes to 
levels or quality of SIRT1 may be related to this result, Western blotting for SIRT1 
was carried out using cells after 24 hr exposure to RES at different concentrations. 
As a representative of the GBM cell lines, the human primary glioma 0906 (pre-
immortalisation) was used. 
4.3.1 Effect of resveratrol on SIRT1 in normal and cancer murine and 
human cells 
The results showed that in both the murine and human normal cell lines, a distinct 
second band was observed with 50 μM RES (Figure 23 A and D red arrows), while 
the cancer cell counterparts showed no second band. Recent literature gives 
evidence for concentration-dependent differential effects using RES in vitro 
(Faragher et al 2011, Peltz et al 2012, Price et al 2012), with altered signalling 
pathways given as a possible explanation. The effect of resveratrol on cleavage or 
splicing of SIRT1 has not been reported, however cleavage and splice variants of 
SIRT1 are known (Chen et al 2012b, Dvir-Ginzberg et al 2011) (Hong et al 2010, 
Shah et al 2012). The smaller species of SIRT1 seen here after 24 hr treatment of 
50 μM RES could be a splice variant or a product of cleavage.  
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Figure 23. Effect of resveratrol on SIRT1 
(Facing page) Murine and human glioma and normal cells were grown for 1 d with or without RES 
at different concentrations, then protein extraction and immuno-blotting for SIRT1 was performed. 
(A) Image from Western blot for C8D1A normal murine astrocytes and (B) quantification for image 
shown in A, with adjustment for β-actin loading differences; (C) Image from Western blot for GL261 
murine glioma cells; (D) Image from Western blot for normal human astrocytes SVG, and for (E) 
primary glioma cell line 0906 pre-immortalisation. Ethanol (ETOH) vehicle was used at the same 
concentration as for 50 μM RES. Red arrows highlight a distinct second band seen on blots. 
4.3.2 Effect of nicotinamide on SIRT1 in normal and cancer murine and 
human astrocytes  
To determine if the Western blot profile of SIRT1 is changed by NAM as observed 
with RES, Western blots were performed on both murine and human normal and 
cancer astrocyte cells after incubation with or without 10 mM NAM for 20 hr 
(murine) or 4 hr (human). 
 
Figure 24. Nicotinamide does not change SIRT1 protein band 
(A) Western blots images showing murine normal and cancer astrocytes incubated with or without 
10 mM NAM for 1 d. Representative of more than three experiments; (B) Western blots showing 
normal human SVG astrocytes and cancer primary glioma cells, 0906, with and without 10 mM 
NAM for 4 hr. 
Unlike RES, NAM did not cleave or affect alternate splicing of Sirt1 in either of the 
murine cell lines at 10 mM after 1 d incubation (Figure 24 A). Also, no evidence of 
cleavage or alternative splicing is seen after 4 hr incubation with 10 mM NAM in 
the primary glioma, 0906, nor in the normal human astrocyte, SVG (Figure 24 B). 
No cleavage was seen at 1 d NAM treatment in normal human SVG cells either 
(results not shown). 
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Part 5:  Results: Oxidative Stress  
Exploring the potential role of SIRT1 in glioma and normal astrocyte cells 
under oxidative stress 
5.1 Introduction to oxidative stress and SIRT1 in GBM 
Oxidative stress occurs continuously, as oxygen radicals known commonly as 
reactive oxygen species (ROS) are formed during normal metabolic activity. 
Glucose is the basic molecule for normal oxidative cellular metabolism where 
glucose is broken down to produce ATP. The brain is a particularly active organ for 
glucose metabolism, consuming over 10% of the body’s glucose and oxygen 
supplies even though it accounts for 1–2% of total body mass (Gjedde 2007), 
therefore it is exposed to much oxidative stress in the normal setting. Low levels of 
ROS and antioxidants have important signalling effects, for example, to stimulate 
growth (Gough & Cotter 2011) and in normal development processes (Dennery 
2007). However, too much ROS will activate defence mechanisms and if these are 
overwhelmed, irreversible cell damage will lead to necrosis or apoptosis. The most 
common ROS are superoxide anion (O2-), hydrogen peroxide (H2O2), and hydroxyl 
radicals (OH-)(Salminen et al 2013).  
An oxidative environment is postulated as one of the reasons cancer cells become 
treatment resistant – with altered signalling pathways that support proliferation, 
metastasis, and genomic instability which also help to propagate disease 
(Toyokuni et al 1995). Glioblastoma is among the hardest of all cancers to treat 
where tumours are resistant to radiation and chemotoxic therapies (Furnari et al 
2007), and an elevated oxidative environment is observed (Silber et al 2002) (Iida 
et al 2001). Reasons for oxidative stress conditions in GBM include inflammatory 
responses, increased nitric oxide from angiongenesis, and hypoxia/reperfusion in 
the necrotic core (Kalaria et al 1996) (Ziche & Morbidelli 2000) (Brown & Bicknell 
2001). Antioxidant treatment can decrease glioma cell proliferation (Martin et al 
2007). 
SIRT1 can be found to decrease oxidative stress effects in some situations and 
increase them in others. (Alcendor et al 2007, Salminen et al 2013). SIRT1 
activities depend on the context of the situation. 
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There is limited research into the role of SIRT1 in astrocytes in oxidative stress in 
relation to glioblastoma. One study found neural progenitor cells (NPCs) will 
preferentially develop into astrocytes under oxidative conditions in a SIRT1 
dependent manner (Prozorovski et al 2008) (Libert et al 2008). In that study, 
activation of SIRT1 suppressed proliferation and supported differentiation of NPCs 
to astrocytes.  
In this thesis, oxidative stress was induced in conjunction with SIRT1 inhibition and 
activation to find a preliminary understanding for role of SIRT1 in oxidative stress in 
glioma compared to normal astrocyte cell lines as described in the previous 
sections. 
Exogenously administered H2O2 is commonly used in vitro to induce oxidative 
stress conditions (Allen & Tresini 2000) (Keyse & Emslie 1992, Park et al 2012) as 
it can cross the plasma membrane and contribute to intracellular oxidative stress 
(Klaunig & Kamendulis 2004). 
5.2 SIRT1 inhibition and activation in glioma and normal cells  
5.2.1 Malignant glioma cells are more resistant to H2O2 than normal 
astrocytes 
To determine susceptibility to H2O2 –induced cell death, cells were treated with 
increasing concentrations of H2O2 for 1 d. Viability was measured with PI exclusion 
using flow cytometry.  
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Figure 25. Malignant glioma cells were more resistant to H2O2 compared to normal 
astrocyte cells.  
Viability for a titration of H2O2 after 20 hr incubation was measured using PI exclusion and flow 
cytometry for (A) murine normal astrocytes C8D1A and murine glioma cell line GL261 (B) GL261 
cells grown in media with 10% or 20% FBS (C) human normal astrocyte cell line SVG, and two 
primary cells lines 0906 and 0713. (D) Three primary glioma cell lines exposed to high 
concentrations of H2O2. PI negative values expressed as a percentage. Experiments from A to C 
values from three experiments are shown; in experiment D, PI percentages shown are the average 
of measurements from three experiments. ** p<0.01 *** p<0.005, **** p<0.001 Student’s t-test, two-
tailed, unpaired. Statistics compared glioma to normal astrocytes.  
The effects of H2O2 on both human and murine paired normal to glioma cell lines 
were analysed. While the murine GL261 and C8D1A cells were ten times more 
resistant than the human cells to H2O2 -induced oxidative stress, both the murine 
and human cancer cells were more H2O2 -resistant compared to the normal cell 
equivalent (Figure 25 A and C).  
The GL261 cells were routinely grown in media with 20% FBS- supplement, 
whereas C8D1A were routinely grown with 10% FBS –supplemented media. To 
find out if the change in FBS affected stress response pathways, the effect of H2O2 
treatment was compared between 20% and 10% FBS-supplemented media in 
0 25 50 75 100 125 150 175
0
20
40
60
80
100
 [H202] mM
P
I 
n
e
g
a
ti
v
e
  
SVG
0906
0713
****
***
****
0 500 1000
0
20
40
60
80
100
 [H202] mM
P
I 
n
e
g
a
ti
v
e
  
0814
0906
1003
0 200 400 600 800 1000 1200
0
20
40
60
80
100
 [H202] mM
P
I 
n
e
g
a
ti
v
e
  
GL261  
C8D1A  
****
0 500 1000
0
20
40
60
80
100
 [H2O2] mM
P
I 
 n
e
g
a
ti
v
e
GL261 20% FBS
GL261 10% FBS
**
A	
D	
B	
C	
%
 
%
 
%
 
%
 
 84 
GL261. The FBS levels appeared not to have an influence on the resistance to 
H2O2 in these cells (Figure 25 B).  
Glioblastoma tumours are heterogeneous, that is, no two patients have the same 
tumour cell phenotypes, therefore three human primary GBM cells were analysed for 
response to H2O2 treatment. There were differences in resistance to H2O2 between 
primary cell lines (Figure 25 D), and interestingly, the 0906 cell line appeared to have 
a large subset of cells that stayed alive despite strong concentrations of H2O2 -- 
around 20% compared to 4-5% in the other primary glioma cells. These 0906 had 
become immortalised in culture, shown in Figure 16. 
5.2.2 Nicotinamide (NAM), a SIRT1 inhibitor rescued normal but not 
malignant cells from lethal oxidative stress 
To determine the contribution of SIRT1 to the peroxide stress response, murine 
normal and malignant astrocyte cells were grown in culture for 1 d, then subjected 
to a lethal concentration of H2O2 for 20 hr, with or without SIRT1 inhibitor NAM, at 
two different concentrations. Viability was measured using the PI exclusion assay 
and flow cytometry. 
Both concentrations of nicotinamide rescued C8D1A cells from a lethal 
concentration of peroxide, whereas neither concentration of NAM rescued the 
malignant GL261 cells from the lethal peroxide levels (Figure 26).  
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Figure 26. Nicotinamide rescued normal but not malignant murine astrocyte cells from 
lethal oxidative stress 
(A and B) Bar graph representations of PI exclusion assay of murine normal cells, C8D1A, and 
malignant glioma cells GL261 after lethal concentrations of H2O2 with 1 mM NAM grown for 20 hr. 
10,000 cells were measured by flow cytometry. Pooled data from three experiments in triplicate for 
both of these were performed (C and D) As in A and B, using 10 mM NAM. Graphs show one 
experiment performed in triplicate for each of these. Student’s t-test, two-tailed, unpaired  
*** p < 0.005, **** p<0.001; ns = not significant. 
5.2.3 Low concentration nicotinamide rescued malignant murine astrocyte 
cells grown in reduced FBS 
C8D1A and GL261 cells were grown in media using 10% or 20% FBS-supplement 
for at least two passages, followed by treatment with a lethal concentration of 
peroxide to ascertain whether the rescue effect by NAM was influenced by change 
in FBS levels. 
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Figure 27. Low concentration nicotinamide rescued malignant murine astrocyte cells with 
reduced FBS 
C8D1A and GL261 cells were grown for more than two passages in media with either 10% or 20% 
FBS, then subjected to a lethal concentration of H2O2 for 20 hr with or without 1 mM or 10 mM 
NAM. Cell viability was assessed by PI exclusion assay and flow cytometry. (A) Graphic 
representation of viability of GL261 cells grown in 20% FBS, with or without H2O2 and 1mM NAM; 
(B and C) As in (A), but with GL261 and C8D1A grown in media with different FBS concentrations 
(D and E) GL261 cells grown in different levels of FBS with and without H2O2 or 10 mM NAM. 
Graphs show: (A and B) three sets of experiments in triplicate (C, D and E) one set in triplicate.  
** p < 0.01, **** p < 0.001 Student’s t-test, two-tailed, unpaired, ns = not significant. 
Surprisingly, when murine glioma GL261 cells were grown in the lower percentage 
of FBS, a rescue was observed with the low concentration of NAM but not at the 
higher concentration (Figure 27 B and D). The increase of FBS did not alter the 
rescue effect for the C8D1A which were rescued with 1 mM NAM even when 
grown in 20% FBS (Figure 27 C).  
5.2.4 Nicotinamide rescued normal but not malignant human astrocyte 
cells 
The rescue effect from a lethal concentration of H2O2 seen in murine cells was 
tested in human cells using SVG and human primary glioma cells. Cells were 
grown in culture with or without H2O2, and with or without NAM, for 20 hr.  
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Figure 28. Nicotinamide rescued normal but not malignant human astrocyte cells from 
lethal oxidative stress 
Cells were grown for 20 hr with or without a lethal concentration of H2O2, with or without 10 mM 
NAM. (A) Dot plot showing flow cytometry gating out of dead cells (first box); histogram showing live 
untreated cells (blue), H2O2 treated (red), and H2O2 with NAM treated (green) cells, from cells 
stained with PI and measured by flow cytometry (second box); graphic representation showing the 
four separate treatments for SVG astrocytes showing PI negative on the y-axis (third box).  
(B) As in A, but for glioma primary cells, 0906. Results from one experiment performed in triplicate. 
*** p < 0.005 Student’s t-test, two-tailed, unpaired, ns = not significant. 
The human cells lines exhibited the same pattern as seen with the murine cells. 
While normal SVG cells were rescued by NAM, glioma primary cells 0906, were 
not rescued by NAM after a lethal peroxide treatment (Figure 28). Further 
experiments using multiple primary glioma cell lines would be useful to confirm this 
result. 
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5.2.5 Resveratrol had an opposing effect to nicotinamide with astrocytes 
under oxidative stress 
The experiment described in the last section was repeated using SIRT1 activator, 
RES, instead of SIRT1 inhibitor. 
 
 
 
 
 
 
 
Figure 29. Resveratrol had no rescue effect to lethal H2O2 -induced oxidative stress in C8D1A or GL261 
Cells were grown for 20 hr with or without a lethal concentration of H2O2 and with or without 50 μM 
RES. (A) C8D1A cells with H2O2 and RES treatment (B) As in A, but for GL261 cells. One 
experiment performed in triplicate. * p < 0.05 Student’s t-test, two-tailed, unpaired. 
This experiment showed neither C8D1A nor GL261 were rescued by RES (Figure 
29). C8D1A cells showed the opposite effect, where RES with H2O2 has a 
significant additive effect on cell death outcome (p < 0.05) (Figure 29 A), which is 
consistent with NAM having a rescue effect, indicating that this could reflect Sirt1 
activity – and a differential Sirt1 role of glioma versus normal cells. 
5.2.6 Length of treatment time influenced the rescue effect of NAM, and the 
additive effect of RES treatment  
To investigate a potential Sirt1 mechanism for the rescue effect of NAM, the same 
experiment was performed as described earlier using C8D1A and GL261 cells, 
with a shorter treatment time of 6.5 hr – and using two lower concentrations of 
H2O2. 
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Figure 30. Nicotinamide rescued murine glioma cells from lethal oxidative stress at an 
early time point, but not at a later time point. Resveratrol had opposing effects 
Cells were grown for 6.5 or 20 hr with three different concentrations of H2O2, with or without 10 mM 
NAM or 50 μM RES. (A) C8D1A grown for 6.5 hr with or without NAM or RES at varying H2O2 
concentrations (B) As in A, but for GL261. One experiment performed in triplicate for each 
treatment. * p <0.05, ** p < 0.01 *** p < 0.005, **** p < 0.001 Student’s t-test, two-tailed, unpaired, 
ns = not significant. 
In all cell lines, RES had opposing effects to NAM with increased cell death when 
RES was added at the same time as H2O2 (Figure 30). The effect of the Sirt1 
inhibitor or activator was greater for the normal C8D1A cell line than for glioma 
cells after 20 hr (Figure 30 C and D). Interestingly, there was a rescue effect for 
GL261 with NAM at the earlier time point, but not at the later time point indicating 
that the differential effect of NAM in GL261 compared to C8D1A takes some time 
for response.  
5.3 Immunoblotting to investigate changes in SIRT1 protein 
levels and H4K16-ac after oxidative stress 
To investigate if SIRT1 levels change under peroxide stress or nicotinamide, cells 
were grown for 20 hr with or without sub-lethal or lethal concentrations of H2O2, 
and with or without NAM. The cells were extracted with whole cell lysis, and 
analysed using Western blotting. 
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5.3.1 A prominent second protein band appeared on Western blots for 
SIRT1 in normal but not malignant cells after H2O2 -induced oxidative 
stress 
Elevated levels of Sirt1 with sub-lethal concentrations of H2O2 was seen for both 
C8D1A and GL261 cell lines after 20 hr treatment (Figure 31 B and D). A lethal 
concentration of H2O2 had no effect on Sirt1 levels in the normal cell line, while in 
the glioma cell line Sirt1 was reduced after a lethal H2O2 concentration. Sirt1 was 
seen to have a second band, at about 80-85 kDa after H2O2 treatment for the 
normal cell line in both concentrations of H2O2, but was not seen in the glioma cell 
line (Figure 31 A red arrows). While the experiment shown here was performed 
only once, this second Sirt1 band was seen in further experiments in the normal 
cells after oxidative stress treatment. NAM treatment had no effect on Sirt1 quantity 
with or without H2O2 (Figure 31 B and D). 
The second band was faintly observable at 6.5 hr in the normal cells but not on the 
glioma cells, suggesting that it takes some time to establish quantity of the putative 
smaller species of Sirt1 under these conditions (Figure 31 E). 
To verify this observation, human SVG normal astrocyte cell line and the primary 
glioma cell line 0713 were treated with a lethal concentration of H2O2, followed by 
whole cell lysis, protein extraction and Western blotting.  
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Figure 31. SIRT1 was cleaved under H2O2 -induced oxidative stress in murine and human 
normal astrocyte cells, but not in malignant cells 
Cells were seeded for 1 d before treatment of H2O2, NAM or combination of both.                           
(A and B) Western blot image and histogram quantification of Sirt1 in C8D1A cells after 20 hr 
treatment of 500 μM or 750 μM H2O2, or 10 mM NAM, or a combination of both. Red arrows indicate 
extra bands for Sirt1; (C and D) As in A and B, but for GL261 cells, where the higher lethal H2O2 
concentration used was 1000 μM; (E) Western blot image of Sirt1 in C8D1A cells after 6.5 hr 
incubation with or without a lethal concentration of H2O2. Red arrow indicates extra band for Sirt1; 
(F) Western blot images of SVG or 0713 cells with or without a lethal concentration of H2O2 for 20 
hr. Note loading control was absent for SVG. Levels of Sirt1 in histograms were adjusted to β-actin 
loading controls. 
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Results confirmed an increase in a second band of hSIRT1 in normal SVG cell line 
but not glioma cells after H2O2 treatment (Figure 31 F). Levels of hSIRT1 had 
decreased for the human primary glioma cells after a lethal concentration of H2O2, 
reflecting the similar result seen in the murine GL261 cells, indicating that this 
result was also typical for SIRT1 in glioma.  
5.3.2 H4K16 acetylation status changed in murine cell lines after 20 hr 
treatment with H2O2 and nicotinamide 
After H2O2 treatment, a smaller fragment of Sirt1 was observed in C8D1A cells, but 
not in GL261 cells. The fragment was lost when NAM was added at the same time 
as H2O2 (Figure 31 A). While this may have something to do with the rescue effect 
seen in the normal cells after H2O2 treatment, it did not explain why the glioma cells 
-re not rescued. To further investigate these responses, H4K16-ac was measured 
after these treatments. Histone extraction followed by immunoblotting was 
performed with and without a lethal concentration of H2O2 and with or without NAM 
treatment for 20 hr in both the normal and glioma cell lines.  
As expected, NAM treatment showed an increase of histone 4 acetylation in both 
the normal and glioma cells (Figure 32 A and B) indicating NAM inhibition of Sirt1 
deacetylation for this residue. Treatment with H2O2 showed an increase in 
deacetylation for both cell lines indicating that Sirt1 activity is increased in oxidative 
stress at the lethal concentration after 20 hr. NAM treatment with H2O2 increased 
H4K16-ac by about 3 x in C8D1A cells, while only 1.3 x in GL261 cells (Figure 32 B 
red arrows), suggesting that increased H4K16-ac relates to stunting the lethal 
stress incurred by H2O2, as seen with the rescue in Figure 26, where C8D1A cells 
were recued from lethal H2O2-induced stress with NAM treatment, but GL261 were 
not rescued. 
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Figure 32. H4K14 acetylation in murine cells after H2O2 or nicotinamide treatment for one 
day 
 Murine C8D1A and GL261 cells were grown for 1 d in culture then treated with a lethal 
concentration of H2O2 or 10 mM NAM, or a combination of both. Histone extraction and western 
blotting followed by immunoblotting for H4K16 acetylation. (A) Western blot images for loading 
control using amido black staining for histone 4 (top panels), and the same membrane probed for 
H4K16-acetyaltion (bottom panels) for C8D1A and GL261 cells. (B) Histogram showing 
quantitatively the Western blot images, relative to each other and adjusted for loading levels. Red 
arrows indicate differences in acetylation of H4K16 after H2O2 treatment and H2O2 plus NAM 
treatment for each cell line. 
5.3.3 H4K16 acetylation changes in murine cell lines after two-hour 
treatment with H2O2 and nicotinamide 
To find out if changes to H4K16-ac after H2O2 and NAM treatment had the same 
result at an earlier time point, histone extraction was performed after 2 hr, followed 
by immunoblotting. 
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Figure 33. H4K16 acetylation in murine cells after H2O2 or nicotinamide treatment for two 
hours 
Cells were seeded for one day before treatment of a lethal concentration of H2O2 or 10 mM NAM for 
2 hr, followed by histone extraction and immunoblotting for H4K16-ac. (A) Western blot image 
showing C8D1A (left panel) and GL261 (right panel) H4K16-ac with or without treatment. Loading 
control was measured using amido black staining for total protein (top panels); (B) histogram 
showing quantification for Western blot images, with H4K16-ac adjusted to loading control. GL261 
cells grown in 20% FBS. 
Untreated GL261 cells had increased H4K16-ac compared to untreated C8D1A 
cells consistent with previous results (Figure 33 B black bars). H2O2 – induced 
stress and NAM treatment showed opposite effects for H4K16-ac in the different 
cell lines. For C8D1A cells, H2O2 or NAM treatment increased acetylation, whereas 
the same treatment decreased H4K16-ac in GL261 cells (Figure 33 B yellow and 
red bars). This indicated different responses to these treatments between the cells. 
It also differs from H4K16-ac measurements made at 20 hr, where GL261 cells had 
increased acetylation as did the C8D1A cells, indicating different actions for Sirt1 
under oxidative stress at different time points as well as between cancer and 
normal cell lines. 
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5.3.4 Localisation changes for Sirt1 in murine normal and cancer 
astrocytes after two-hour H202 or nicotinamide treatment 
In previous results, untreated GL261 cells had higher H4K16-ac levels compared 
to the normal astrocyte cell line, C8D1A. Correspondingly, Sirt1 was aberrantly 
found in the cytoplasm GL261 cells, where it was found predominantly in the 
nucleus in C8D1A cells. It was postulated that changes in localisation of Sirt1 could 
explain the results seen in histone acetylation after 2 hr H2O2 or NAM treatment in 
these cell lines. To find this out, nuclear/cytoplasmic extraction was performed at 
the same time as the histone extraction in Section 5.3.3.  
 
Figure 34. Localisation changes for Sirt1 in murine normal and glioma astrocytes after 
two-hour H2O2 or nicotinamide treatment  
Nuclear /cytoplasmic extraction was undertaken for C8D1A and GL261 cells after 2 hr treatment of 
H2O2 at a lethal concentration, or 10 mM NAM using the two buffers made up in the lab, as 
described in Andrews et al (Andrews & Faller 1991). Western blotting followed by probing for Sirt1 
was performed for (A) cytoplasmic compartment and (C) nucleic compartments separately. β-actin 
was used as the loading control for both compartments, purity of extraction was not tested, and 
results were analysed by image J and graphically represented (B and D), red lines explained in the 
text. 
Results indicated increased Sirt1 in the cytoplasm in untreated GL261 cells 
compared to increased levels of nucleic-localised Sirt1 in untreated C8D1A cells, 
consistent with all previous results (black bars Figure 34 B and D). Treatment with 
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H2O2 increased Sirt1 in the cytoplasm of the C8D1A cells and decreased Sirt1 in 
the cytoplasm for the GL261 cells, consistent with H4K16 acetylation results seen 
in earlier (Figure 33). NAM treatment appeared to decrease the level of Sirt1 in the 
cytoplasm for both cells (Figure 34 B purple thatched bars). The results from the 
blot for the nuclear compartment were not always consistent, with the cytoplasmic 
results. This could be explained by a poor extraction either in quantity or purity, 
therefore this experiment needs repeating. However, results for the cytoplasmic 
compartment showed a clearer immunoblot and were more consistent with results 
seen with histone extraction in Section 5.3.3, which was done using a portion of the 
cells from the same experiment. Taken together with immunofluorescent 
experimental results shown in Section 3.3, the combined evidence suggests that 
Sirt1 in untreated glioma cells is localised differently to normal cells, and this 
localisation is affected differently under oxidative stress and NAM treatment. 
Additionally, these changes alter between 2 hr and 1 d.  
5.3.5 Nuclear/cytoplasmic changes for hSIRT in human SVG astrocytes and 
primary glioma cells after four-hour H2O2 treatment  
To verify the results in the response to H2O2 treatment where Sirt1 in the mouse 
model suggested altered localisation after treatment, human astrocyte cell line, 
SVG, and primary glioma cell line 0906 were exposed to 100 μM and 120 μM 
(lethal dose) for four-hour and extracted using formaldehyde crosslinking before 
nuclear/cytoplasmic extraction. 
FL-hSIRT1 was not seen clearly in these results. While hSIRT1 was seen clearly in 
the Western blots for whole cell lysis extraction seen earlier, a similar result 
showing reduced or absent FL-hSIRT1 this was seen in the other 
nuclear/cytoplasmic extraction using SVG cells after crosslinking (Figure 15).  
FL-hSIRT1 could have been lost during extraction, or perhaps it was in the form of 
a trimer – kept intact after crosslinking, and was too large for detection in this 
experiment. There is evidence in the literature to support this (Guo et al 2012).  
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However, a number of other bands running further in the gel were present, as in 
other extractions, and a different pattern of these bands was seen after treatment. 
While it is possible these smaller bands are non-specific antibody binding, as 
mentioned before, smaller hSIRT1 species have been reported, in particular a 
band at 68 kDa, 75 kDa and 80 kDa.  
 
Figure 35. hSIRT1 localisation changes in SVG and primary glioma cells 0906 after four-
hour H2O2 treatment 
SVG and 0906 primary glioma cells were seeded for one day, then treated for four-hour with a lethal 
concentration of H2O2 (100 μM for SVG, 100 μM for 0906), 10 mM NAM or 50 μM RES followed by 
nuclear/cytoplasmic extraction using the NE-PER kit with prior formaldehyde fixing (as described in 
methods section) and immunoblotting with hSIRT1 antibody. (A) FL-hSIRT1 and smaller species of 
hSIRT1 in treated and untreated SVG cells and for (B) treated and untreated 0906 (post-
immortalisation) cells. C= cytoplasmic compartment, N= nuclear compartment. Loading controls 
were attempted but were unsuccessful. 
Untreated 0906 cells had more cytoplasmic smaller species than SVG cells (Figure 
35 black asterisks). This was consistent with previous experiments that 
consistently showed more cytoplasmic SIRT1 in glioma cells compared to normal 
astrocytes. After H2O2 treatment, the smaller hSIRT1 species was decreased in the 
nuclear compartment for SVG cells, but increased in the nuclear compartment for 
0906 cells, and consistent with this was an increase and decrease in the 
cytoplasmic compartments respectively (Figure 35, coloured arrows). 
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These results, while preliminary, provide an indication that the response of hSIRT1 
may involve smaller species of hSIRT1 and changes in localisation under oxidative 
stress. Importantly, these responses are different between normal and glioma cells.  
5.4 Sub-cellular localisation changes for SIRT1 after NAM or 
RES treatment 
SIRT1 has different localisation profiles in untreated glioblastoma and normal cells. 
It was therefore investigated whether the effect of NAM and RES might be related 
to differences in localisation of SIRT1.  
Extractions of nucleus and cytoplasm were conducted with and without NAM for 
murine GL261 and C8D1A cells after 20 hr incubation, and for human glioma and 
SVG normal astrocytes after four-hour incubation with NAM or RES. Formaldehyde 
fixation prior to extraction was used.  
5.4.1 Nuclear/cytoplasmic fractionation and Western blotting for SIRT1 
after RES or NAM treatment in human normal astrocytes and primary 
glioma cells 
After 1 d incubation with NAM, there appeared to be decreased cytoplasmic and 
increased nuclear FL-Sirt1 in murine GL261 cells, but no effect on Sirt1 localisation 
in C8D1A cells (Figure 36 A and B, orange and red arrows). NAM treatment for 
four hours showed increased smaller species of hSIRT1 in the cytoplasm of SVG, 
with a possible decrease of these in the nucleus (Figure 36 C light blue and dark 
blue arrows – third and fourth lanes), however NAM treatment results were unclear 
for the human primary glioma 0906 cells. Treatment with RES increased nuclear 
FL-hSIRT1 after 4-hr treatment in 0906 (Figure 36 D, red arrow). Levels of both 
smaller species of hSIRT1 changed after RES and NAM treatment in the 
cytoplasm of SVG cells (Figure 36 C, light blue arrows), while a possible increase 
in the faster running molecule (possibly the 75 kDa fragment) for 0906 increased in 
the nucleic but particularly in the cytoplasmic compartment of 0906 cells after RES 
treatment (Figure 36 C, dark blue arrows last two lanes). No loading or purity 
controls were successfully used in this Western blot. The antibodies did not work 
for unknown reasons. These results are preliminary, and need verification. 
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These results suggest a change in SIRT1 localisation after NAM or RES treatment, 
and possible cleaving or stabilisation patterns for SIRT1 smaller species under 
these conditions.  
 
Figure 36. Altered localisation of SIRT1 with NAM or RES treatment 
Western blot images for SIRT1 after nuclear-cytoplasmic extractions. (A) Extraction using buffers A 
and B as described Section 2.2.3 for murine cell lines C8D1A and GL261. Incubation with NAM for 
20 h. β-actin was used as a loading control, and more β-actin was observed in the nucleus of 
GL261. This was seen in other experiments indicating that was the nuclear fraction. (B and C) 
Extraction using NE-Per kit after formaldehyde fixation, as described in methods section, for SVG 
and 0906 cells. NAM and RES incubation 4 h. Red arrows show increased FL-SIRT1 compared to 
untreated cells, light blue arrows indicate decreased smaller SIRT1 species, dark blue arrow 
indicates increased common smaller SIRT1 species. Abbreviations: N= nuclear compartment; C = 
cytoplasmic compartment. 
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5.4.2 Immunofluorescent staining for hSIRT1 in primary glioma cells after 
NAM treatment 
To find out if changes in localisation were valid for NAM treatment of human primary 
glioma cells, another method was attempted. Immunofluorescent staining was 
performed with and without 2 hr treatment of 10 mM NAM in three primary glioma cell 
lines. hSIRT1 was stained green, and using image J, 100 or more non-dividing cells 
were characterised for localisation in untreated cells or NAM-treated cells. 
In each of the three primary gliomas assessed for hSIRT1 localisation, the effect of 
NAM treatment showed a more nuclear or a predominantly nuclear hSIRT1 profile 
compared to untreated cells (Table 6 and Figure 37). While this method does not 
discern between different species of hSIRT1, it does indicate a change in 
abundance of overall nuclear hSIRT1 after NAM treatment for these cells.  
Table 6. Cell counts for sub-cellular localisation of hSIRT1 in primary glioma cells with 
and without NAM treatment 
 
	
 nuclear predominantly cytoplasmic predominantly 50/50 total 
  nuclear  cytoplasmic   
1005       
Untreated 49 86 0 0 8 143 
NAM 85 85 1 1 6 178 
       
1003       
Untreated 36 163 16 13 23 251 
NAM 41 262 0 0 3 306 
       
0814       
Untreated 2 49 0 10 31 92 
NAM 9 88 0 0 12 109 
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Figure 37. Immunofluorescence of hSIRT1 in primary glioma cells after NAM treatment 
Human glioma cells were grown for two days on 8-well chamber slides before treatment of 10 mM 
NAM. After two hours, the cells were fixed using paraformaldehyde and incubated with hSIRT1 
antibody, and secondary antibody, which fluoresced green. DAPI was used to stain for nuclei. At 
least 100 non-dividing cells were assessed by eye for hSIRT1 localisation for each of three primary 
cell lines with or without treatment (A) An example of one field of view for one primary glioma cell 
line, 1005, for untreated and NAM-treated cells (B) Pie charts representing results from treated and 
untreated for three primary cell lines. Raw data taken from cells counted and assessed for sub-
cellular localisation, presented in Table 6 (previous page). 
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5.5 SIRT1 in the cytoplasm co-localised with mitochondria  
5.5.1 hSIRT1 associates and alters mitochondria in normal astrocyte 
response to oxidative stress  
It has been reported that some sirtuins associate with mitochondria, in particular 
SIRT3 (Webster et al 2012). SIRT1 has also been identified with mitochondrial 
associated molecules, for example PGC1-α (Sugden et al 2010) but more recent 
research has identified the 75 kDa SIRT1 fragment and mitochondria associating 
directly to inhibit cytochrome c release and apoptosis in chondrocytes 
(Oppenheimer et al 2012). Several different experiments in this thesis indicated 
that under oxidative stress, SIRT1 in normal astrocytes had an increased presence 
the cytoplasm. To find out if SIRT1 affected mitochondria under oxidative stress in 
normal astrocytes, C8D1A cells were treated for 2 hr with H2O2 with or without 
NAM. Median fluorescent intensties (MFI) for Mitotracker green (MTG) and 
Mitotracker red (MTR) were used to assess changes in mitochondrial membrane 
potential (MTR) and mitochondrial mass (MTG), in C8D1A normal murine 
astrocytes. 
Additionally, MTG and hSIRT1 antibody immunofluorescent staining were used to 
assess co-localisation of hSIRT1 with mitochondria visually using human SVG 
astrocytes. Immunofluorescent experiments using C8D1A were similarly 
undertaken, but results were unclear.  
  
  103 
 Figure 38. Inhibition of Sirt1 affects mitochondrial mass in normal murine astrocytes under 
mild oxidative stress 
(A and B) C8D1A cells were grown for 1 d, then treated with different concentrations of H2O2 or 
NAM for 2 hr, then harvested and incubated with MTR (A) or MTG (B) and measured by flow 
cytometry for changes in mean fluorescent intensity (MFI) for MTG/MTR, n=3.  
Results showed that for C8D1A cells, after H2O2 -induced stress MTR the median 
fluorescent intensity (MFI) was reduced in a concentration-dependent manner, 
however NAM treatment did not change the outcome, suggesting Sirt1 is not 
involved in membrane potential changes after oxidative stress (Figure 38 A). MTG 
results showed that MFI increased with H2O2 -induced stress, but was significantly 
reduced with NAM treatment in combination with a lethal concentration of H2O2 
only (Figure 38 B), suggesting that Sirt1 may have some role in changes of 
mitochondrial mass under H2O2 –induced stress. Analysis of immunofluorescent 
staining indicated that hSIRT1 was more cytoplasmic after H2O2 treatment for 2 hr 
in normal SVG astrocytes (Figure 39 A arrows), and co-localisation of hSIRT1 with 
mitochondria was occurring (Figure 39 A and B merge panels -orange colour). 
Different morphology of mitochondria was observed before and after treatment in 
normal SVG cells, where long filamentous mitochondria became more punctate 
after treatment (Figure 39 C), which could be related to hSIRT1 activity at 
mitochondria, given MTG measurements changed under oxidative stress and NAM 
treatment. Similar experiments for glioma cells were unsuccessful. 
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Figure 39. hSIRT1 is increased in the cytoplasm and associates with mitochondria under 
sub-lethal oxidative stress 
(Facing page)  
(A) SVG cells were grown in 8-well chamber slides for two days before treatment for 2 hr with 50 
μM H2O2, fixed and stained for hSIRT1 (red), nuclei (blue) using DAPI, and mitochondria (green) 
using MTG, arrows point to some examples of fluorescent hSIRT1 that has become visible after 
treatment; (B) one SVG cell on higher magnification showing hSIRT1 with mitochondria after 50 μM 
H2O2 treatment for 2 hr; (C) morphological changes in mitochondria of SVG cells untreated or 
treated for 2 hr with H2O2, fixed and stained with hSIRT1 (red) or MTG (green).  
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Part 6:  Discussion 
Glioblastoma is a disease with a dire outlook for the patient. Treatment for this 
cancer has remained largely unchanged over the last ten years, and the need to 
find new ways to tackle this disease is important. The objective of this thesis was to 
investigate the potential role of SIRT1 in glioblastoma in the context of cell 
proliferation and under oxidative stress.  
SIRT1 is well known to have considerable involvement in maintaining homeostasis 
in many different cell types in relation to metabolic changes and under oxidative 
stress conditions. Oxidative stress, cell proliferation and altered metabolic function 
are conditions highly relevant to the progression of glioblastoma (Bartkova et al 
2010). However, to date there is little research into the role of SIRT1 in GBM. 
6.1 SIRT1 in untreated normal astrocytes and glioma cells 
6.1.1 SIRT1 protein levels in glioma and normal astrocytes 
Research into the levels of protein or RNA expression levels for SIRT1 in many 
different cancers has become of more interest in recent years, but there is scant 
research into SIRT1 levels in GBM.  
A recent study measuring hSIRT1 levels in 43 clinical samples taken from patients 
with brain tumours from WHO Grade I-IV, show RNA expression of hSIRT1 is 
increased in grades I-III, but is decreased in grade IV tumours compared to normal 
tissue (Annabi et al 2012). Notably there was only one sample for GBM grade IV in 
that study. Reduced levels of SIRT1 are seen in GBM grade IV samples (n=77) 
compared to normal brain tissue (n=23) in an earlier study (Wang et al 2008), 
however Dixit et al found elevated SIRT1 protein in human GBM tumour tissue 
compared to surrounding normal tissue (Dixit et al 2012), and another study found 
mice with Sirt1 knocked down had increased survival rates after radiotherapy  
(Chang et al 2009).  
Results in this study showed that in the murine glioma cell line, GL261, levels of 
Sirt1 were increased compared to the normal murine astrocyte, C8D1A however 
this did not reach significance. Human primary glioma cells taken from patients 
with glioblastoma tended to show less hSIRT1 compared to the human astrocyte 
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cell line, SVG, in both Western blotting and intracellular staining. This conflict in 
SIRT1 level results between glioma and normal cells between species could be 
because of the general differences between the cell signaling patterns within each 
cell line, and particularly because the normal cell comparison in the human model 
is an immortalised cell line. In support of this, one primary glioma cell line, 0906, 
went into a quiescent phase while in culture, after which it changed to become 
smaller, faster proliferating cells (personal observation), indicating it had 
spontaneously immortalised (Gillio-Meina et al 2000). When hSIRT1 levels were 
analysed in post-immortalised cells, there was an increase compared to pre-
immortalised cells, suggesting that immortalised cells have increased SIRT1. This 
could be important in the context of GBM, for example one study using post-
mortem brain tissue taken from fifty patients with GBM uncovered that it was 
predominantly the small anaplastic cells that were responsible for the proliferative 
and invasive nature of the disease (Giangaspero & Burger 1983). Additionally, 
normal astrocytes are capable of dedifferentiating to become mobile, faster 
proliferating cells  (Leavitt et al 1999) and this is thought to be one way glioma is 
initiated or reestablished after treatment (Maher et al 2001).  
However, it is possible that SIRT1 is expressed less in normal brain cells 
compared to cells from glioblastoma. In support of this, one study which analysed 
tumours from the World Health Organisation (WHO) Grade I-III reported increased 
SIRT1 compared to normal brain tissue, however WHO Grade IV (glioblastoma) 
had comparatively decreased hSIRT1 (Annabi et al 2012), suggesting different 
roles for hSIRT1 at different stages of the disease.  Another study of lung cancer 
found hSIRT1 activity increased in airway epithelium of smokers but not in non-
smokers, yet hSIRT1 activity was significantly decreased in lung adenocarcinoma 
indicating a protective function for hSIRT1 in an oxidative environment, which was 
lost after cells were transformed (Beane et al 2012). This may also explain some 
conflicting research, for example in research for prostate cancer where in one 
study SIRT1 expression is elevated (Huffman et al 2007) and in another it is 
reduced (Lapointe et al 2004). 
6.1.2 Unidentified protein bands on Western blots – potential significance 
Several protein bands were seen after immunoblotting for SIRT1. A band at around 
75 kDa was seen on human and mouse cells. The faster migrating molecule at 
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about 75 kDa on the Western blots for primary glioma cells was greater in 
proportion to FL-SIRT1 than for normal  SVG astrocytes. While usually secondary 
proteins bands on Western blots would be ignored as non-specific protein binding, 
a truncated SIRT1 species has been listed on the NCBI BioSystems database and 
is an accepted isoform of hSIRT named SirT1 75 kDa fragment, and so this 
potential fragment of SIRT1 seen on immunoblots was not ignored in this study. 
The roles of these putative SIRT1 forms may be important. For example, TNFα 
stimulation generates a 75 kDa SIRT1 fragment which moves to the cytoplasm and 
associates with mitochondria to mitigate apoptosis in osteoarthritic chondrocytes 
(Oppenheimer et al 2012); caspases cleave SIRT1 and alter location from the 
nucleus to the cytoplasm in apoptotic HeLa cells (Ohsawa & Miura 2006).  A 
smaller caspase-1 cleaved SIRT1 fragment of around 80 kDa was found in adipose 
tissue in an inflammatory microenvironment (Chalkiadaki & Guarente 2012a). 
Additionally, a smaller splice variant of SIRT1, called SIRT1-Δ2/9, at 17 kDa and 
34 kDa (suggested to be a dimer of the smaller one) is seen in a range of human 
normal tissue and human colorectal cancer cell lines, which binds and maintains 
p53 and opposes the action of FL-SIRT1 (Shah et al 2012). Cathepsin SIRT1 
cleavage in endothelial progenitor cells induced premature senescence (Chen et al 
2012b). Interestingly, cathepsin B is found elevated in glioblastoma cell lines 
(Konduri et al 2001) and elevated cathepsin S expression in astrocytomas is linked 
to tumour progression and poor prognosis for patients with glioblastoma (Flannery 
et al 2006). 
A stress inducible splice variant of SIRT1, SIRT1-Δ8, migrating at 95 kDa is found 
in human epithelial cells, and in normal mouse tissue including brain (Lynch et al 
2010). Yet another SIRT1 isoform formed from NLRP3 inflammasome-activated 
caspase-1 has been identified in adipocytes at 80 (Chalkiadaki & Guarente 2012a). 
This variant species, only identified using a carboxy-terminal SIRT1 antibody, was 
found to be much less stable than FL-Sirt1 and conferred an altered metabolic cell 
function (Chalkiadaki & Guarente 2012a). It is possible that this is the isoform of 
SIRT1 seen on the blots here, although with the murine cells, no secondary bands 
were seen using a carboxy-terminal Sirt1 antibody. 
Other possible reasons to see different sizes of SIRT1 proteins on the blot include 
proteosomal cleavage and degradation of SIRT1, which is reported for SIRT1 (Gao 
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et al 2011), or SIRT1 mutants arising from DNA mutations in the cancer cells. 
SIRT1 is mapped on chromosome 10 (10q21.3) (Mahlknecht & Voelter-Mahlknecht 
2009) and 10q is identified as one of the areas in glioblastoma with the most 
frequent mutations (Inda et al 2003). Polymorphisms have been found in the SIRT1 
gene for several diseases (Figarska et al 2013) (Zheng et al 2012) (Mohtavinejad 
et al 2015). Polymorphisms in the promoter region could account for different 
transcripts of SIRT1.  For example, the single nucleotide polymorphism rs3758391 
T/C, contains a P53 binding site, and the SNP results in nutrient sensitive SIRT1 
expression alteration (Naqvi et al 2010). 
Verification is needed for the identification of these potential hSIRT1 species, by 
mass spectrometry. 
6.1.3 SIRT1 activity in untreated glioma and normal astrocytes 
Results from whole cell protein extraction and Western blot experiments did not 
show clearly if SIRT1 expression levels were increased or reduced for glioma cells 
compared to normal astrocytes. To investigate further, the focus was turned toward 
SIRT1 activity rather than expression, which is not necessarily related to levels of 
protein. SIRT1 is a stress response molecule, and activity of SIRT1 changes 
according to the local microenvironment. 
Histone 4 is a major substrate for SIRT1 in the nucleus, where deacetylation of 
lysine 16 (H4K16) on this histone residue is common and quite specific for SIRT1 
(Imai et al 2000). Deacetylation of this residue has linked life span extension, 
metabolism and genomic silencing to the activity of SIRT1 (Imai et al 2000). 
Furthermore hypoacetylation of H4K16 has been observed in a number of human 
cancers (Fraga et al 2005), and HDAC inhibitors have been investigated in the 
treatment of a number of cancers, including glioblastoma (Egler et al 2008).  
Investigating H4K16-ac was performed using histone extraction and Western 
blotting. As SIRT1 deacetylates this substrate, decreased acetylation indicates 
more SIRT1 activity. Our results showed that in murine cells, GL261 cells had 
consistently higher H4K16-ac compared to the normal astrocyte C8D1A cell line, 
however this did not reach significance. On examining the H4K16-ac status in a 
panel of human primary glioma cell lines and SVG, a variable acetylation status 
was found for primary cells, some of which showed increased H4K16-ac and 
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others decreased H4K16-ac compared to SVG cells.  H4K16-ac neither correlated 
to survival nor to hSIRT1 protein levels. However, unexpectedly, H4K16-ac tended 
to be increased in primary cells with more hSIRT1 protein.  
Hypoacetylation of H4K16 has been found in many cancers, including 
neuroblastoma, and hypoacetylation on this residue accumulates in the 
tumourigenic process (Fraga et al 2005), yet this was not found in analysis of these 
cells. Again, it could be because the comparison normal astrocyte, SVG is an 
immortalised cell line and may not have H4K16 acetylation patterns in the same 
way as the primary astrocytes in normal brain tissue. 
Additionally, other members of Class III HDACs including SIRT2 and SIRT3 are 
also known to deacetylate H4K16 (Vaquero et al 2007), and so it cannot be 
concluded that the changes in histone acetylation were solely due to SIRT1 
activity.  
6.1.4 SIRT1 localisation is aberrant in glioma cells 
Analysis of immunofluorescent microscopy and imaging revealed SIRT1 was 
located predominantly in the nucleus for both murine and human normal astrocyte 
cell lines, but for the murine glioma cell line and every human primary glioma cell 
tested, SIRT1 was found both in the cytoplasm as well as in the nucleus. This 
result was compelling, due to the fact that both species had the same result and 
also because both C8D1A and GL261 in the murine model are immortalised cell 
lines, while only SVG in the human model is an immortalised cell line, suggesting 
aberrant localisation is more likely to be a facet of glioma cell phenotype rather 
than because cells are immortalised.  
Results for nuclear/cytoplasmic extractions and immunoblotting for SIRT1 were 
less convincing with immunoblots showing SIRT1 predominantly in the cytoplasmic 
compartment for all cells, even with reasonably pure compartmental fractionation. 
A novel technique was tried, using a mild cross-linking process before fractionation 
and Western blotting. Using this technique, SIRT1 was found in a localisation 
pattern for glioma and normal astrocytes in both mouse and human that agreed 
with the IF images. However, using controls for loading and purity of 
compartmental separation presented difficulties.  
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Other research shows SIRT1 can change localisation in a dynamic process.  
SIRT1 has both nuclear localisation and export signals, and there are both nuclear 
and cytoplasmic localisation patterns for SIRT1 in normal cells and tissue  (Tanno 
et al 2007). Whether SIRT moved location during the extraction process, or there 
was a differential SIRT1 stabilisation between nuclear and cytoplasmic 
compartments, with differences between the glioma and normal cells could be 
assessed in future studies.  
During the course of this research aberrant cytoplasmic SIRT1 was reported for 
several other cancers (Byles et al 2010), but this is the first time, to my knowledge 
that it is reported for glioblastoma. 
SIRT1 is found in the nucleus in most cells of the nervous system that have been 
studied so far (Zakhary et al 2010), but can be found predominantly in the 
cytoplasm in some subsets of neurons, in relation to differentiation signals or 
affecting neurite outgrowth (Sugino et al 2010). Given that dedifferentiation and 
invasion are central elements of GBM, cytoplasmic SIRT1 in glioma cells needs 
further exploration. 
6.2 SIRT1 in relation to proliferation of glioma cells compared 
to normal astrocytes 
6.2.1 SIRT1 levels and activity in normal and glioma cells in relation to cell 
proliferation 
Knockdown of SIRT1 delayed mitotic entry, enhanced apoptosis and decreased 
proliferation in glioma cell lines (Qu et al 2012), however the role SIRT1 takes in 
primary glioma cells could be different to the role it takes in established cell lines. 
No study showing the involvement of SIRT1 in the proliferation of primary glioma 
cells could be found. 
In this study, the MTT reduction assay was used to assess cell proliferation. MTT 
reduction measures the metabolic state of the cells over a two-hour period. For 
cells in a culture dish this measures the additive metabolic activity for all the cells in 
the dish. So when measured at one time point and then another time point, and the 
difference between the two is calculated, the result reflects the change in number 
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of cells in the dish. I tested cells for this difference at different seeding levels to find 
out if confluency of cells altered the calculation for proliferation, and it did not 
(results not shown).  
The murine glioma and normal astrocyte were used along with human SVG 
compared to the primary glioma cells.  
6.2.2 Comparing FL-SIRT1 levels and H4K16-ac in relation to proliferation 
rates in glioma and astrocyte cell lines  
Analysis of MTT results for C8D1A and GL261 showed that the glioma cells had a 
significantly increased proliferation rate compared to the normal cell line, and an 
increase in Sirt1 levels which did not reach significance, however. When the 
analysis was made for human primary cells, there was also a trend for increased 
hSIRT1 levels in relation to increased proliferation which also did not reach 
significance. The SVG and four primary cells tested for hSIRT1 levels against 
proliferation showed that hSIRT1 levels did reflect the different proliferation rates of 
the cells. Taken together, these results suggested that FL-SIRT is linked to 
increased proliferation in these cells. In support of this, immortalised 0906 cells 
showed a significantly higher proliferation rate compared to pre-immortalised cells, 
with a corresponding increase in hSIRT1. 
On investigation into cell proliferation in relation to H4K16-ac results showed that in 
murine cells there was a significant increase in proliferation rates between normal 
and glioma cell lines, that was reflected by increased acetylation of H4K16 
between the two cell lines (non-significant however). In the human cells, a panel of 
glioma cells showed that there was relationship between increased H4K16-ac and 
greater cell proliferation agreeing with the murine data. Taken together, these 
results suggested less SIRT1 activity on H4K16 with increased proliferation, but 
more SIRT1 activity on this residue with increased metabolic rates.  
6.2.3 SIRT1 inhibition and activation effects for glioma and normal cells in 
relation to cell proliferation 
Nicotinamide (NAM) and resveratrol (RES) were used for SIRT1 inhibition and 
activation respectively.  
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Treatment with NAM decreased proliferation in all cells tested, and importantly, 
there was a different response to treatment between glioma and normal cells. The 
effect of NAM on proliferation was more statistically significant for GL261 cells 
compared to C8D1A cells. However, the effect of NAM showed a difference that 
had a greater negative value, indicating a stronger inhibitory effect. This highlights 
difficulties in working with the MTT assay as a measure of proliferation.  NAM 
treatment was more effective to decrease the proliferation of human cancer cells 
compared to normal cells also, and no results were negative. This suggested 
again, that there was a role of SIRT1 in cancer cell proliferation in GBM.  When 18 
primary human gliomas were analysed for cell proliferation with and without NAM, 
there was a significant effect of NAM to decreased proliferation in all these cells 
measured together. A study with normal and cancer epithelial cells found siRNA 
silencing of SIRT1 did not affect normal cells but in cancer cells, proliferation is 
arrested and apoptosis is enhanced (Ford et al 2005). The Ford et al SIRT1 knock-
down study also suggests that cancer cells may be more vulnerable to SIRT1 
knock-down compared to normal cells.  NAM is known to have many other cellular 
effects besides SIRT1 inhibition. NAM is also anti-inflammatory and has antioxidant 
effects (Lappas & Permezel 2011) (Godin et al 2011). NAM also inhibits Poly (ADP 
ribose) polymerase (PARP) involved in DNA repair and affects other sirtuins 
(Avalos et al 2005, Clark et al 1971). 
RES treatment increased cell proliferation for GL261 murine glioma cells, and also 
for the human primary cells 0713 and 0906 (pre-immortalisation), reinforcing the 
likelihood of SIRT1 involvement to increase cell proliferation in these cells, with a 
differential between normal and glioma cells. 
In contrast to that result, in SVG and 0906 cells post immortalisation, RES 
decreased proliferation. These different and unexpected responses indicated that 
these cells may have different cell signaling pathways for hSIRT1 compared to the 
primary cells pre-immortalisation.  Additionally, RES at low concentration 
decreased proliferation in murine cells, which may reflect a toxic effect of ethanol, 
the vehicle for RES seen in other cells, but this is not likely given the result for SVG 
cells where ethanol showed the least toxic effect, and even at 50 μM RES, SVG 
cells showed significance in decreased proliferation. Alternatively, it may indicate 
non-SIRT1 cellular effects, which are concentration dependent. It has been seen 
before that RES has different cellular effects depending on duration and dosage 
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(Peltz et al 2012), and it has other cellular effects besides SIRT1 activation. In fact, 
specific activation of SIRT1 by RES is widely disputed (Pacholec et al 2010). Some 
believe that activation of SIRT1 by RES is an in vitro artifact (Kaeberlein et al 2005, 
Pacholec et al 2010), others think that RES works by activating non-SIRT1 targets. 
In particular, RES activates AMP activated Kinase (AMPK) (Dasgupta & Milbrandt 
2007) which inhibits phosphodiesterases (PDEs), ATPase or complex III in the 
electron transport chain, and ultimately activates SIRT1 downstream by elevating 
levels of SIRT1 co-substrate NAD+ (Canto & Auwerx 2009). However, dose 
dependent RES treatment has been seen to stimulate AMPK and improve 
mitochondrial function, which is SIRT1 dependent (Price et al 2012).  
However there are some studies to show RES is activating SIRT1 specifically in 
increased proliferation (Rathbone et al 2009). 
Studies using SIRT1 knock-down or over-expression, or using other inhibitors for 
example sirtinol or EX-527 and activators like SRT1720 (Solomon et al 2006) may 
help elucidate the role of SIRT1 in glioma and normal cells.   
Additionally, using different measures for cell proliferation, for example 5-bromo-2'-
deoxyuridine (BrdU) incorporation or trypan blue exclusion assay to verify these 
results is needed.   
6.2.4 Protein changes for SIRT1 after treatment with resveratrol or 
nicotinamide 
Normal and glioma cells were treated with NAM or RES to check for changes to 
SIRT1 protein. Results showed that in C8D1A there was an increase in Sirt1 
protein levels after RES treatment at the higher concentrations used (25 and 50 
μM), but no increase was seen GL261, SVG nor 0906 primary cells. Other studies 
have shown increased SIRT1 expression levels (Rathbone et al 2009)  (Morita et al 
2012). This result needs repeating.  
More convincing though was an unexpected second band for SIRT1 in blots for 
normal cells in both mouse and human cells after 50 μM RES. This was not seen 
for the cancer cells. It is possible that change in SIRT1 protein under RES 
treatment is responsible for different cellular responses. This also highlights a 
possible difference in stabilisation of SIRT1 between cancer and normal cells.  
 116 
SIRT1 phosphorylation is shown to alter stability of this protein and the functional 
changes on SIRT1 due to phosphorylation are unknown in GBM. However, JNK2 
phosphorylation of serine 27 on SIRT1 confers protein stability in a panel of cancer 
cell lines (omitting glioblastoma), where it was almost undetectable in normal cell 
lines (Ford et al 2008). Previous studies have identified phosphorylation of SIRT1 
and not changes to mRNA levels are responsible for changes in SIRT1 levels 
(Ford et al 2008), to sustain cell proliferation (Sasaki et al 2008), and to alter SIRT1 
localisation and activity (Nasrin et al 2009). JNK signaling is over activated in GBM 
(Bubici & Papa 2014), and it may be an informative next step to identify any SIRT1 
phosphorylation differences between normal and glioma cells.  
NAM treatment did not show any alteration for SIRT1 levels for any of the cells 
tested. 
6.3  SIRT1 in glioma and normal cells under oxidative stress 
Results in this research showed that resistance to H2O2 was greater for glioma 
cells both with murine GL261 and human primary glioma cells compared to the 
normal astrocyte cell lines. This result was not unexpected, as normal cells are 
often less resistant to oxidative stress compared to cancer cells as cancer cells 
have increased anti-oxidant mechanisms (Oberley & Oberley 1997). Other possible 
signaling pathways that could be different between glioma and normal cells to give 
cancer cells more resistance could involve P53 mutations which are common in 
GBM (Reifenberger et al 1996) (Gross et al 2005). In a study using glioma cell 
lines, knock-down of p53 reduced H2O2-induced cell death (Datta et al 2002). 
SIRT1 regulates the expression of p53 and confers resistance under oxidative 
stress (Luo et al 2001), so at least in p53+ cells, SIRT1 can keep cells resistant to 
oxidative stress.   
6.3.1 SIRT1 inhibition and activation effects in glioma and normal cells 
under oxidative stress 
To assess what effects SIRT1 activity has in response to H2O2 – induced oxidative 
stress, nicotinamide (NAM) and resveratrol (RES) were used for SIRT1 inhibition 
and activation in glioma and normal astrocyte cell cultures exposed to H2O2 – 
induced oxidative stress.  
  117 
6.3.2 SIRT1 protein changes under oxidative stress 
Under oxidative stress conditions, SIRT1 levels appeared to increase after 
exposure to non-lethal concentrations of H2O2 in murine normal and glioma cells, 
but this was decreased after exposure to a lethal concentration of H2O2. Glioma 
cells had a greater decrease in hSIRT1 after the lethal H2O2 treatment in both 
murine and human cell lines compared to the normal cells. This was unexpected 
as human and mouse normal cells were less resistant to oxidative stress compared 
to the glioma cells. This suggests SIRT1 may not be responsible for the resistance 
to oxidative stress in glioma cells. However, if further studies verify SIRT1 does 
confer resistance it would lead to questions about protein stability of SIRT1 
between glioma and normal cells. 
A clear second protein band was observed on a Western blot for normal cells in 
both the murine and human cells after oxidative stress, but was absent in the 
glioma cells. This qualitative difference in the normal astrocytes under oxidative 
stress is reported here for the first time and offers another difference between the 
cancer and non-cancer cells that may be worth exploring further.  The band sizes 
show that in SVG cells this potential hSIRT1 fragment was around 68-75 kDa, 
while it appeared around 80-90 kDa for the C8D1A cells. This faster migrating 
protein seen after oxidative stress may have been a product of proteosomal 
cleavage or it could be a product of cleavage to create another form of SIRT1 with 
specific functions under these conditions as discussed earlier.  
6.3.3 SIRT1 inhibition and activation in relation to glioma and normal cells 
under oxidative stress  
To investigate the role of SIRT1 in the oxidative stress response, a SIRT1 inhibitor, 
nicotinamide (NAM) and SIRT1 activator, resveratrol (RES) were used in 
conjunction with H2O2-induced oxidative stress. 
On analysis of SIRT1 inhibition and activation under oxidative stress it was found 
that after 20 hr H2O2-induced oxidative stress, NAM rescued normal cells but not 
glioma cells from lethal concentrations in both murine and human cells, and RES 
increased cell death at sub-lethal concentrations of H2O2. The opposing outcomes 
for these treatments suggest SIRT1 involvement in the response to oxidative stress 
in these cells, and also show a difference in this response between glioma and 
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normal cells, where NAM rescues normal cells but not glioma cells from prolonged 
lethal oxidative stress.  
Explaining a potential mechanism for the rescue for SIRT1 inhibition, involves 
SIRT1 activating a cell death pathway at this level of stress. Cell death could occur 
via the nuclear factor kappa-light-chain-enhancer of B cells (NFκB) pathway. 
Aberrant NFκB activation is thought to play an important part in gliomagenesis 
(Korkolopoulou et al 2008) (Bhat et al 2013) through aberrant signaling rather than 
inflammatory responses (Vineshkumar et al 2014). In particular, increased 
p65/RelA subunit of NFκB correlates with higher grade glioma, and primary 
cultures derived from GBMs show constitutively activated NFκB with increased 
nuclear localisation of p65/RelA compared to normal astrocytes (Robe et al 2004). 
Typically, the p65/RelA subunit functions to promote the anti-apoptotic response, 
however it is found to activate pro-apoptotic genes also (Kucharczak et al 2003). In 
addition to this, under some cytotoxic conditions, this subunit can repress another 
set of genes that are anti-apoptotic, like Bcl-xL resulting in a p65/RelA association 
with histone deacetylase HDAC1 and resulting in cell death (Campbell et al 2004). 
SIRT1 has been shown to regulate NFκB through deacetylation of p65/RelA and 
can augment the apoptotic response (Yeung et al 2004). There is also other ways 
that p65/RelA can actively promote cell death, where the tumour suppressor, 
alternative reading frame (ARF) initiates phosphorylation of p65/RelA, creating an 
HDAC1 docking site and sensitising cells to TNFα induced cell death (Rocha et al 
2005).  Moreover, this atypical p65/RelA response, when activated, was found to 
be dominant over the more normal anti-apoptotic NFκB response. Next steps to 
find this out could be assessing the way the cells are dying (by apoptosis or 
necrosis), levels under different conditions, and assessing using inhibition and 
activation of SIRT1 on acetylation of p65/RelA.  
It remains possible, that the effects for both NAM and RES are not specific to 
SIRT1 activity in this rescue effect. This needs to be tested. 
6.3.4 Localisation changes for SIRT1 under oxidative stress 
Immunoblotting for H4K16-ac revealed that NAM treatment increased H4K16-ac in 
normal cells after two-hour H2O2 treatment but reduced H4K16-ac for glioma cells.  
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This suggested a different action for SIRT1 in glioma cell response to oxidative 
stress at an early time point compared to normal astrocytes.  
Results in this thesis also showed murine glioma cells were rescued from a lethal 
dose of H2O2 at an earlier time point (6.5 hours), and these same cells, if grown in 
less serum were rescued even at the later time point, after a lower concentration of 
NAM treatment. Nuclear /cytoplasmic extraction and immunoblot experiments 
indicate that at an earlier time point, H2O2 treatment increased nuclear sirt1 in 
murine glioma cells, but increased cytoplasmic Sirt1 in normal astrocytes, agreeing 
with the H4K16-ac changes. Follow up nuclear/cytoplasmic experiments agreed 
with murine results where after oxidative stress for a short duration, potentially 
truncated isoforms of hSIRT1 had increased in the cytoplasm of a human primary 
cell line, and conversely, increased in the nucleus of human normal astrocyte cells.  
Nuclear/cytoplasmic extractions suggested decreased Sirt1 in the cytoplasm after 
NAM treatment in murine cells, but data were unclear from blots for nuclear 
compartments.  After immunofluorescent imaging analysis of human primary 
glioma cells, after NAM treatment at the earlier time point hSIRT1 was confirmed to 
be increased in the nuclear compartment.  
Taken together, SIRT1 has different responses to oxidative environments and 
NAM treatment after different durations of exposure. These different responses 
could involve changes in localisation and different isoforms of SIRT1. Changes in 
localisation of SIRT1 after NAM treatment could explain the results seen where 
there was a rescue from a lethal concentration of H2O2 in GL261 cells at an early 
time point, and when a low concentration of NAM was used. One postulation is that 
aberrant cytoplasmic SIRT1 moves to the nucleus after NAM treatment, and 
prevents the action of NAM inhibiting cytoplasmic SIRT1 from promoting a cell 
death pathway as in the normal cell response. However, this treatment takes some 
time to affect the localisation changes, and a low concentration of NAM was not 
sufficient to induce SIRT1 to change localisation.  
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6.3.5 SIRT1 associates with mitochondria in normal astrocyte cells 
Results in this study showed SIRT1 increased in the cytoplasm in the normal 
astrocyte cell response to a short exposure to oxidative stress, and that after 
oxidative stress in normal but not glioma cells, a new protein band was seen on 
blots for both human and mouse cells.  In a recent study, cathepsin cleavage of 
SIRT1 due to increased tumour necrosis factor alpha (TNFα) in chondrocytes 
results in a stable but enzymatically inactive 75 kDa SIRT1 fragment incapable of 
binding chromatin that is exported to the cytoplasm where it associates with 
mitochondria to mitigate apoptosis  (Dvir-Ginzberg et al 2011) (Oppenheimer et al 
2012). From this it was postulated that normal astrocytes have a similar response 
under oxidative stress, where relocalisation of this smaller fragment of SIRT1 
moves to mitochondria. 
Mitochondrial membrane potential and mitochondrial content were measured in 
normal murine astrocytes, using MitoTracker® red and green FM respectively 
(MTR and MTG).  NAM treatment made no difference to membrane potential 
changes after peroxide-induced stress, however at the lethal dose, NAM treatment 
reduced mitochondrial mass significantly. Additionally, after fixation and staining 
SVG normal human astrocytes for hSIRT1 analysis of IF photographs showed that 
after a short duration of oxidative stress, an increased level of cytoplasmic hSIRT1 
was observed, which was co-localised with mitochondria. In addition, we observed 
that after H2O2 treatment, mitochondria morphology appeared to change from long 
filaments to more punctate structures.  
In an ishemic/reperfusion study inducing oxidative stress in rat cardiomyocytes, 
treatment with antioxidant curcumin attenuated the oxidative damage to 
mitichondria and stabilised mitochondral membrane potential through activation of 
SIRT1 (Yang et al 2013). There are numerous other studies showing SIRT1 effects 
on mitochondria, although none were found at the time of writing this thesis that 
associated morphological changes of mitochondria associating with SIRT1 action. 
However, it has been shown that morphological changes to mitochondria affect cell 
apoptosis (Lee et al 2004). The function for SIRT1 at mitochondria in astroocytes 
under oxidative stress warrants further investigation, and could be important to 
understanding disease other than glioblastoma, for example neurodegenerative 
diseases which have chronic increased oxidative environments.  
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6.4 Potential therapeutic value of nicotinamide 
NAM treatment in conjunction with lethal oxidative stress rescued normal cells, but 
glioma cells died. Perhaps this could be of therapeutic interest, in particular for 
potentially protecting normal cells when patients undergo chemo- and radiation 
treatments, which create oxidative environments. 
In addition, NAM treatment may inhibit proliferation in fast proliferating cells that 
are responsible for migration and tumour recurrence.  
RES treatment has been widely observed to have an increased toxic effect on 
cancer compared to normal cells, including for glioma cells (Figueiro et al 2013) 
(Jiang et al 2009). However, there are unresolved problems associated with 
treating patients with RES that include bioavailability (it gets broken down in the 
liver) and toxicity (Tome-Carneiro et al 2013). NAM, like RES is a natural product 
(the water soluble form of vitamin B3), but has good bioavailability and is well 
tolerated until very high doses are used (Sibtain et al 2002), and there have been 
some promising results using NAM in the treatment for bladder cancer (Hoskin et 
al 1997) and head and neck cancer (Saunders et al 1997). 
6.5 Conclusions and future directions 
Glioblastoma is a complex disease, and SIRT1 is a ubiquitous molecule involved in 
many different cell-signaling responses responding differently under changing 
conditions, changing response according to length of exposure to conditions, and 
this will not be the same for different cell types. Unraveling the details of SIRT1 in 
glioblastoma will take time. This research represents a preliminary investigation 
into the potential role of SIRT1 in this disease.  
Many results were obtained by one or few experimental repeats, or with too few 
samples, and need verifying. This was often because the experimental repeats 
failed. In particular extractions for nuclear and cytoplasmic compartments and 
Western blotting for SIRT1 were difficult, and single experiments only were 
performed with some controls lost. Also, repeating human or mouse model 
verification experiments were often omitted. This was sometimes because the 
importance of the result was not discovered until later, for example SIRT1 
responses of between two and six hours are different to the responses at one day.  
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However, there were some significant results in this research which give good 
directions for research in the future which are listed here: 
1. Aberrant cytoplasmic SIRT1 in glioma cells. Investigating the activity of SIRT1 
in the cytoplasm, and whether it confers an altered response to cell 
proliferation, or a change in oxidative stress resistance or response is important 
to the understanding of the role of SIRT1 in this disease.  
2. NAM treatment inhibits proliferation in glioma cells more effectively than for 
normal cells, even for immortalised normal astrocytes, indicating a significant 
difference in cell signalling that could be useful in treatment development. 
Elucidating the role of SIRT1 in this response using knock-down, other 
inhibitors or overexpression studies is needed. 
3. NAM treatment rescues normal but not glioma cells under lethal oxidative 
stress. This also could be of use therapeutically, and the function for SIRT1 in 
this response needs clarification. 
4. Modified forms of SIRT1 with altered mass could play a part in the differential 
responses for glioma and normal astrocytes. Identification and characterisation 
these potential isoforms by mass spectrometry, and where and under what 
conditions they occur needs exploration.  
 
 
 
  123 
Part 7:  References 
Abdelmohsen K, Pullmann R, Jr., Lal A, Kim HH, Galban S, et al. 2007. 
Phosphorylation of HuR by Chk2 regulates SIRT1 expression. Mol Cell 25: 
543-57 
Al-Bahrani R, Tuertcher D, Zailaie S, Abuetabh Y, Nagamori S, et al. 2015. 
Differential SIRT1 expression in hepatocellular carcinomas and 
cholangiocarcinoma of the liver. Annals of clinical and laboratory science 45: 
3-9 
Alcendor RR, Gao S, Zhai P, Zablocki D, Holle E, et al. 2007. Sirt1 regulates aging 
and resistance to oxidative stress in the heart. Circ Res 100: 1512-21 
Allen BK, Stathias V, Maloof ME, Vidovic D, Winterbottom EF, et al. 2015. 
Epigenetic pathways and glioblastoma treatment: insights from signaling 
cascades. J Cell Biochem 116: 351-63 
Allen RG, Tresini M. 2000. Oxidative stress and gene regulation. Free Radic Biol 
Med 28: 463-99 
Andrews NC, Faller DV. 1991. A rapid micropreparation technique for extraction of 
DNA-binding proteins from limiting numbers of mammalian cells. Nucleic 
Acids Res 19: 2499 
Annabi B, Lord-Dufour S, Vezina A, Beliveau R. 2012. Resveratrol Targeting of 
Carcinogen-Induced Brain Endothelial Cell Inflammation Biomarkers MMP-9 
and COX-2 is Sirt1-Independent. Drug Target Insights 6: 1-11 
Avalos JL, Bever KM, Wolberger C. 2005. Mechanism of sirtuin inhibition by 
nicotinamide: altering the NAD(+) cosubstrate specificity of a Sir2 enzyme. 
Mol Cell 17: 855-68 
Bartkova J, Hamerlik P, Stockhausen MT, Ehrmann J, Hlobilkova A, et al. 2010. 
Replication stress and oxidative damage contribute to aberrant constitutive 
activation of DNA damage signalling in human gliomas. Oncogene 29: 
5095-102 
Beane J, Cheng L, Soldi R, Zhang X, Liu G, et al. 2012. SIRT1 Pathway 
Dysregulation in the Smoke-Exposed Airway Epithelium and Lung Tumor 
Tissue. Cancer Res 72: 5702-11 
Beckner ME, Chen X, An J, Day BW, Pollack IF. 2005. Proteomic characterization 
of harvested pseudopodia with differential gel electrophoresis and specific 
antibodies. Lab Invest 85: 316-27 
Berenguer M, Martinez L, Giorgetti-Peraldi S, Le Marchand-Brustel Y, Govers R. 
2010. A serum factor induces insulin-independent translocation of GLUT4 to 
the cell surface which is maintained in insulin resistance. PLoS One 5: 
e15560 
Berridge MV, Tan AS. 1993. Characterization of the cellular reduction of 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT): subcellular 
localization, substrate dependence, and involvement of mitochondrial 
electron transport in MTT reduction. Arch Biochem Biophys 303: 474-82 
Bhat KP, Balasubramaniyan V, Vaillant B, Ezhilarasan R, Hummelink K, et al. 
2013. Mesenchymal differentiation mediated by NF-kappaB promotes 
radiation resistance in glioblastoma. Cancer cell 24: 331-46 
Bitterman KJ, Anderson RM, Cohen HY, Latorre-Esteves M, Sinclair DA. 2002. 
Inhibition of silencing and accelerated aging by nicotinamide, a putative 
negative regulator of yeast sir2 and human SIRT1. J Biol Chem 277: 45099-
107 
Blander G, Guarente L. 2004. The Sir2 family of protein deacetylases. Annual 
review of biochemistry 73: 417-35 
Borra MT, Langer MR, Slama JT, Denu JM. 2004. Substrate specificity and kinetic 
mechanism of the Sir2 family of NAD+-dependent histone/protein 
deacetylases. Biochemistry 43: 9877-87 
Bradbury C, Khanim F, Hayden R, Bunce CM, White DA, et al. 2005. Histone 
deacetylases in acute myeloid leukaemia show a distinctive pattern of 
expression that changes selectively in response to deacetylase inhibitors. 
Leukemia 19: 1751-59 
 124 
Bresgen N, Jaksch H, Bauer HC, Eckl P, Krizbai I, Tempfer H. 2006. Astrocytes 
are more resistant than cerebral endothelial cells toward geno- and 
cytotoxicity mediated by short-term oxidative stress. J Neurosci Res 84: 
1821-8 
Broadley K, Larsen L, Herst PM, Smith RA, Berridge MV, McConnell MJ. 2011a. 
The novel phloroglucinol PMT7 kills glycolytic cancer cells by blocking 
autophagy and sensitizing to nutrient stress. J Cell Biochem 112: 1869-79 
Broadley KW, Hunn MK, Farrand KJ, Price KM, Grasso C, et al. 2011b. Side 
population is not necessary or sufficient for a cancer stem cell phenotype in 
glioblastoma multiforme. Stem cells 29: 452-61 
Brooks CL, Gu W. 2009. How does SIRT1 affect metabolism, senescence and 
cancer? Nat Rev Cancer 9: 123-8 
Brown NS, Bicknell R. 2001. Hypoxia and oxidative stress in breast cancer. 
Oxidative stress: its effects on the growth, metastatic potential and response 
to therapy of breast cancer. Breast Cancer Res 3: 323-7 
Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, et al. 2004. Stress-
dependent regulation of FOXO transcription factors by the SIRT1 
deacetylase. Science 303: 2011-5 
Bubici C, Papa S. 2014. JNK signalling in cancer: in need of new, smarter 
therapeutic targets. Br J Pharmacol 171: 24-37 
Byles V, Chmilewski LK, Wang J, Zhu L, Forman LW, et al. 2010. Aberrant 
cytoplasm localization and protein stability of SIRT1 is regulated by 
PI3K/IGF-1R signaling in human cancer cells. International journal of 
biological sciences 6: 599-612 
Caito S, Rajendrasozhan S, Cook S, Chung S, Yao H, et al. 2010. SIRT1 is a 
redox-sensitive deacetylase that is post-translationally modified by oxidants 
and carbonyl stress. FASEB J 24: 3145-59 
Campbell KJ, Rocha S, Perkins ND. 2004. Active repression of antiapoptotic gene 
expression by RelA(p65) NF-kappa B. Mol Cell 13: 853-65 
Canto C, Auwerx J. 2009. PGC-1alpha, SIRT1 and AMPK, an energy sensing 
network that controls energy expenditure. Curr Opin Lipidol 20: 98-105 
Cao YW, Li YC, Wan GX, Du XM, Li F. 2015. Clinicopathological and prognostic 
role of SIRT1 in breast cancer patients: a meta-analysis. International 
journal of clinical and experimental medicine 8: 616-24 
Carafa V, Nebbioso A, Altucci L. 2012. Sirtuins and disease: the road ahead. 
Frontiers in pharmacology 3: 4 
Chalkiadaki A, Guarente L. 2012a. High-Fat Diet Triggers Inflammation-Induced 
Cleavage of SIRT1 in Adipose Tissue To Promote Metabolic Dysfunction. 
Cell Metab 16: 180-8 
Chalkiadaki A, Guarente L. 2012b. Sirtuins mediate mammalian metabolic 
responses to nutrient availability. Nat Rev Endocrinol 8: 287-96 
Chang CJ, Hsu CC, Yung MC, Chen KY, Tzao C, et al. 2009. Enhanced 
radiosensitivity and radiation-induced apoptosis in glioma CD133-positive 
cells by knockdown of SirT1 expression. Biochem Biophys Res Commun 
380: 236-42 
Chen J, Li Y, Yu TS, McKay RM, Burns DK, et al. 2012a. A restricted cell 
population propagates glioblastoma growth after chemotherapy. Nature 488: 
522-6 
Chen J, Xavier S, Moskowitz-Kassai E, Chen R, Lu CY, et al. 2012b. Cathepsin 
cleavage of sirtuin 1 in endothelial progenitor cells mediates stress-induced 
premature senescence. Am J Pathol 180: 973-83 
Cheng Y, Takeuchi H, Sonobe Y, Jin S, Wang Y, et al. 2014. Sirtuin 1 attenuates 
oxidative stress via upregulation of superoxide dismutase 2 and catalase in 
astrocytes. Journal of neuroimmunology 269: 38-43 
Clark JB, Ferris GM, Pinder S. 1971. Inhibition of nuclear NAD nucleosidase and 
poly ADP-ribose polymerase activity from rat liver by nicotinamide and 5'-
methyl nicotinamide. Biochim Biophys Acta 238: 82-5 
Clarke J, Penas C, Pastori C, Komotar RJ, Bregy A, et al. 2013. Epigenetic 
pathways and glioblastoma treatment. Epigenetics 8: 785-95 
  125 
Cohen HY, Miller C, Bitterman KJ, Wall NR, Hekking B, et al. 2004. Calorie 
restriction promotes mammalian cell survival by inducing the SIRT1 
deacetylase. Science 305: 390-2 
Dasgupta B, Milbrandt J. 2007. Resveratrol stimulates AMP kinase activity in 
neurons. Proc Natl Acad Sci U S A 104: 7217-22 
Datta K, Babbar P, Srivastava T, Sinha S, Chattopadhyay P. 2002. p53 dependent 
apoptosis in glioma cell lines in response to hydrogen peroxide induced 
oxidative stress. The international journal of biochemistry & cell biology 34: 
148-57 
Dennery PA. 2007. Effects of oxidative stress on embryonic development. Birth 
Defects Res C Embryo Today 81: 155-62 
Dion MF, Altschuler SJ, Wu LF, Rando OJ. 2005. Genomic characterization 
reveals a simple histone H4 acetylation code. Proceedings of the National 
Academy of Sciences of the United States of America 102: 5501-06 
Dixit D, Sharma V, Ghosh S, Mehta VS, Sen E. 2012. Inhibition of Casein kinase-2 
induces p53-dependent cell cycle arrest and sensitizes glioblastoma cells to 
tumor necrosis factor (TNFalpha)-induced apoptosis through SIRT1 
inhibition. Cell Death Dis 3: e271 
Dreyfuss JM, Johnson MD, Park PJ. 2009. Meta-analysis of glioblastoma 
multiforme versus anaplastic astrocytoma identifies robust gene markers. 
Mol Cancer 8: 71 
Dubrow R, Darefsky AS, Jacobs DI, Park LS, Rose MG, et al. 2013. Time trends in 
glioblastoma multiforme survival: the role of temozolomide. Neuro Oncol 15: 
1750-61 
Dunn GP, Rinne ML, Wykosky J, Genovese G, Quayle SN, et al. 2012. Emerging 
insights into the molecular and cellular basis of glioblastoma. Genes Dev 26: 
756-84 
Dvir-Ginzberg M, Gagarina V, Lee EJ, Booth R, Gabay O, Hall DJ. 2011. Tumor 
necrosis factor alpha-mediated cleavage and inactivation of SirT1 in human 
osteoarthritic chondrocytes. Arthritis Rheum 63: 2363-73 
Egler V, Korur S, Failly M, Boulay JL, Imber R, et al. 2008. Histone deacetylase 
inhibition and blockade of the glycolytic pathway synergistically induce 
glioblastoma cell death. Clin Cancer Res 14: 3132-40 
Fadul CE, Fisher JL, Hampton TH, Lallana EC, Li Z, et al. 2011. Immune response 
in patients with newly diagnosed glioblastoma multiforme treated with 
intranodal autologous tumor lysate-dendritic cell vaccination after radiation 
chemotherapy. Journal of immunotherapy 34: 382-9 
Faragher RG, Burton DG, Majecha P, Fong NS, Davis T, et al. 2011. Resveratrol, 
but not dihydroresveratrol, induces premature senescence in primary human 
fibroblasts. Age (Dordr) 33: 555-64 
Fassl A, Tagscherer KE, Richter J, Berriel Diaz M, Alcantara Llaguno SR, et al. 
2012. Notch1 signaling promotes survival of glioblastoma cells via EGFR-
mediated induction of anti-apoptotic Mcl-1. Oncogene 31: 4698-708 
Figarska SM, Vonk JM, Boezen HM. 2013. SIRT1 polymorphism, long-term 
survival and glucose tolerance in the general population. PLoS One 8: 
e58636 
Figueiro F, Bernardi A, Frozza RL, Terroso T, Zanotto-Filho A, et al. 2013. 
Resveratrol-loaded lipid-core nanocapsules treatment reduces in vitro and in 
vivo glioma growth. J Biomed Nanotechnol 9: 516-26 
Flannery T, McQuaid S, McGoohan C, McConnell RS, McGregor G, et al. 2006. 
Cathepsin S expression: An independent prognostic factor in glioblastoma 
tumours--A pilot study. Int J Cancer 119: 854-60 
Ford J, Ahmed S, Allison S, Jiang M, Milner J. 2008. JNK2-dependent regulation of 
SIRT1 protein stability. Cell Cycle 7: 3091-7 
Ford J, Jiang M, Milner J. 2005. Cancer-specific functions of SIRT1 enable human 
epithelial cancer cell growth and survival. Cancer Res 65: 10457-63 
Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, et al. 2005. Loss 
of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a 
common hallmark of human cancer. Nat Genet 37: 391-400 
 126 
Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, et al. 2007. Malignant 
astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 21: 
2683-710 
Gao Z, Zhang J, Kheterpal I, Kennedy N, Davis RJ, Ye J. 2011. Sirtuin 1 (SIRT1) 
protein degradation in response to persistent c-Jun N-terminal kinase 1 
(JNK1) activation contributes to hepatic steatosis in obesity. J Biol Chem 
286: 22227-34 
Gardner PJ, Yazid S, Chu CJ, Copland DA, Adamson P, et al. 2015. TNFalpha 
Regulates SIRT1 Cleavage during Ocular Autoimmune Disease. Am J 
Pathol  
Ghosh HS, McBurney M, Robbins PD. 2010. SIRT1 negatively regulates the 
mammalian target of rapamycin. PLoS One 5: e9199 
Giammona LM, Panuganti S, Kemper JM, Apostolidis PA, Lindsey S, et al. 2009. 
Mechanistic studies on the effects of nicotinamide on megakaryocytic 
polyploidization and the roles of NAD+ levels and SIRT inhibition. Exp 
Hematol 37: 1340-52 e3 
Giangaspero F, Burger PC. 1983. Correlations between cytologic composition and 
biologic behavior in the glioblastoma multiforme. A postmortem study of 50 
cases. Cancer 52: 2320-33 
Gillio-Meina C, Swan CL, Crellin NK, Stocco DM, Chedrese PJ. 2000. Generation 
of stable cell lines by spontaneous immortalization of primary cultures of 
porcine granulosa cells. Molecular reproduction and development 57: 366-
74 
Gjedde A. 2007. Coupling of brain function to metabolism: evaluation of energy 
requirements  In Handbook of Neurochemistry and Molecular Neurobiology, 
ed. A Lajtha 
Godin AM, Ferreira WC, Rocha LT, Seniuk JG, Paiva AL, et al. 2011. 
Antinociceptive and anti-inflammatory activities of nicotinamide and its 
isomers in different experimental models. Pharmacol Biochem Behav 99: 
782-8 
Gough DR, Cotter TG. 2011. Hydrogen peroxide: a Jekyll and Hyde signalling 
molecule. Cell Death Dis 2: e213 
Gross MW, Kraus A, Nashwan K, Mennel HD, Engenhart-Cabillic R, Schlegel J. 
2005. Expression of p53 and p21 in primary glioblastomas. Strahlentherapie 
und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] 181: 
164-71 
Guo X, Kesimer M, Tolun G, Zheng X, Xu Q, et al. 2012. The NAD(+)-dependent 
protein deacetylase activity of SIRT1 is regulated by its oligomeric status. 
Sci Rep 2: 640 
Haigis MC, Guarente LP. 2006. Mammalian sirtuins--emerging roles in physiology, 
aging, and calorie restriction. Genes Dev 20: 2913-21 
Haigis MC, Sinclair DA. 2010. Mammalian sirtuins: biological insights and disease 
relevance. Annu Rev Pathol 5: 253-95 
Han L, Zhou R, Niu J, McNutt MA, Wang P, Tong T. 2010. SIRT1 is regulated by a 
PPAR{gamma}-SIRT1 negative feedback loop associated with senescence. 
Nucleic Acids Res 38: 7458-71 
Hariharan N, Maejima Y, Nakae J, Paik J, Depinho RA, Sadoshima J. 2010. 
Deacetylation of FoxO by Sirt1 Plays an Essential Role in Mediating 
Starvation-Induced Autophagy in Cardiac Myocytes. Circ Res 107: 1470-82 
Hasegawa K, Wakino S, Yoshioka K, Tatematsu S, Hara Y, et al. 2008. Sirt1 
protects against oxidative stress-induced renal tubular cell apoptosis by the 
bidirectional regulation of catalase expression. Biochem Biophys Res 
Commun 372: 51-6 
Hasegawa K, Yoshikawa K. 2008. Necdin regulates p53 acetylation via Sirtuin1 to 
modulate DNA damage response in cortical neurons. J Neurosci 28: 8772-
84 
Hendrix ND, Wu R, Kuick R, Schwartz DR, Fearon ER, Cho KR. 2006. Fibroblast 
growth factor 9 has oncogenic activity and is a downstream target of Wnt 
signaling in ovarian endometrioid adenocarcinomas. Cancer Res 66: 1354-
62 
  127 
Herranz D, Maraver A, Canamero M, Gomez-Lopez G, Inglada-Perez L, et al. 
2013. SIRT1 promotes thyroid carcinogenesis driven by PTEN deficiency. 
Oncogene 32: 4052-6 
Hida Y, Kubo Y, Murao K, Arase S. 2007. Strong expression of a longevity-related 
protein, SIRT1, in Bowen's disease. Archives of dermatological research 
299: 103-6 
Hiraga S, Ohnishi T, Izumoto S, Miyahara E, Kanemura Y, et al. 1998. Telomerase 
activity and alterations in telomere length in human brain tumors. Cancer 
Res 58: 2117-25 
Hisahara S, Chiba S, Matsumoto H, Tanno M, Yagi H, et al. 2008. Histone 
deacetylase SIRT1 modulates neuronal differentiation by its nuclear 
translocation. Proc Natl Acad Sci U S A 105: 15599-604 
Hong EH, Lee SJ, Kim JS, Lee KH, Um HD, et al. 2010. Ionizing radiation induces 
cellular senescence of articular chondrocytes via negative regulation of 
SIRT1 by p38 kinase. J Biol Chem 285: 1283-95 
Hori YS, Kuno A, Hosoda R, Horio Y. 2013. Regulation of FOXOs and p53 by 
SIRT1 modulators under oxidative stress. PLoS One 8: e73875 
Hoskin PJ, Saunders MI, Phillips H, Cladd H, Powell ME, et al. 1997. Carbogen 
and nicotinamide in the treatment of bladder cancer with radical 
radiotherapy. Br J Cancer 76: 260-3 
Hou J, Chong ZZ, Shang YC, Maiese K. 2010. Early apoptotic vascular signaling is 
determined by Sirt1 through nuclear shuttling, forkhead trafficking, bad, and 
mitochondrial caspase activation. Current neurovascular research 7: 95-112 
Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, et al. 2003. Small 
molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. 
Nature 425: 191-6 
Huang B, Cheng X, Wang D, Peng M, Xue Z, et al. 2014. Adiponectin promotes 
pancreatic cancer progression by inhibiting apoptosis via the activation of 
AMPK/Sirt1/PGC-1alpha signaling. Oncotarget 5: 4732-45 
Huffman DM, Grizzle WE, Bamman MM, Kim J-s, Eltoum IA, et al. 2007. SIRT1 is 
significantly elevated in mouse and human prostate cancer. Cancer 
Research 67: 6612-18 
Hunn MK, Bauer E, Wood CE, Gasser O, Dzhelali M, et al. 2015. Dendritic cell 
vaccination combined with temozolomide retreatment: results of a phase I 
trial in patients with recurrent glioblastoma multiforme. J Neurooncol 121: 
319-29 
Iida T, Furuta A, Kawashima M, Nishida J, Nakabeppu Y, Iwaki T. 2001. 
Accumulation of 8-oxo-2'-deoxyguanosine and increased expression of 
hMTH1 protein in brain tumors. Neuro Oncol 3: 73-81 
Ikenoue T, Inoki K, Zhao B, Guan KL. 2008. PTEN acetylation modulates its 
interaction with PDZ domain. Cancer Res 68: 6908-12 
Imai S, Armstrong CM, Kaeberlein M, Guarente L. 2000. Transcriptional silencing 
and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 
403: 795-800 
Inda MM, Fan X, Munoz J, Perot C, Fauvet D, et al. 2003. Chromosomal 
abnormalities in human glioblastomas: gain in chromosome 7p correlating 
with loss in chromosome 10q. Mol Carcinog 36: 6-14 
Jiang H, Shang X, Wu H, Gautam SC, Al-Holou S, et al. 2009. Resveratrol 
downregulates PI3K/Akt/mTOR signaling pathways in human U251 glioma 
cells. J Exp Ther Oncol 8: 25-33 
Jiang Y, Sun Y, Yuan Y. 2012. [Mechanism of temozolomide-induced anti-tumor 
effects on glioblastoma cells in vitro is via ROS-dependent SIRT1 signaling 
pathway]. Zhonghua Zhong Liu Za Zhi 34: 734-8 
Jin Q, Yan T, Ge X, Sun C, Shi X, Zhai Q. 2007. Cytoplasm-localized SIRT1 
enhances apoptosis. J Cell Physiol 213: 88-97 
Kaeberlein M, McDonagh T, Heltweg B, Hixon J, Westman EA, et al. 2005. 
Substrate-specific activation of sirtuins by resveratrol. J Biol Chem 280: 
17038-45 
Kaeberlein M, McVey M, Guarente L. 1999. The SIR2/3/4 complex and SIR2 alone 
promote longevity in Saccharomyces cerevisiae by two different 
mechanisms. Genes Dev 13: 2570-80 
 128 
Kalaria RN, Premkumar DR, Pax AB, Cohen DL, Lieberburg I. 1996. Production 
and increased detection of amyloid beta protein and amyloidogenic 
fragments in brain microvessels, meningeal vessels and choroid plexus in 
Alzheimer's disease. Brain Res Mol Brain Res 35: 58-68 
Kanfi Y, Peshti V, Gozlan YM, Rathaus M, Gil R, Cohen HY. 2008. Regulation of 
SIRT1 protein levels by nutrient availability. FEBS Lett 582: 2417-23 
Keyse SM, Emslie EA. 1992. Oxidative stress and heat shock induce a human 
gene encoding a protein-tyrosine phosphatase. Nature 359: 644-7 
Kheirollahi M, Mehrazin M, Kamalian N, Mohammadi-asl J, Mehdipour P. 2013. 
Telomerase activity in human brain tumors: astrocytoma and meningioma. 
Cellular and molecular neurobiology 33: 569-74 
Kim EJ, Kho JH, Kang MR, Um SJ. 2007. Active regulator of SIRT1 cooperates 
with SIRT1 and facilitates suppression of p53 activity. Mol Cell 28: 277-90 
Kim JE, Chen J, Lou Z. 2008. DBC1 is a negative regulator of SIRT1. Nature 451: 
583-6 
Klaunig JE, Kamendulis LM. 2004. The role of oxidative stress in carcinogenesis. 
Annu Rev Pharmacol Toxicol 44: 239-67 
Konduri S, Lakka SS, Tasiou A, Yanamandra N, Gondi CS, et al. 2001. Elevated 
levels of cathepsin B in human glioblastoma cell lines. International journal 
of oncology 19: 519-24 
Korkolopoulou P, Levidou G, Saetta AA, El-Habr E, Eftichiadis C, et al. 2008. 
Expression of nuclear factor-kappaB in human astrocytomas: relation to pI 
kappa Ba, vascular endothelial growth factor, Cox-2, microvascular 
characteristics, and survival. Hum Pathol 39: 1143-52 
Krakstad C, Chekenya M. 2010. Survival signalling and apoptosis resistance in 
glioblastomas: opportunities for targeted therapeutics. Mol Cancer 9: 135 
Kucharczak J, Simmons MJ, Fan Y, Gelinas C. 2003. To be, or not to be: NF-
kappaB is the answer--role of Rel/NF-kappaB in the regulation of apoptosis. 
Oncogene 22: 8961-82 
Kume S, Haneda M, Kanasaki K, Sugimoto T, Araki S, et al. 2006. Silent 
information regulator 2 (SIRT1) attenuates oxidative stress-induced 
mesangial cell apoptosis via p53 deacetylation. Free Radic Biol Med 40: 
2175-82 
Kurdistani SK, Grunstein M. 2003. Histone acetylation and deacetylation in yeast. 
Nature Reviews Molecular Cell Biology 4: 276-84 
Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, et al. 2006. 
Resveratrol improves mitochondrial function and protects against metabolic 
disease by activating SIRT1 and PGC-1alpha. Cell 127: 1109-22 
Landry J, Slama JT, Sternglanz R. 2000. Role of NAD(+) in the deacetylase activity 
of the SIR2-like proteins. Biochem Biophys Res Commun 278: 685-90 
Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, et al. 2004. Gene expression 
profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl 
Acad Sci U S A 101: 811-6 
Lappas M, Permezel M. 2011. The anti-inflammatory and antioxidative effects of 
nicotinamide, a vitamin B(3) derivative, are elicited by FoxO3 in human 
gestational tissues: implications for preterm birth. J Nutr Biochem 22: 1195-
201 
Lau AW, Liu P, Inuzuka H, Gao D. 2014. SIRT1 phosphorylation by AMP-activated 
protein kinase regulates p53 acetylation. American journal of cancer 
research 4: 245-55 
Leavitt BR, Hernit-Grant CS, Macklis JD. 1999. Mature astrocytes transform into 
transitional radial glia within adult mouse neocortex that supports directed 
migration of transplanted immature neurons. Exp Neurol 157: 43-57 
Lee IH, Cao L, Mostoslavsky R, Lombard DB, Liu J, et al. 2008. A role for the NAD-
dependent deacetylase Sirt1 in the regulation of autophagy. Proc Natl Acad 
Sci U S A 105: 3374-9 
Lee SE, Paques F, Sylvan J, Haber JE. 1999. Role of yeast SIR genes and mating 
type in directing DNA double-strand breaks to homologous and non-
homologous repair paths. Current biology : CB 9: 767-70 
  129 
Lee YJ, Jeong SY, Karbowski M, Smith CL, Youle RJ. 2004. Roles of the 
mammalian mitochondrial fission and fusion mediators Fis1, Drp1, and 
Opa1 in apoptosis. Mol Biol Cell 15: 5001-11 
Li L, Sun Q, Li Y, Yang Y, Yang Y, et al. 2015. Overexpression of SIRT1 Induced 
by Resveratrol and Inhibitor of miR-204 Suppresses Activation and 
Proliferation of Microglia. Journal of molecular neuroscience : MN  
Li L, Yuan L, Luo J, Gao J, Guo J, Xie X. 2012. MiR-34a inhibits proliferation and 
migration of breast cancer through down-regulation of Bcl-2 and SIRT1. Clin 
Exp Med  
Li Y, Backesjo CM, Haldosen LA, Lindgren U. 2009. Resveratrol inhibits 
proliferation and promotes apoptosis of osteosarcoma cells. Eur J 
Pharmacol 609: 13-8 
Libert S, Cohen D, Guarente L. 2008. Neurogenesis directed by Sirt1. Nat Cell Biol 
10: 373-4 
Lim SK, Llaguno SR, McKay RM, Parada LF. 2011. Glioblastoma multiforme: a 
perspective on recent findings in human cancer and mouse models. BMB 
reports 44: 158-64 
Lin JN, Lin VC, Rau KM, Shieh PC, Kuo DH, et al. 2010. Resveratrol modulates 
tumor cell proliferation and protein translation via SIRT1-dependent AMPK 
activation. J Agric Food Chem 58: 1584-92 
Lino MM, Merlo A. 2011. PI3Kinase signaling in glioblastoma. J Neurooncol 103: 
417-27 
Lino MM, Merlo A, Boulay JL. 2010. Notch signaling in glioblastoma: a 
developmental drug target? BMC medicine 8: 72 
Liu G, Yuan X, Zeng Z, Tunici P, Ng H, et al. 2006. Analysis of gene expression 
and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol 
Cancer 5: 67 
Liu TF, Yoza BK, El Gazzar M, Vachharajani VT, McCall CE. 2011. NAD+-
dependent SIRT1 deacetylase participates in epigenetic reprogramming 
during endotoxin tolerance. J Biol Chem 286: 9856-64 
Liu Y, Dentin R, Chen D, Hedrick S, Ravnskjaer K, et al. 2008. A fasting inducible 
switch modulates gluconeogenesis via activator/coactivator exchange. 
Nature 456: 269-73 
Lou G, Liu Y, Wu S, Xue J, Yang F, et al. 2015. The p53/miR-34a/SIRT1 Positive 
Feedback Loop in Quercetin-Induced Apoptosis. Cellular physiology and 
biochemistry : international journal of experimental cellular physiology, 
biochemistry, and pharmacology 35: 2192-202 
Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, et al. 2007. The 2007 
WHO classification of tumours of the central nervous system. Acta 
Neuropathol 114: 97-109 
Lu M, Sarruf DA, Li P, Osborn O, Sanchez-Alavez M, et al. 2013. Neuronal Sirt1 
deficiency increases insulin sensitivity in both brain and peripheral tissues. J 
Biol Chem 288: 10722-35 
Luo J, Nikolaev AY, Imai S, Chen D, Su F, et al. 2001. Negative control of p53 by 
Sir2alpha promotes cell survival under stress. Cell 107: 137-48 
Lynch CJ, Shah ZH, Allison SJ, Ahmed SU, Ford J, et al. 2010. SIRT1 undergoes 
alternative splicing in a novel auto-regulatory loop with p53. PLoS One 5: 
e13502 
Maher EA, Furnari FB, Bachoo RM, Rowitch DH, Louis DN, et al. 2001. Malignant 
glioma: genetics and biology of a grave matter. Genes Dev 15: 1311-33 
Mahlknecht U, Voelter-Mahlknecht S. 2009. Chromosomal characterization and 
localization of the NAD+-dependent histone deacetylase gene sirtuin 1 in 
the mouse. Int J Mol Med 23: 245-52 
Mantel CR, Wang RH, Deng C, Broxmeyer HE. 2008. Sirt1, notch and stem cell 
"age asymmetry". Cell Cycle 7: 2821-5 
Marmorstein R. 2001. Structure of histone deacetylases: insights into substrate 
recognition and catalysis. Structure 9: 1127-33 
Martin SG, Laroche T, Suka N, Grunstein M, Gasser SM. 1999. Relocalization of 
telomeric Ku and SIR proteins in response to DNA strand breaks in yeast. 
Cell 97: 621-33 
 130 
Martin V, Herrera F, Garcia-Santos G, Antolin I, Rodriguez-Blanco J, Rodriguez C. 
2007. Signaling pathways involved in antioxidant control of glioma cell 
proliferation. Free Radic Biol Med 42: 1715-22 
Megee PC, Morgan BA, Smith MM. 1995. Histone H4 and the maintenance of 
genome integrity. Genes & Development 9: 1716-27 
Merksamer PI, Liu Y, He W, Hirschey MD, Chen D, Verdin E. 2013. The sirtuins, 
oxidative stress and aging: an emerging link. Aging (Albany NY) 5: 144-50 
Mohtavinejad N, Nakhaee A, Harati H, Poodineh J, Afzali M. 2015. SIRT1 gene is 
associated with cardiovascular disease in the Iranian population. The 
Egyptian Journal of Medical Human Genetics  
Morita Y, Wada-Hiraike O, Yano T, Shirane A, Hirano M, et al. 2012. Resveratrol 
promotes expression of SIRT1 and StAR in rat ovarian granulosa cells: an 
implicative role of SIRT1 in the ovary. Reproductive biology and 
endocrinology : RB&E 10: 14 
Nakane K, Fujita Y, Terazawa R, Atsumi Y, Kato T, et al. 2012. Inhibition of 
cortactin and SIRT1 expression attenuates migration and invasion of 
prostate cancer DU145 cells. International Journal of Urology 19: 71-79 
Nakatani K, Yoshimi N, Mori H, Yoshimura S, Sakai H, et al. 1997. The significant 
role of telomerase activity in human brain tumors. Cancer 80: 471-6 
Naqvi A, Hoffman TA, DeRicco J, Kumar A, Kim CS, et al. 2010. A single-
nucleotide variation in a p53-binding site affects nutrient-sensitive human 
SIRT1 expression. Hum Mol Genet 19: 4123-33 
Narayan RS, Fedrigo CA, Stalpers LJ, Baumert BG, Sminia P. 2013. Targeting the 
Akt-pathway to improve radiosensitivity in glioblastoma. Current 
pharmaceutical design 19: 951-7 
Nasrin N, Kaushik VK, Fortier E, Wall D, Pearson KJ, et al. 2009. JNK1 
phosphorylates SIRT1 and promotes its enzymatic activity. PLoS One 4: 
e8414 
Newcomb EZ, D. 2009. The Murine GL261 Glioma Experimental Model to Assess 
Novel Brain Tumor Treatments  In CNS Cancer, ed. M E, pp. pp 227-41: 
Humana Press 
Nie Y, Erion DM, Yuan Z, Dietrich M, Shulman GI, et al. 2009. STAT3 inhibition of 
gluconeogenesis is downregulated by SirT1. Nat Cell Biol 11: 492-500 
North BJ, Verdin E. 2004. Sirtuins: Sir2-related NAD-dependent protein 
deacetylases. Genome biology 5: 224 
Oberley TD, Oberley LW. 1997. Antioxidant enzyme levels in cancer. Histol 
Histopathol 12: 525-35 
Ohsawa S, Miura M. 2006. Caspase-mediated changes in Sir2alpha during 
apoptosis. FEBS Lett 580: 5875-9 
Oppenheimer H, Gabay O, Meir H, Haze A, Kandel L, et al. 2012. 75-kd sirtuin 1 
blocks tumor necrosis factor alpha-mediated apoptosis in human 
osteoarthritic chondrocytes. Arthritis Rheum 64: 718-28 
Ota H, Eto M, Kano MR, Ogawa S, Iijima K, et al. 2008. Cilostazol inhibits oxidative 
stress-induced premature senescence via upregulation of Sirt1 in human 
endothelial cells. Arteriosclerosis, thrombosis, and vascular biology 28: 
1634-9 
Oudard S, Arvelo F, Miccoli L, Apiou F, Dutrillaux AM, et al. 1996. High glycolysis 
in gliomas despite low hexokinase transcription and activity correlated to 
chromosome 10 loss. Br J Cancer 74: 839-45 
Pacholec M, Bleasdale JE, Chrunyk B, Cunningham D, Flynn D, et al. 2010. 
SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of 
SIRT1. J Biol Chem 285: 8340-51 
Pan M, Yuan H, Brent M, Ding EC, Marmorstein R. 2012. SIRT1 contains N- and 
C-terminal regions that potentiate deacetylase activity. J Biol Chem 287: 
2468-76 
Park SJ, Lee JH, Kim HY, Choi YH, Park JS, et al. 2012. Astrocytes, but not 
microglia, rapidly sense H(2)O(2)via STAT6 phosphorylation, resulting in 
cyclooxygenase-2 expression and prostaglandin release. J Immunol 188: 
5132-41 
  131 
Pelicano H, Xu RH, Du M, Feng L, Sasaki R, et al. 2006. Mitochondrial respiration 
defects in cancer cells cause activation of Akt survival pathway through a 
redox-mediated mechanism. J Cell Biol 175: 913-23 
Peltz L, Gomez J, Marquez M, Alencastro F, Atashpanjeh N, et al. 2012. 
Resveratrol exerts dosage and duration dependent effect on human 
mesenchymal stem cell development. PLoS One 7: e37162 
Pillai VB, Sundaresan NR, Gupta MP. 2014. Regulation of Akt signaling by sirtuins: 
its implication in cardiac hypertrophy and aging. Circ Res 114: 368-78 
Price NL, Gomes AP, Ling AJ, Duarte FV, Martin-Montalvo A, et al. 2012. SIRT1 is 
required for AMPK activation and the beneficial effects of resveratrol on 
mitochondrial function. Cell Metab 15: 675-90 
Prozorovski T, Schulze-Topphoff U, Glumm R, Baumgart J, Schroter F, et al. 2008. 
Sirt1 contributes critically to the redox-dependent fate of neural progenitors. 
Nat Cell Biol 10: 385-94 
Pruitt K, Zinn RL, Ohm JE, McGarvey KM, Kang SH, et al. 2006. Inhibition of 
SIRT1 reactivates silenced cancer genes without loss of promoter DNA 
hypermethylation. PLoS Genet 2: e40 
Qu Y, Zhang J, Wu S, Li B, Liu S, Cheng J. 2012. SIRT1 promotes proliferation 
and inhibits apoptosis of human malignant glioma cell lines. Neurosci Lett 
525: 168-72 
Rathbone CR, Booth FW, Lees SJ. 2009. Sirt1 increases skeletal muscle precursor 
cell proliferation. European journal of cell biology 88: 35-44 
Rauscher FJ, 3rd. 2005. It is time for a Human Epigenome Project. Cancer Res 65: 
11229 
Raver-Shapira N, Marciano E, Meiri E, Spector Y, Rosenfeld N, et al. 2007. 
Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. 
Mol Cell 26: 731-43 
Reifenberger J, Ring GU, Gies U, Cobbers L, Oberstrass J, et al. 1996. Analysis of 
p53 mutation and epidermal growth factor receptor amplification in recurrent 
gliomas with malignant progression. J Neuropathol Exp Neurol 55: 822-31 
Reynes G, Vila V, Martin M, Parada A, Fleitas T, et al. 2011. Circulating markers of 
angiogenesis, inflammation, and coagulation in patients with glioblastoma. J 
Neurooncol 102: 35-41 
Robe PA, Bentires-Alj M, Bonif M, Rogister B, Deprez M, et al. 2004. In vitro and in 
vivo activity of the nuclear factor-kappaB inhibitor sulfasalazine in human 
glioblastomas. Clin Cancer Res 10: 5595-603 
Rocha S, Garrett MD, Campbell KJ, Schumm K, Perkins ND. 2005. Regulation of 
NF-kappaB and p53 through activation of ATR and Chk1 by the ARF tumour 
suppressor. EMBO J 24: 1157-69 
Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM, Puigserver P. 2005. 
Nutrient control of glucose homeostasis through a complex of PGC-1alpha 
and SIRT1. Nature 434: 113-8 
Rogina B, Helfand SL. 2004. Sir2 mediates longevity in the fly through a pathway 
related to calorie restriction. Proc Natl Acad Sci U S A 101: 15998-6003 
Salminen A, Kaarniranta K, Kauppinen A. 2013. Crosstalk between Oxidative 
Stress and SIRT1: Impact on the Aging Process. Int J Mol Sci 14: 3834-59 
Salminen A, Kauppinen A, Suuronen T, Kaarniranta K. 2008. SIRT1 longevity 
factor suppresses NF-kappaB -driven immune responses: regulation of 
aging via NF-kappaB acetylation? BioEssays : news and reviews in 
molecular, cellular and developmental biology 30: 939-42 
Sanchez-Carbayo M, Socci ND, Lozano J, Saint F, Cordon-Cardo C. 2006. 
Defining molecular profiles of poor outcome in patients with invasive bladder 
cancer using oligonucleotide microarrays. J Clin Oncol 24: 778-89 
Sasaki T, Maier B, Koclega KD, Chruszcz M, Gluba W, et al. 2008. 
Phosphorylation regulates SIRT1 function. PLoS One 3: e4020 
Saunders LR, Verdin E. 2007. Sirtuins: critical regulators at the crossroads 
between cancer and aging. Oncogene 26: 5489-504 
Saunders MI, Hoskin PJ, Pigott K, Powell ME, Goodchild K, et al. 1997. 
Accelerated radiotherapy, carbogen and nicotinamide (ARCON) in locally 
advanced head and neck cancer: a feasibility study. Radiother Oncol 45: 
159-66 
 132 
Schneider CA, Rasband WS, Eliceiri KW. 2012. NIH Image to ImageJ: 25 years of 
image analysis. Nature methods 9: 671-5 
Shah ZH, Ahmed SU, Ford JR, Allison SJ, Knight JR, Milner J. 2012. A 
deacetylase-deficient SIRT1 variant opposes full-length SIRT1 in regulating 
tumor suppressor p53 and governs expression of cancer-related genes. Mol 
Cell Biol 32: 704-16 
Sibtain A, Hill S, Goodchild K, Shah N, Saunders M, Hoskin PJ. 2002. The 
modification of human tumour blood flow using pentoxifylline, nicotinamide 
and carbogen. Radiother Oncol 62: 69-76 
Silber JR, Bobola MS, Blank A, Schoeler KD, Haroldson PD, et al. 2002. The 
apurinic/apyrimidinic endonuclease activity of Ape1/Ref-1 contributes to 
human glioma cell resistance to alkylating agents and is elevated by 
oxidative stress. Clin Cancer Res 8: 3008-18 
Sinclair DA, Guarente L. 1997. Extrachromosomal rDNA circles--a cause of aging 
in yeast. Cell 91: 1033-42 
Smith CM, Gafken PR, Zhang ZL, Gottschling DE, Smith JB, Smith DL. 2003. 
Mass spectrometric quantification of acetylation at specific lysines within the 
amino-terminal tail of histone H4. Analytical Biochemistry 316: 23-33 
Solomon JM, Pasupuleti R, Xu L, McDonagh T, Curtis R, et al. 2006. Inhibition of 
SIRT1 catalytic activity increases p53 acetylation but does not alter cell 
survival following DNA damage. Mol Cell Biol 26: 28-38 
Stenzinger A, Endris V, Klauschen F, Sinn B, Lorenz K, et al. 2013. High SIRT1 
expression is a negative prognosticator in pancreatic ductal 
adenocarcinoma. BMC Cancer 13: 450 
Stuenkel W, Peh BK, Tan YC, Nayagam VM, Wang X, et al. 2007. Function of the 
SIRT1 protein deacetylase in cancer. Biotechnology Journal 2: 1360-68 
Sugden MC, Caton PW, Holness MJ. 2010. PPAR control: it's SIRTainly as easy 
as PGC. J Endocrinol 204: 93-104 
Sugino T, Maruyama M, Tanno M, Kuno A, Houkin K, Horio Y. 2010. Protein 
deacetylase SIRT1 in the cytoplasm promotes nerve growth factor-induced 
neurite outgrowth in PC12 cells. FEBS Lett 584: 2821-6 
Sulaiman M, Matta MJ, Sunderesan NR, Gupta MP, Periasamy M, Gupta M. 2010. 
Resveratrol, an activator of SIRT1, upregulates sarcoplasmic calcium 
ATPase and improves cardiac function in diabetic cardiomyopathy. Am J 
Physiol Heart Circ Physiol 298: H833-43 
Sun L, Li H, Chen J, Dehennaut V, Zhao Y, et al. 2013. A SUMOylation-dependent 
pathway regulates SIRT1 transcription and lung cancer metastasis. Journal 
of the National Cancer Institute 105: 887-98 
Sundaresan NR, Pillai VB, Wolfgeher D, Samant S, Vasudevan P, et al. 2011. The 
deacetylase SIRT1 promotes membrane localization and activation of Akt 
and PDK1 during tumorigenesis and cardiac hypertrophy. Sci Signal 4: ra46 
Tafani M, Di Vito M, Frati A, Pellegrini L, De Santis E, et al. 2011. Pro-inflammatory 
gene expression in solid glioblastoma microenvironment and in hypoxic 
stem cells from human glioblastoma. J Neuroinflammation 8: 32 
Tanno M, Sakamoto J, Miura T, Shimamoto K, Horio Y. 2007. Nucleocytoplasmic 
shuttling of the NAD+-dependent histone deacetylase SIRT1. J Biol Chem 
282: 6823-32 
Tiberi L, van den Ameele J, Dimidschstein J, Piccirilli J, Gall D, et al. 2012. BCL6 
controls neurogenesis through Sirt1-dependent epigenetic repression of 
selective Notch targets. Nature neuroscience 15: 1627-35 
Tissenbaum HA, Guarente L. 2001. Increased dosage of a sir-2 gene extends 
lifespan in Caenorhabditis elegans. Nature 410: 227-30 
Tome-Carneiro J, Larrosa M, Gonzalez-Sarrias A, Tomas-Barberan FA, Garcia-
Conesa MT, Espin JC. 2013. Resveratrol and clinical trials: the crossroad 
from in vitro studies to human evidence. Current pharmaceutical design 19: 
6064-93 
Toyokuni S, Okamoto K, Yodoi J, Hiai H. 1995. Persistent oxidative stress in 
cancer. FEBS Lett 358: 1-3 
Vaquero A, Scher M, Lee DH, Erdjument-Bromage H, Tempst P, Reinberg D. 
2004. Human SirT1 interacts with histone H1 and promotes formation of 
facultative heterochromatin. Molecular Cell 16: 93-105 
  133 
Vaquero A, Sternglanz R, Reinberg D. 2007. NAD(+)-dependent deacetylation of 
H4 lysine 16 by class IIIHDACs. Oncogene 26: 5505-20 
Vineshkumar PT, Kimmo JH, Sharmistha C, Amyn AH. 2014. The role of NF-κB in 
the pathogenesis of glioma. Molecular & Cellular Oncology 1 
Vlashi E, Lagadec C, Vergnes L, Matsutani T, Masui K, et al. 2011. Metabolic state 
of glioma stem cells and nontumorigenic cells. Proc Natl Acad Sci U S A 
108: 16062-7 
Wang B, Hasan MK, Alvarado E, Yuan H, Wu H, Chen WY. 2011. NAMPT 
overexpression in prostate cancer and its contribution to tumor cell survival 
and stress response. Oncogene 30: 907-21 
Wang C, Chen L, Hou X, Li Z, Kabra N, et al. 2006. Interactions between E2F1 and 
SirT1 regulate apoptotic response to DNA damage. Nat Cell Biol 8: 1025-31 
Wang R-H, Sengupta K, Li C, Kim H-S, Cao L, et al. 2008. Impaired DNA damage 
response, genome instability, and tumorigenesis in SIRT1 mutant mice. 
Cancer cell 14: 312-23 
Wang YQ, Cao Q, Wang F, Huang LY, Sang TT, et al. 2015. SIRT1 protects 
against oxidative stress-induced endothelial progenitor cells apoptosis by 
inhibiting FOXO3a via FOXO3a ubiquitination and degradation. J Cell 
Physiol  
Webster BR, Lu Z, Sack MN, Scott I. 2012. The role of sirtuins in modulating redox 
stressors. Free Radic Biol Med 52: 281-90 
Wu A, Ying Z, Gomez-Pinilla F. 2006. Oxidative stress modulates Sir2alpha in rat 
hippocampus and cerebral cortex. Eur J Neurosci 23: 2573-80 
Wu M, Pastor-Pareja JC, Xu T. 2010. Interaction between Ras(V12) and scribbled 
clones induces tumour growth and invasion. Nature 463: 545-8 
Yang H, Zhang W, Pan H, Feldser HG, Lainez E, et al. 2012. SIRT1 activators 
suppress inflammatory responses through promotion of p65 deacetylation 
and inhibition of NF-kappaB activity. PLoS One 7: e46364 
Yang Y, Duan W, Lin Y, Yi W, Liang Z, et al. 2013. SIRT1 activation by curcumin 
pretreatment attenuates mitochondrial oxidative damage induced by 
myocardial ischemia reperfusion injury. Free Radic Biol Med 65: 667-79 
Yang Y, Fu W, Chen J, Olashaw N, Zhang X, et al. 2007. SIRT1 sumoylation 
regulates its deacetylase activity and cellular response to genotoxic stress. 
Nat Cell Biol 9: 1253-62 
Ye F, Zhang Y, Liu Y, Yamada K, Tso JL, et al. 2013. Protective properties of 
radio-chemoresistant glioblastoma stem cell clones are associated with 
metabolic adaptation to reduced glucose dependence. PLoS One 8: e80397 
Yeung F, Hoberg JE, Ramsey CS, Keller MD, Jones DR, et al. 2004. Modulation of 
NF-kappaB-dependent transcription and cell survival by the SIRT1 
deacetylase. EMBO J 23: 2369-80 
Yoon H, Shin SH, Shin DH, Chun YS, Park JW. 2014. Differential roles of Sirt1 in 
HIF-1alpha and HIF-2alpha mediated hypoxic responses. Biochem Biophys 
Res Commun 444: 36-43 
Yoshizaki T, Milne JC, Imamura T, Schenk S, Sonoda N, et al. 2009. SIRT1 exerts 
anti-inflammatory effects and improves insulin sensitivity in adipocytes. Mol 
Cell Biol 29: 1363-74 
Zakhary SM, Ayubcha D, Dileo JN, Jose R, Leheste JR, et al. 2010. Distribution 
analysis of deacetylase SIRT1 in rodent and human nervous systems. Anat 
Rec (Hoboken) 293: 1024-32 
Zhang B, Chen J, Cheng AS, Ko BC. 2014. Depletion of sirtuin 1 (SIRT1) leads to 
epigenetic modifications of telomerase (TERT) gene in hepatocellular 
carcinoma cells. PLoS One 9: e84931 
Zhang F, Li ZL, Xu XM, Hu Y, Yao JH, et al. 2015. Protective effects of icariin-
mediated SIRT1/FOXO3 signaling pathway on intestinal 
ischemia/reperfusion-induced acute lung injury. Mol Med Rep 11: 269-76 
Zheng J, Chen LL, Xiao F, Hu X, Deng X, Li H. 2012. Three single nucleotide 
variants of the SIRT1 gene are associated with overweight in a Chinese 
population: a case control study. Endocrine journal 59: 229-37 
Zhou Y, Zhou Y, Shingu T, Feng L, Chen Z, et al. 2011. Metabolic alterations in 
highly tumorigenic glioblastoma cells: preference for hypoxia and high 
dependency on glycolysis. J Biol Chem 286: 32843-53 
 134 
Zhu GY, Shi BZ, Li Y. 2014. FoxM1 regulates Sirt1 expression in glioma cells. 
European review for medical and pharmacological sciences 18: 205-11 
Ziche M, Morbidelli L. 2000. Nitric oxide and angiogenesis. J Neurooncol 50: 139-
48 
Zu Y, Liu L, Lee MY, Xu C, Liang Y, et al. 2010. SIRT1 promotes proliferation and 
prevents senescence through targeting LKB1 in primary porcine aortic 
endothelial cells. Circ Res 106: 1384-93 
 
